BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12N 15/12, 15/63, C12P 21/00
C07K 13/00

A1

(11) International Publication Number: WO 92/19734

(43) International Publication Date: 12 November 1992 (12.11.92)

(21) International Application Number: PCT/US92/03651

(22) International Filing Date: 1 May 1992 (01.05.92)

(30) Priority data:
695,189 3 May 1991 (03.05.91) US
791,923 14 November 1991 (14.11.91) US

(71) Applicants: YALE UNIVERSITY [US/US]; 216 Prospect Street, New Haven, CT 06511 (US). INDIANA UNIVERSITY FOUNDATION [US/US]; Showalter House, P.O. Box 500, Bloomington, IN 47402 (US).

(72) Inventors: ARTAVANIS-TSAKONAS, Spyridon ; 192 Ridgewood Avenue, Hamden, CT 06517 (US). MUSKAVITCH, Marc, Alan, Telander ; 1308 Elliston Drive, Bloomington, IN 47401 (US). FEHON, Richard, Grant ; REBAY, Ilaria ; BLAUMUELLER, Christine, Marie ; Dept. of Biology-KBT, Yale University, 219 Prospect Street, New Haven, CT 06511 (US). SHEPARD, Scott, Brockewell ; 50, Cutler Lane, Chestnut Hill, MA 02167 (US).

(74) Agent: MISROCK, S., Leslie; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), NO, SE (European patent).

Published
With international search report.

(54) Title: BINDING DOMAINS IN NOTCH AND DELTA PROTEINS



(57) Abstract

The present invention relates to nucleotide sequences of the human *Notch* and *Delta* genes, and amino acid sequences of their encoded proteins, as well as fragments thereof containing an antigenic determinant or which are functionally active. The invention is also directed to fragments (termed herein "adhesive fragments"), and the sequences thereof, of the proteins ("toporythmic proteins") encoded by toporythmic genes which mediate homotypic or heterotypic binding to toporythmic proteins. Toporythmic genes, as used herein, refers to the genes *Notch*, *Delta* and *Serrate*, as well as other members of the *Delta/Serrate* family which may be identified, e.g., by the methods described herein. Antibodies to human *Notch* and to adhesive fragments are additionally provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

BINDING DOMAINS IN NOTCH AND DELTA PROTEINS

This invention was made in part with government support under Grant numbers GM 19093 and NS 26084 awarded by the Department of Health and Human Services. The government has certain rights in the invention.

1. INTRODUCTION

The present invention relates to the human Notch and Delta genes and their encoded products. The invention also relates to sequences (termed herein "adhesive sequences") within the proteins encoded by toporythmic genes which mediate homotypic or heterotypic binding to sequences within proteins encoded by toporythmic genes. Such genes include but are not limited to Notch, Delta, and Serrate.

2. BACKGROUND OF THE INVENTION

Genetic analyses in Drosophila have been extremely useful in dissecting the complexity of developmental pathways and identifying interacting loci. However, understanding the precise nature of the processes that underlie genetic interactions requires a knowledge of the biochemical properties of the protein products of the genes in question.

Null mutations in any one of the zygotic neurogenic loci -- Notch (N), Delta (Dl), mastermind (mam), Enhancer of Split (E(spl), neuralized (neu), and big brain (bib) --result in hypertrophy of the nervous system at the expense of ventral and lateral epidermal structures. This effect is due to the misrouting of epidermal precursor cells into a neuronal pathway, and implies that neurogenic gene function is necessary to divert cells within the neurogenic region from a neuronal fate to an

epithelial fate. Studies that assessed the effects of laser ablation of specific embryonic neuroblasts in grasshoppers (Doe and Goodman 1985, Dev. Biol. 111, 206-219) have shown that cellular interactions between neuroblasts and the surrounding accessory cells serve to inhibit these accessory cells from adopting a neuroblast fate. Together, these genetic and developmental observations have led to the hypothesis that the protein products of the neurogenic loci function as components of a cellular interaction mechanism necessary for proper epidermal development (Artavanis-Tsakonas, 1988, Trends Genet. 4, 95-100).

Sequence analyses (Wharton et al., 1985, Cell 43, 567-581; Kidd et al., 1986, Mol. Cell. Biol. 6, 3094-3108; Vassin et al., 1987, EMBO J. 6, 3431-3440; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735) have shown that two of the neurogenic loci, Notch and Delta, appear to encode transmembrane proteins that span the membrane a single time. The Notch gene encodes a ~300 kd protein (we use "Notch" to denote this protein) with a large N-terminal extracellular domain that includes 36 epidermal growth factor (EGF)-like tandem repeats followed by three other cysteine-rich repeats, designated Notch/lin-12 repeats (Wharton et al., 1985, Cell 43, 567-581; Kidd et al., 1986, Mol. Cell Biol. 6, 3094-3108; Yochem et al., 1988, Nature 335, 547-550). Delta encodes a ~100 kd protein (we use "Delta" to denote DLZM, the protein product of the predominant zygotic and maternal transcripts; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735) that has nine EGF-like repeats within its extracellular domain (Vassin et al., 1987, EMBO J. 6, 3431-3440; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735). Although little is known about the functional significance of these repeats, the EGF-like

motif has been found in a variety of proteins, including those involved in the blood clotting cascade (Furie and Furie, 1988, Cell 53, 505-518). In particular, this motif has been found in extracellular proteins such as the blood clotting factors IX and X (Rees et al., 1988, EMBO J. 7, 2053-2061; Furie and Furie, 1988, Cell 53, 505-518), in other Drosophila genes (Knust et al., 1987, EMBO J. 761-766; Rothberg et al., 1988, Cell 55, 1047-1059), and in some cell-surface receptor proteins, such as thrombomodulin (Suzuki et al., 1987, EMBO J. 6, 1891-1897) and LDL receptor (Sudhof et al., 1985, Science 228, 815-822). A protein binding site has been mapped to the EGF repeat domain in thrombomodulin and urokinase (Kurosawa et al., 1988, J. Biol. Chem 263, 5993-5996; Appella et al., 1987, J. Biol. Chem. 262, 4437-4440).

An intriguing array of interactions between Notch and Delta mutations has been described (Vassin, et al., 1985, J. Neurogenet. 2, 291-308; Shepard et al., 1989, Genetics 122, 429-438; Xu et al., 1990, Genes Dev., 4, 464-475). A number of genetic studies (summarized in Alton et al., 1989, Dev. Genet. 10, 261-272) has indicated that the gene dosages of Notch and Delta in relation to one another are crucial for normal development. A 50% reduction in the dose of Delta in a wild-type Notch background causes a broadening of the wing veins creating a "delta" at the base (Lindsley and Grell, 1968, Publication Number 627, Washington, D.C., Carnegie Institute of Washington). A similar phenotype is caused by a 50% increase in the dose of Notch in a wild-type Delta background (a "Confluens" phenotype; Welshons, 1965, Science 150, 1122-1129). This Delta phenotype is partially suppressed by a reduction in the Notch dosage. R cent w rk in our laboratories has shown

that lethal interactions between alleles that correlate with alterations in the EGF-like repeats in Notch can be rescued by reducing the dose of Delta (Xu et al., 1990, Genes Dev. 4, 464-475). Xu et al. (1990, Genes Dev. 4, 464-475) found that null mutations at either Delta or mam suppress lethal interactions between heterozygous combinations of certain Notch alleles, known as the Abruptex (Ax) mutations. Ax alleles are associated with missense mutations within the EGF-like repeats of the Notch extracellular domain (Kelley et al., 1987, Cell 51, 539-548; Hartley et al., 1987, EMBO J. 6, 3407-3417).

Notch is expressed on axonal processes during the outgrowth of embryonic neurons (Johansen et al., 1989, J. Cell Biol. 109, 2427-2440; Kidd et al., 1989, Genes Dev. 3, 1113-1129).

A study has shown that certain Ax alleles of Notch can severely alter axon pathfinding during sensory neural outgrowth in the imaginal discs, although it is not yet known whether aberrant Notch expression in the axon itself or the epithelium along which it grows is responsible for this defect (Palka et al., 1990, Development 109, 167-175).

3. SUMMARY OF THE INVENTION

The present invention relates to nucleotide sequences of the human Notch and Delta genes, and amino acid sequences of their encoded proteins, as well as fragments thereof containing an antigenic determinant or which are functionally active. The invention is also directed to fragments (termed herein "adhesive fragments"), and the sequences thereof, of the proteins ("toporythmic proteins") encoded by toporythmic genes which mediate homotypic or heterotypic binding to toporythmic proteins.

Toporythmic genes, as used herein, refers to the genes Notch, Delta, and Serrate, as well as other members of the Delta/Serrate family which may be identified, e.g., by the methods described in Section 5.3, infra. Analogs and derivatives of the adhesive fragments which retain binding activity are also provided. Antibodies to human Notch and to adhesive fragments are additionally provided.

In specific embodiments, the adhesive fragment of Notch is that fragment comprising the Notch sequence most homologous to Drosophila Notch EGF-like repeats 11 and 12; the adhesive fragment of Delta mediating heterotypic binding is that fragment comprising the sequence most homologous to Drosophila Delta amino acids 1-230; the adhesive fragment of Delta mediating homotypic binding is that fragment comprising the sequence most homologous to Drosophila Delta amino acids 32-230; and the adhesive fragment of Serrate is that fragment comprising the sequence most homologous to Drosophila Serrate amino acids 85-283 or 79-282.

3.1. DEFINITIONS

As used herein, the following terms shall have the meanings indicated:

AA	=	amino acid
EGF	=	epidermal growth factor
ELR	=	EGF-like (homologous) repeat
IC	=	intracellular
PCR	=	polymerase chain reaction

As used herein, underscoring the name of a gene shall indicate the gene, in contrast to its encoded protein product which is indicated by the name of the gene in the absence of any underscoring. For example, "Notch" shall mean the Notch gene, whereas

"Notch" shall indicate the protein product of the Notch gene.

4. DESCRIPTION OF THE FIGURES

Figure 1. Expression Constructs and Experimental Design for Examining Notch-Delta Interactions. S2 cells at log phase growth were transiently transfected with one of the three constructs shown. Notch encoded by the MG11a minigene (a cDNA/genomic chimeric construct: cDNA-derived sequences are represented by stippling, genomically derived sequences by diagonal-hatching (Ramos et al., 1989, Genetics 123, 337-348)) was expressed following insertion into the metallothionein promoter vector pRmHa-3 (Bunch et al., 1988, Nucl. Acids Res. 16, 1043-1061). Delta encoded by the Dl1 cDNA (Kopczynski et al., 1988, Genes Dev. 2, 1723-1735) was expressed after insertion into the same vector. The extracellular Notch (ECN1) variant was derived from a genomic cosmid containing the complete Notch locus (Ramos et al., 1989, Genetics 123, 337-348) by deleting the coding sequence for amino acids 1790-2625 from the intracellular domain (denoted by δ; Wharton et al., 1985, Cell 43, 567-581), leaving 25 membrane-proximal residues from the wild-type sequence fused to a novel 59 amino acid tail (see Experimental Procedures, Section 6.1, infra). This construct was expressed under control of the Notch promoter region. For constructs involving the metallothionein vector, expression was induced with $CuSO_4$ following transfection. Cells were then mixed, incubated under aggregation conditions, and scored for their ability to aggregate using specific antisera and immunofluorescence microscopy to visualize expressing cells. MT, metallothionein promoter; ATG, translation

start site; TM, transmembrane domain; 3' N, Notch gene polyadenylation signal; 3' Adh, polyadenylation signal from Adh gene; 5' N, Notch gene promoter region.

Figure 2. Expression of Notch and Delta in Cultured Cells. (A) Lysates of nontransfected (S2) and Notch-transfected (N) cells induced with 0.7 mM $CuSO_4$ for 12-16 hr were prepared for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), run on 3%-15% gradient gels, and blotted to nitrocellulose. Notch was visualized using a monoclonal antibody (MAb C17.9C6) against the intracellular domain of Notch. Multiple bands below the major band at 300 kd may represent degradation products of Notch. (B) Lysates of nontransfected (S2) and Delta-transfected (Dl) cells visualized with a monoclonal antibody (MAb 201) against Delta. A single band of ~105 kd is detected. In both cases, there is no detectable endogenous Notch or Delta in the S2 cell line nor are there cross-reactive species. In each lane, 10 μl of sample (prepared as described in Experimental Procedures) was loaded.

Figure 3. S2 Cells That Express Notch and Delta Form Aggregates. In all panels, Notch is shown in green and Delta in red.

(A) A single Notch$^+$ cell. Note the prominent intracellular stain, including vesicular structures as well as an obviously unstained nucleus.

(A) Bright-field micrograph of same field, showing specificity of antibody staining.

(B) A single Delta$^+$ cell. Staining is primarily at the cell surface.

(B) Bright-field micrograph of same field.

(C) Aggregate of Delta$^+$ cells from a 24 hr aggregation experiment. Note against that staining is primarily at the cell surface.

(D)-(F) An aggregate of Notch$^+$ and Delta$^+$ cells formed from a 1:1 mixture of singly transfected cell populations that was allowed to aggregate overnight at room temperature. (D) shows Notch$^+$ cells in this aggregate; (E) shows Delta$^+$ cells; and (F) is a double exposure showing both cell types. Bands of Notch and Delta are prominent at points of contact between Notch$^+$ and Delta$^+$ cells (arrows). In (F), these bands appear yellow because of the coincidence of green and red at these points. The apparently doubly stained single cell (*) is actually two cells (one on top of the other), one expressing Notch and the other Delta.

(G) and (H) Pseudocolor confocal micrographs of Notch$^+$-Delta$^+$ cell aggregates. Note that in (G) extensions (arrows) formed by at least two Delta$^+$ cells completely encircle the Notch$^+$ cell in the center of the aggregate. (H) shows an aggregate formed from a 2 hr aggregation experiment performed at 4°C. Intense bands of Notch are apparent within regions of contact with Delta$^+$ cells.

(I) An aggregate composed of Delta$^+$ cells and cells that express only the extracellular domain of Notch (ECN1 construct). Scale bar = 10 μm.

Figure 4. Notch and Delta are Associated in Cotransfected Cells. Staining for Notch is shown in the left column (A, C, and E) and that for Delta is shown in the right column (B, D, and F).

(A) and (B) S2 cell cotransfected with both Notch and Delta constructs. In general, there was a good correlation between Notch and Delta localization at the cell surface (arrows).

(C) and (D) Cotransfected cells were exposed to polyclonal anti-Notch antiserum (a 1:250 dilution of each anti-extracellular domain antiserum) for 1 hr at room temperature before fixation and staining with specific antisera. Note punctate staining of Notch and Delta and the correlation of their respective staining (arrows).

(E) and (F) Cells cotransfected with the extracellular Notch (ECN1) and Delta constructs, induced, and then patched using anti-Notch polyclonal antisera. There was a close correlation between ECN1 and Delta staining at the surface as observed for full-length Notch. Scale bar = 10 μm.

Figure 5. Coimmunoprecipitation Shows that Delta and Notch are Associated in Lysates from Transfected S2 and Drosophila Embryonic Cells. In all experiments, Delta was precipitated from NP-40/deoxycholate lysates using a polyclonal anti-Delta rat antiserum precipitated with fixed Staph A cells, and proteins in the precipitated fraction were visualized on Western blots (for details, see Experimental Procedures). Lanes 1, 2, 3, and 5: Notch visualized with MAb C17.9C6; Lanes 4 and 6: Delta visualized using MAb 201.

In (A), lanes 1 and 2 are controls for these experiments. Lane 1 shows a polyclonal anti-Delta immunoprecipitation from cells that express Notch alone visualized for Notch. No Notch was detectable in this sample, indicating that the polyclonal anti-Delta does not cross-react with Notch. Lane 2 shows Notch-Delta cotransfected cells immunoprecipitated with Staph A without initial treatment with anti-Delta antiserum and visualized for Notch, demonstrating that Notch is not precipitated nonspecifically by the Staph A or secondary antibody. Lane 3 shows protein

precipitated with anti-Delta antiserum visualized for Delta (Dl), and lane 4 shows the same sample visualized for Notch (N). Lane 4 shows that Notch coprecipitates with immunoprecipitated Delta. Note that Notch appears as a doublet as is typical for Notch in immunoprecipitates.

(B) shows the same experiment using embryonic lysates rather than transfected cell lysates. Lane 5 shows protein precipitated with anti-Delta antiserum visualized for Delta (Dl), and lane 6 shows the same sample visualized for Notch (N). These lanes demonstrate that Notch and Delta are stably associated in embryo lysates. Bands (in all lanes) below the Delta band are from Staph A (SA) and the anti-Delta antiserum heavy (H) and light (L) chains.

Figure 6. Notch Expression Constructs and the Deletion Mapping of the Delta/Serrate Binding Domain. S2 cells in log phase growth were transiently transfected with the series of expression constructs shown; the drawings represent the predicted protein products of the various Notch deletion mutants created. All expression constructs were derived from construct #1 pMtNMg. Transiently transfected cells were mixed with Delta expressing cells from the stably transformed line L49-6-7 or with transiently transfected Serrate expressing cells, induced with $CuSO_4$, incubated under aggregation conditions and then scored for their ability to aggregate using specific antisera and immunofluorescence microscopy. Aggregates were defined as clusters of four or more cells containing both Notch and Delta/Serrate expressing cells. The values given for % Aggregation refer to the percentage of all Notch expressing cells found in such clusters either with Delta (Dl) (left column) or with Serrate (Ser) (right column). The

various Notch deletion constructs ar represented diagrammatically with splice lines indicating the ligation junctions. Each EGF repeat is denoted as a stippled rectangular box and numbers of the EGF repeats on either side of a ligation junction are noted. At the ligation junctions, partial EGF repeats produced by the various deletions are denoted by open boxes and closed brackets (for example see #23 ΔCla+EGF(10-12)). Constructs #3-13 represent the ClaI deletion series. As diagrammed, four of the ClaI sites, in repeats 7, 9, 17 and 26, break the repeat in the middle, immediately after the third cysteine (denoted by open box repeats; see Figure 7 for further clarification), while the fifth and most 3' site breaks neatly between EGF repeats 30 and 31 (denoted by closed box repeat 31; again see Figure 7). In construct #15 split, EGF repeat 14 which carries the split point mutation, is drawn as a striped box. In construct #33 ΔCla+XEGF(10-13), the Xenopus Notch derived EGF repeats are distinguished from Drosophila repeats by a different pattern of shading. SP, signal peptide; EGF, epidermal growth factor repeat; N, Notch/lin-12 repeat; TM, transmembrane domain; cdc10, cdc10/ankyrin repeats; PA, putative nucleotide binding consensus sequence; opa, polyglutamine stretch termed opa; Dl, Delta; Ser, Serrate.

Figure 7. Detailed Structure of Notch Deletion Constructs #19-24: Both EGF Repeats 11 and 12 are Required for Notch-Delta Aggregation. EGF repeats 10-13 are diagrammed at the top showing the regular spacing of the six cysteine residues (C). PCR products generated for these constructs (names and numbers as given in Figure 6) are represented by the heavy black lines and the exact endpoints are noted relative to the various EGF repeats. Ability to

aggregate with Delta is recorded as (+) or (-) for each construct. The PCR fragments either break the EGF repeats in the middle, just after the third cysteine in the same place as four out of the five ClaI sites, or exactly in between two repeats in the same place as the most C-terminal ClaI site.

Figure 8. Comparison of Amino Acid Sequence of EGF Repeats 11 and 12 from Drosophila and Xenopus Notch. The amino acid sequence of EGF repeats 11 and 12 of Drosophila Notch (Wharton et al., 1985, Cell 43:567-581; Kidd et al., 1986, Mol. Cell Biol. 6:3094-3108) is aligned with that of the same two EGF repeats from Xenopus Notch (Coffman et al., 1990, Science 249:1438-1441). Identical amino acids are boxed. The six conserved cysteine residues of each EGF repeat and the Ca^{++} binding consensus residues (Rees et al., 1988, EMBO J. 7:2053-2061) are marked with an asterisk (*). The leucine to proline change found in the Xenopus PCR clone that failed to aggregate is noted underneath.

Figure 9. Constructs Employed in this Study. Schematic diagrams of the Delta variants defined in Table IV are shown. Extracellular, amino-proximal terminus is to the left in each case. S, signal peptide; "EGF", EGF-like motifs; M, membrane-spanning helix; H, stop-transfer sequence; solid lines, other Delta sequences; hatched lines, neuroglian sequences. Arrowheads indicate sites of translatable linker insertions. Sca, ScaI; Nae, NaeI; Bam, BamHI; Bgl, BglII; ELR, EGF-like repeat; Bst, BstEII; Dde, DdeI; Stu, StuI; NG1-NG5, Delta-neuroglian chimeras.

Figure 9A. Dependence of Aggregation on Input DNA Amounts. A, Heterotypic aggregation observed using S2 cell populations transiently

transfected, respectively, with varied amounts of pMTD11 DNA (2, 4, 10 or 20 μg/plate) that were subsequently incubated under aggregation conditions with S2 cell populations transiently transfected with a constant amount of pMtNMg DNA (20 μg/plate). Data presented are mean fraction (%) of Delta cells in aggregates of four or more cells ± standard error for each input DNA amount (N = 3 replicates, except 2 μg and 10 μg inputs for which N = 2). A minimum of 100 Delta-expressing cells were counted for each replicate. B, Homotypic aggregation observed using S2 cell populations transiently transfected, respectively, with varied amounts of pMTD11 DNA (2, 4, 10 or 20 μg/plate) that were subsequently incubated under aggregation conditions. Data presented are mean fraction (%) of Delta cells in aggregates of four or more cells ± standard error for each input DNA amount (N = 3 replicates). A minimum of 500 Delta-expressing cells were counted for each replicate.

Figure 10. Delta-Serrate Amino-Terminal Sequence Alignment. Residues are numbered on the basis of conceptual translation of Delta (D1, upper sequence (SEQ ID NO:3); beginning at amino acid 24, ending at amino acid 226) and Serrate (Ser, lower sequence (SEQ ID NO:4); beginning at amino acid 85, ending at amino acid 283) coding sequences. Vertical lines between the two sequences indicates residues that are identical within the Delta and Serrate sequences, as aligned. Dots represent gaps in the alignment. Boxes enclose cysteine residues within the aligned regions. N1, amino-proximal domain 1; N2, amino-proximal domain 2; N3, amino-proximal domain 3. Translatable insertions associated with STU B [replacement of Delta amino acid 132 (A) with GKIFP] and NAE B [insertion of RKIF between Delta amino acid

197 and amin acid 198] constructs, respectively, are depicted above the wild type Delta sequence.

Figure 11. Potential Geometries of Delta-Notch Interactions. A, Potential register of Delta (left) and Notch (right) molecules interacting between opposing plasma membranes. B, Potential register of Delta (left) and Notch (right) molecules interacting within the same plasma membranes. ELR, EGF-like repeat; open boxes, EGF-like repeats; dotted boxes, LNR repeats; solid boxes, membrane-spanning helices. Delta amino-terminal domain and Delta and Notch intracellular domains represented by ovals.

Figure 12. Potential Geometries of Delta-Delta Interactions. A and B, Potential register of Delta molecules interacting between opposing plasma membranes. B, Potential register of Delta molecules interacting within the same plasma membranes. Open boxes, EGF-like repeats; solid boxes, membrane-spanning helices. Delta amino-terminal extracellular and intracellular domains represented by ovals.

Figure 13. Primary Nucleotide Sequence of the Delta cDNA Dl1 (SEQ ID NO:5) and Delta amino acid sequence (SEQ ID NO:6) The DNA sequence of the 5'-3' strand of the Dl1 cDNA is shown, which contains a number of corrections in comparison to that presented in Kopczynksi et al. (1988, Genes Dev. 2, 1723-1735).

Figure 14. Primary Nucleotide Sequence of the Neuroglian cDNA 1B7A-250 (SEQ ID NO:7). This is the DNA sequence of a portion of the 5'-3' strand of the 1B7A-250 cDNA (A.J. Bieber, pers. comm.; Hortsch et al., 1990, Neuron 4, 697-709). Nucleotide 2890 corresponds to the first nucleotide of an isoleucine codon that encodes amino acid 952 of the conceptually translated neuroglian-long form protein.

Figure 15. Nucleic Acid Sequence Homologies Between Serrate and Delta. A portion of the Drosophila Serrate nucleotide sequence (SEQ ID NO:8), with the encoded Serrate protein sequence (SEQ ID NO:9) written below, (Fleming et al., 1990, Genes & Dev. 4, 2188-2201 at 2193-94) is shown. The four regions showing high sequence homology with the Drosophila Delta sequence are numbered above the line and indicated by brackets. The total region of homology spans nucleotide numbers 627 through 1290 of the Serrate nucleotide sequence (numbering as in Figure 4 of Fleming et al., 1990, Genes & Dev. 4, 2188-2201).

Figure 16. Primers used for PCR in the Cloning of Human Notch. The sequence of three primers used for PCR to amplify DNA in a human fetal brain cDNA library are shown. The three primers, cdc1 (SEQ ID NO:10), cdc2 (SEQ ID NO:11), and cdc3 (SEQ ID NO:12), were designed to amplify either a 200 bp or a 400 bp fragment as primer pairs cdc1/cdc2 or cdc1/cdc3, respectively. I: inosine.

Figure 17. Schematic Diagram of Human Notch Clones. A schematic diagram of human Notch is shown. Heavy bold-face lines below the diagram show that portion of the Notch sequence contained in each of the four cDNA clones. The location of the primers used in PCR, and their orientation, are indicated by arrows.

Figure 18. Human Notch Sequences Aligned with Drosophila Notch Sequence. Numbered vertical lines correspond to Drosophila Notch coordinates. Horizontal lines below each map show where clones lie relative to stretches of sequence (thick horizontal lines).

Figure 19. Nucleotide Sequences of Human Notch Contained in Plasmid cDNA Clone hN2k. Figure

19A: The DNA sequenc (SEQ ID NO:13) of a portion of the human Notch insert is shown, starting at the EcoRI site at the 3' end, and proceeding in the 3' to 5' direction. Figure 19B: The DNA sequence (SEQ ID NO:14) of a portion of the human Notch insert is shown, starting at the EcoRI site at the 5' end, and proceeding in the 5' to 3' direction. Figure 19C: The DNA sequence (SEQ ID NO:15) of a portion of the human Notch insert is shown, starting 3' of the sequence shown in Figure 19B, and proceeding in the 5' to 3' direction. The sequences shown are tentative, subject to confirmation by determination of overlapping sequences.

Figure 20. Nucleotide Sequences of Human Notch Contained in Plasmid cDNA clone hN3k. Figure 20A: The DNA sequence (SEQ ID NO:16) of a portion of the human Notch insert is shown, starting at the EcoRI site at the 3' end, and proceeding in the 3' to 5' direction. Figure 20B: The DNA sequence (SEQ ID NO:17) of a portion of the human Notch insert is shown, starting at the EcoRI site at the 5' end, and proceeding in the 5' to 3' direction. Figure 20C: The DNA sequence (SEQ ID NO:18) of a portion of the human Notch insert is shown, starting 3' of the sequence shown in Figure 20B, and proceeding in the 5' to 3' direction. Figure 20D: The DNA sequence (SEQ ID NO:19) of a portion of the human Notch insert is shown, starting 5' of the sequence shown in Figure 20A, and proceeding in the 3' to 5' direction. The sequences shown are tentative, subject to confirmation by determination of overlapping sequences.

Figure 21. Nucleotide Sequences of Human Notch Contained in Plasmid cDNA clone hN4k. Figure 21A: The DNA sequence (SEQ ID NO:20) of a portion of the human Notch insert is shown, starting at the EcoRI

site at the 5' end, and proceeding in the 5' to 3' direction. Figure 21B: The DNA sequence (SEQ ID NO:21) of a portion of the human Notch insert is shown, starting near the 3' end, and proceeding in the 3' to 5' direction. The sequences shown are tentative, subject to confirmation by determination of overlapping sequences.

Figure 22. Nucleotide Sequences of Human Notch Contained in Plasmid cDNA Clone hN5k. Figure 22A: The DNA sequence (SEQ ID NO:22) of a portion of the human Notch insert is shown, starting at the EcoRI site at the 5' end, and proceeding in the 5' to 3' direction. Figure 22B: The DNA sequence (SEQ ID NO:23) of a portion of the human Notch insert is shown, starting near the 3' end, and proceeding in the 3' to 5' direction. Figure 22C: The DNA sequence (SEQ ID NO:24) of a portion of the human Notch insert is shown, starting 3' of the sequence shown in Figure 22A, and proceeding in the 5' to 3' direction. Figure 22D: The DNA sequence (SEQ ID NO:25) of a portion of the human Notch insert is shown, starting 5' of the sequence shown in Figure 22B, and proceeding in the 3' to 5' direction. The sequences shown are tentative, subject to confirmation by determination of overlapping sequences.

Figure 23. DNA (SEQ ID NO:31) and Amino Acid (SEQ ID NO:34) Sequences of Human Notch Contained in Plasmid cDNA Clone hN3k.

Figure 24. DNA (SEQ ID NO:33) and Amino Acid (SEQ ID NO:34) Sequences of Human Notch Contained in Plasmid cDNA Clone hN5k.

Figure 25. Comparison of hN5k With Other Notch Homologs. Figure 25A. Schematic representation of Drosophila Notch. Indicated are the signal sequence (signal), the 36 EGF-like repeats, the three

Notch/lin-12 repeats, the transmembran domain (TM), the six CDC10 repeats, the OPA repeat, and the PEST (proline, glutamic acid, serine, threonine)-rich region. Figure 25B. Alignment of the deduced amino acid sequence of hN5k with sequences of other Notch homologs. Amino acids are numbered on the left side. The cdc10 and PEST-rich regions are both boxed, and individual cdc10 repeats are marked. Amino acids which are identical in three or more sequences are highlighted. The primers used to clone hN5k are indicated below the sequences from which they were designed. The nuclear localization sequence (NLS), casein kinase II (CKII), and cdc2 kinase (cdc2) sites of the putative CcN motif of the vertebrate Notch homologs are boxed. The possible bipartite nuclear targeting sequence (BNTS) and proximal phosphorylation sites of Drosophila Notch are also boxed.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to nucleotide sequences of the human Notch and Delta genes, and amino acid sequences of their encoded proteins. The invention further relates to fragments (termed herein "adhesive fragments") of the proteins encoded by toporythmic genes which mediate homotypic or heterotypic binding to toporythmic proteins or adhesive fragments thereof. Toporythmic genes, as used herein, shall mean the genes Notch, Delta, and Serrate, as well as other members of the Delta/Serrate family which may be identified, e.g. by the methods described in Section 5.3, infra.

The nucleic acid and amino acid sequences and antibodies thereto of the invention can be used for the detection and quantitation of mRNA for human Notch and Delta and adhesive molecules, to study

expression thereof, to produce human Notch and Delta and adhesive sequences, in the study and manipulation of differentiation processes.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention will be divided into the following sub-sections:

(i) Identification of and the sequences of toporythmic protein domains that mediate binding to toporythmic protein domains;

(ii) The cloning and sequencing of human Notch and Delta;

(iii) Identification of additional members of the Delta/Serrate family;

(iv) The expression of toporythmic genes;

(v) Identification and purification of the expressed gene product; and

(vi) Generation of antibodies to toporythmic proteins and adhesive sequences thereof.

5.1. IDENTIFICATION OF AND THE SEQUENCES OF TOPORYTHMIC PROTEIN DOMAINS THAT MEDIATE BINDING TO TOPORYTHMIC PROTEIN DOMAINS

The invention provides for toporythmic protein fragments, and analogs or derivatives thereof, which mediate homotypic or heterotypic binding (and thus are termed herein "adhesive"), and nucleic acid sequences relating to the foregoing.

In a specific embodiment, the adhesive fragment of Notch is that comprising the portion of Notch most homologous to ELR 11 and 12, i.e., amino acid numbers 447 through 527 (SEQ ID NO:1) of the Drosophila Notch sequence (see Figure 8). In another specific embodiment, the adhesive fragment of Delta mediating homotypic binding is that comprising the

portion of Delta most homologous to about amino acid numbers 32-230 of the Drosophila Delta sequence (SEQ ID NO:6). In yet another specific embodiment, the adhesive fragment of Delta mediating binding to Notch is that comprising the portion of Delta most homologous to about amino acid numbers 1-230 of the Drosophila Delta sequence (SEQ ID NO:6). In a specific embodiment relating to an adhesive fragment of Serrate, such fragment is that comprising the portion of Serrate most homologous to about amino acid numbers 85-283 or 79-282 of the Drosophila Serrate sequence (see Figure 10 (SEQ ID NO:4), and Figure 15 (SEQ ID NO:9)).

The nucleic acid sequences encoding toporythmic adhesive domains can be isolated from porcine, bovine, feline, avian, equine, or canine, as well as primate sources and any other species in which homologs of known toporythmic genes [including but not limited to the following genes (with the publication of sequences in parentheses): Notch (Wharton et al., 1985, Cell 43, 567-581), Delta (Vassin et al., 1987, EMBO J. 6, 3431-3440; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735; note corrections to the Kopczynski et al. sequence found in Figure 13 hereof (SEQ ID NO:5 and SEQ ID NO:6)) and Serrate (Fleming et al., 1990, Genes & Dev. 4, 2188-2201)] can be identified. Such sequences can be altered by substitutions, additions or deletions that provide for functionally equivalent (adhesive) molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as the adhesive sequences may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of the Notch, Delta, or Serrate genes which

are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the adhesive protein fragments or derivatives thereof, of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of the adhesive domains including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Adhesive fragments of toporythmic proteins and potential derivatives, analogs or peptides related to adhesive toporythmic protein sequences, can be tested for the desired binding activity e.g., by the in vitro aggregation assays described in the examples herein. Adhesive derivatives or adhesive analogs of adhesive fragments of toporythmic proteins include but are not limited to those peptides which are substantially homologous to the adhesive fragments, or

wh se encoding nucleic acid is capable of hybridizing to the nucleic acid sequence encoding the adhesive fragments, and which peptides and peptide analogs have positive binding activity e.g., as tested in vitro by an aggregation assay such as described in the examples sections infra. Such derivatives and analogs are envisioned and within the scope of the present invention.

The adhesive-protein related derivatives, analogs, and peptides of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned adhesive protein-encoding gene sequence can be modified by any of numerous strategies known in the art (Maniatis, T., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated in vitro. In the production of the gene encoding a derivative, analog, or peptide related to an adhesive domain, care should be taken to ensure that the modified gene remains within the same translational reading frame as the adhesive protein, uninterrupted by translational stop signals, in the gene region where the desired adhesive activity is encoded.

Additionally, the adhesive-encoding nucleic acid sequence can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to

facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem 253, 6551), use of TAB® linkers (Pharmacia), etc.

Manipulations of the adhesive sequence may also be made at the protein level. Included within the scope of the invention are toporythmic protein fragments, analogs or derivatives which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, $NaBH_4$; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

In addition, analogs and peptides related to adhesive fragments can be chemically synthesized. For example, a peptide corresponding to a portion of a toporythmic protein which mediates the desired aggregation activity in vitro can be synthesized by use of a peptide synthesizer.

Another specific embodiment of the invention relates to fragments or derivatives of a Delta protein which have the ability to bind to a second Delta protein or fragment or derivative thereof, but do not bind to Notch. Such binding or lack thereof can be assayed in vitro as described in Section 8. By way of example, but not limitation, such a Delta derivative is that containing an insertion of the tetrapeptide

Arg-Lys-Ile-Phe between Delta residues 198 and 199 of the Drosophila protein.

5.2. THE CLONING AND SEQUENCING OF HUMAN NOTCH AND DELTA

The invention further relates to the amino acid sequences of human Notch and human Delta and fragments and derivatives thereof which comprise an antigenic determinant (i.e., can be recognized by an antibody) or which are functionally active, as well as nucleic acid sequences encoding the foregoing. "Functionally active" material as used herein refers to that material displaying one or more known functional activities associated with the full-length (wild-type) protein product, e.g., in the case of Notch, binding to Delta, binding to Serrate, antigenicity (binding to an anti-Notch antibody), etc.

In specific embodiments, the invention provides fragments of a human Notch protein consisting of at least 40 amino acids, or of at least 77 amino acids. In other embodiments, the proteins of the invention comprise or consist essentially of the intracellular domain, transmembrane region, extracellular domain, cdc10 region, Notch/lin-12 repeats, or the EGF-homologous repeats, or any combination of the foregoing, of a human Notch protein. Fragments, or proteins comprising fragments, lacking some or all of the EGF-homologous repeats of human Notch are also provided.

In other specific embodiments, the invention is further directed to the nucleotide sequences and subsequences of human Notch and human Delta consisting of at least 25 nucleotides, at least 50 nucleotides, or at least 121 nucleotides. Nucleic acids encoding the proteins and protein fragments described above are also pr vided, as well as nucleic acids complementary

to and capable of hybridizing to such nucleic acids. In one embodiment, such a complementary sequence may be complementary to a human Notch cDNA sequence of at least 25 nucleotides, or of at least 121 nucleotides. In a preferred aspect, the invention relates to cDNA sequences encoding human Notch or a portion thereof. In a specific embodiment, the invention relates to the nucleotide sequence of the human Notch gene or cDNA, in particular, comprising those sequences depicted in Figures 19, 20, 21 and/or 22 (SEQ ID NO:13 through NO:25), or contained in plasmids hN3k, hN4k, or hN5k (see Section 9, infra), and the encoded Notch protein sequences. As is readily apparent, as used herein, a "nucleic acid encoding a fragment or portion of a Notch protein" shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of the Notch protein and not other portions of the Notch protein.

In a preferred, but not limiting, aspect of the invention, a human Notch DNA sequence can be cloned and sequenced by the method described in Section 9, infra.

A preferred embodiment for the cloning of human Delta, presented as a particular example but not by way of limitation follows:

A human expression library is constructed by methods known in the art. For example, human mRNA is isolated, cDNA is made and ligated into an expression vector (e.g., a bacteriophage derivative) such that it is capable of being expressed by the host cell into which it is then introduced. Various screening assays can then be used to select for the expressed human Delta product. In one embodiment, selection can be carried out on the basis of positive binding to the adhesive domain of human Notch, (i.e., that portion of

human Notch most homologous to Drosophila ELR 11 and 12 (SEQ ID NO:1)). In an alternative embodiment, anti-Delta antibodies can be used for selection.

In another preferred aspect, PCR is used to amplify the desired sequence in the library, prior to selection. For example, oligonucleotide primers representing part of the adhesive domains encoded by a homologue of the desired gene can be used as primers in PCR.

The above-methods are not meant to limit the following general description of methods by which clones of human Notch and Delta may be obtained.

Any human cell can potentially serve as the nucleic acid source for the molecular cloning of the Notch and Delta gene. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired human cell. (See, for example Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNAse in the

presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, if an amount of a portion of a Notch or Delta (of any species) gene or its specific RNA, or a fragment thereof e.g., the adhesive domain, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, Science 196, 180; Grunstein, M. And Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72, 3961). Those DNA fragments with substantial homology to the probe will hybridize. It is also possible to identify the appropriate fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection can be carried out on the basis of the properties of the gene. Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isolectric focusing behavior, proteolytic digestion maps, in vitro aggregation activity ("adhesiveness") or antigenic properties as known for Notch or Delta.

If an antibody to Notch or Delta is available, the Notch or Delta protein may be identified by binding of labeled antibody to the putatively Notch or Delta synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.

The Notch or Delta gene can also be identified by mRNA selection by nucleic acid hybridization followed by in vitro translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified Notch or Delta DNA of another species (e.g., Drosophila). Immunoprecipitation analysis or functional assays (e.g., aggregation ability in vitro; see examples infra) of the in vitro translation products of the isolated products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against Notch or Delta protein. A radiolabelled Notch or Delta cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe to identify the Notch or Delta DNA fragments from among other genomic DNA fragments.

Alternatives to isolating the Notch or Delta genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the Notch or Delta gene. For example, RNA for cDNA cloning of the Notch or Delta gene can be isolated from cells which express Notch or Delta.

Other methods are possible and within the scope of the invention.

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and Notch or Delta gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionization, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated Notch or Delta gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The human Notch and Delta sequences provided by the instant invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in human Notch and in human Delta, and those encoded amino acid sequences with functionally equivalent amino acids, all as described supra in Section 5.1 for adhesive portions of toporythmic proteins.

5.3. IDENTIFICATION OF ADDITIONAL MEMBERS OF THE DELTA/SERRATE FAMILY

A rational search for additional members of the Delta/Serrate gene family may be carried out using an approach that takes advantage of the existence of the conserved segments of strong homology between Serrate and Delta (see Figure 10, SEQ ID NO:3 and NO:4). For example, additional members of this gene family may be identified by selecting, from among a diversity of nucleic acid sequences, those sequences that are homologous to both Serrate and Delta (see Figure 13 (SEQ ID NO:5), and Figure 15 (SEQ ID NO:8)), and further identifying, from among the selected sequences, those that also contain nucleic acid sequences which are non-homologous to Serrate and Delta. The term "non-homologous" may be construed to mean a region which contains at least about 6

contiguous nucleotides in which at least about two nucleotides differ from Serrate and Delta sequence.

For example, a preferred specific embodiment of the invention provides the following method. Corresponding to two conserved segments between Delta and Serrate, Delta AA 63-73 and Delta AA 195-206 (see Figure 13, SEQ ID NO:6), sets of degenerate oligonucleotide probes of about 10-20 nucleotides may be synthesized, representing all of the possible coding sequences for the amino acids found in either Delta and Serrate for about three to seven contiguous codons. In another embodiment, oligonucleotides may be obtained corresponding to parts of the four highly conserved regions between Delta and Serrate shown in Figure 15 (SEQ ID NO:8 and NO:9), i.e., that represented by Serrate AA 124-134, 149-158, 214-219, and 250-259. The synthetic oligonucleotides may be utilized as primers to amplify by PCR sequences from a source (RNA or DNA) of potential interest. (PCR can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp™)). This might include mRNA or cDNA or genomic DNA from any eukaryotic species that could express a polypeptide closely related to Serrate and Delta. By carrying out the PCR reactions, it may be possible to detect a gene or gene product sharing the above-noted segments of conserved sequence between Serrate and Delta. If one chooses to synthesize several different degenerate primers, it may still be possible to carry out a complete search with a reasonably small number of PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the unknown g ne and Serrate or Delta. If a segment of a

previously unknown member of the Serrate/Delta gene family is amplified successfully, that segment may be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit the determination of the unknown gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis. In this fashion, additional genes encoding "adhesive" proteins may be identified.

In addition, the present invention provides for the use of the Serrate/Delta sequence homologies in the design of novel recombinant molecules which are members of the Serrate/Delta gene family but which may not occur in nature. For example, and not by way of limitation, a recombinant molecule can be constructed according to the invention, comprising portions of both Serrate and Delta genes. Such a molecule could exhibit properties associated with both Serrate and Delta and portray a novel profile of biological activities, including agonists as well as antagonists. The primary sequence of Serrate and Delta may also be used to predict tertiary structure of the molecules using computer simulation (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 3824-3828); Serrate/Delta chimeric recombinant genes could be designed in light of correlations between tertiary structure and biological function. Likewise, chimeric genes comprising portions of any one or more members of the toporythmic gene family (e.g., Notch) may be constructed.

5.4. THE EXPRESSION OF TOPORYTHMIC GENES

The nucleotide sequence coding for an adhesive fragment of a toporythmic protein

(preferably, Notch, Serrate, or Delta), or an adhesive analog or derivativ thereof, or human Notch or Delta or a functionally active fragment or derivative thereof, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native toporythmic gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In a specific embodiment, the adhesive portion of the Notch gene, e.g., that encoding EGF-like repeats 11 and 12, is expressed. In another embodiment, the adhesive portion of the Delta gene, e.g., that encoding amino acids 1-230, is expressed. In other specific embodiments, the human Notch or human Delta gene is expressed, or a sequence encoding a functionally active portion of human Notch or Delta. In yet another embodiment, the adhesive portion of the Serrate gene is expressed.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate

transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination).

Expression of nucleic acid sequence encoding a toporythmic protein or peptide fragment may be regulated by a second nucleic acid sequence so that the toporythmic protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a toporythmic protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control toporythmic gene expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290, 304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22, 787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296, 39-42); prokaryotic expression vectors such as the β-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75, 3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80, 21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242, 74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., Nature 303, 209-213). or the cauliflower mosaic virus 35S RNA promoter (Gardner, et al., 1981, Nucl. Acids Res. 9, 2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310, 115-120); promoter elements from yeast or other fungi such as the Gal 4

promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38, 639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50, 399-409; MacDonald, 1987, Hepatology 7, 425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315, 115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38, 647-658; Adames et al., 1985, Nature 318, 533-538; Alexander et al., 1987, Mol. Cell. Biol. 7, 1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45, 485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1, 268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5, 1639-1648; Hammer et al., 1987, Science 235, 53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1, 161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315, 338-340; Kollias et al., 1986, Cell 46, 89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48, 703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314, 283-286), and gonadotropic releasing hormone gene control region which is active

in the hypothalamus (Mason et al., 1986, Science 234, 1372-1378).

Expression vectors containing toporythmic gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted toporythmic gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the toporythmic gene is inserted within the marker gene sequence of the vector, recombinants containing the toporythmic insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the toporythmic gene product in vitro assay systems, e.g., aggregation (adhesive) ability (see Sections 6-8, infra).

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the

expression vectors which can be used include, but are not limited t , the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered toporythmic protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous mammalian toporythmic protein. Furthermore, different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents.

In other specific embodiments, the adhesive toporythmic protein, fragment, analog, or derivative may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined to a heterologous protein sequence). Such a chimeric product can be made by ligating the

appropriate nucleic acid sequ nces encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer.

Both cDNA and genomic sequences can be cloned and expressed.

In other embodiments, a human Notch cDNA sequence may be chromosomally integrated and expressed. Homologous recombination procedures known in the art may be used.

5.4.1. IDENTIFICATION AND PURIFICATION OF THE EXPRESSED GENE PRODUCT

Once a recombinant which expresses the toporythmic gene sequence is identified, the gene product may be analyzed. This can be achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis.

Once the toporythmic protein is identified, it may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay, including, but not limited to, aggregation assays (see Sections 6-8).

5.5. GENERATION OF ANTIBODIES TO TOPORYTHMIC PROTEINS AND ADHESIVE SEQUENCES THEREOF

According to the invention, toporythmic protein fragments or analogs or derivatives thereof

which mediate homotypic or heterotypic binding, or human Notch or human Delta proteins or fragments thereof, may be used as an immunogen to generate anti-toporythmic protein antibodies. Such antibodies can be polyclonal or monoclonal. In a specific embodiment, antibodies specific to EGF-like repeats 11 and 12 of Notch may be prepared. In other embodiments, antibodies reactive with the "adhesive portion" of Delta can be generated. One example of such antibodies may prevent aggregation in an in vitro assay. In another embodiment, antibodies specific to human Notch are produced.

Various procedures known in the art may be used for the production of polyclonal antibodies to a toporythmic protein or peptide. In a particular embodiment, rabbit polyclonal antibodies to an epitope of the human Notch protein encoded by a sequence depicted in Figure 19, 20, 21 or 22 (SEQ ID NO:13 through NO:25), or a subsequence thereof, can be obtained. For the production of antibody, various host animals can be immunized by injection with the native toporythmic protein, or a synthetic version, or fragment thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhold limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.

For preparation of monoclonal antibodies directed toward a toporythmic protein sequence, any

technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256, 495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4, 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the $F(ab')_2$ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay). For example, to select antibodies which recognize the adhesive domain of a toporythmic protein, one may assay generated hybridomas for a product which binds to a protein fragment containing such domain. For selection of an antibody specific to human Notch, one can select on the basis of positive binding to human Notch and a lack of binding to Drosophila Notch.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the protein sequences of the invention. For example, various immunoassays known in the art can be used, including but not limited to

competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, fluorescent immunoassays, protein A immunoassays, and immunoelectrophoresis assays, to name but a few.

5.6. DELIVERY OF AGENTS INTO NOTCH-EXPRESSING CELLS

The invention also provides methods for delivery of agents into Notch-expressing cells. As discussed in Section 8 infra, upon binding to a Notch protein on the surface of a Notch-expressing cell, Delta protein appears to be taken up into the Notch-expressing cell. The invention thus provides for delivery of agents into a Notch-expressing cell by conjugation of an agent to a Delta protein or an adhesive fragment or derivative thereof capable of binding to Notch, and exposing a Notch-expressing cell to the conjugate, such that the conjugate is taken up by the cell. The conjugated agent can be, but is not limited to, a label or a biologically active agent. The biologically active agent can be a therapeutic agent, a toxin, a chemotherapeutic, a growth factor, an enzyme, a hormone, a drug, a nucleic acid, (e.g., antisense DNA or RNA), etc. In one embodiment, the label can be an imaging agent, including but not limited to heavy metal contrast agents for x-ray imaging, magnetic resonance imaging agents, and radioactive nuclides (i.e., isotopes) for radio-imaging. In a preferred aspect, the agent is conjugated to a site in the amino terminal half of the Delta molecule.

The Delta-agent conjugate can be delivered to the Notch-expressing cell by exposing the Notch-expressing cell to cells expressing the Delta-agent conjugate or exposing the Notch-expressing cell to the Delta-agent conjugate in a solution, suspension, or other carrier. Where delivery is in vivo, the Delta-agent conjugate can be formulated in a pharmaceutically acceptable carrier or excipient, to comprise a pharmaceutical composition. The pharmaceutically acceptable carrier can comprise saline, phosphate buffered saline, etc. The Delta-agent conjugate can be formulated as a liquid, tablet, pill, powder, in a slow-release form, in a liposome, etc., and can be administered orally, intravenously, intramuscularly, subcutaneously, intraperitoneally, to name but a few routes, with the preferred choice readily made based on the knowledge of one skilled in the art.

6. MOLECULAR INTERACTIONS BETWEEN THE PROTEIN PRODUCTS OF THE NEUROGENIC LOCI NOTCH AND DELTA, TWO EGF-HOMOLOGOUS GENES IN DROSOPHILA

To examine the possibility of intermolecular association between the products of the Notch and Delta genes, we studied the effects of their expression on aggregation in Drosophila Schneider's 2 (S2) cells (Fehon et al., 1990, Cell 61, 523-534). We present herein direct evidence of intermolecular interactions between Notch and Delta, and describe an assay system that will be used in dissecting the components of this interaction. We show that normally nonadhesive Drosophila S2 cultured cells that express Notch bind specifically to cells that express Delta, and that this aggregation is calcium dependent. Furthermore, while cells that express Notch do n t bind to one another, cells that express Delta do bind

to one another, suggesting that Notch and Delta can compete for binding to Delta at the cell surface. We also present evidence indicating that Notch and Delta form detergent-soluble complexes both in cultured cells and embryonic cells, suggesting that Notch and Delta interact directly at the molecular level in vitro and in vivo. Our analyses suggest that Notch and Delta proteins interact at the cell surface via their extracellular domains.

6.1. EXPERIMENTAL PROCEDURES

6.1.1. EXPRESSION CONSTRUCTS

For the Notch expression construct, the 6 kb HpaI fragment from the 5' end of the Notch coding sequence in MgIIa (Ramos et al., 1989, Genetics 123, 337-348) was blunt-end ligated into the metallothionein promoter vector pRmHa-3 (Bunch, et al., 1988, Nucl. Acids Res. 16, 1043-1061) after the vector had been cut with EcoRI and the ends were filled with the Klenow fragment of DNA polymerase I (Maniatis et al., 1982, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory)). A single transformant, incorrectly oriented, was isolated. DNA from this transformant was then digested with SacI, and a resulting 3 kb fragment was isolated that contained the 5' end of the Notch coding sequence fused to the polylinker from pRmHa-3. This fragment was then ligated into the SacI site of pRmHa-3 in the correct orientation. DNA from this construct was digested with KpnI and XbaI to remove must of the Notch sequence and all of the Adh polyadenylation signal in pRmHa-3 and ligated to an 11 kb KpnI-XbaI fragment from MgIIa containing the rest of the Notch coding sequence and 3' s quences necessary for

polyadenylation. In the resulting construct, designated pMtNMg, the metallothionein promoter in pRmHa-3 is fused to Notch sequences starting 20 nucleotides upstream of the translation start site.

For the extracellular Notch construct (ECN1), the CosP479BE Notch cosmid (Ramos et al., 1989, Genetics 123, 337-348), which contains all Notch genomic sequences necessary for normal Notch function in vivo, was partially digested with AatII. Fragment ends were made blunt using the exonuclease activity of T4 DNA polymerase (Maniatis et al., 1982, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory)), and the fragments were then redigested completely with StuI. The resulting fragments were separated in a low melting temperature agarose gel (SeaPlaque, FMC BioProducts), and the largest fragment was excised. This fragment was then blunt-end ligated to itself. This resulted in an internal deletion of the Notch coding sequences from amino acid 1790 to 2625 inclusive (Wharton et al., 1985, Cell 43, 567-581), and a predicted frameshift that produces a novel 59 amino acid carboxyl terminus. (The ligated junction of this construct has not been checked by sequencing.)

For the Delta expression construct, the Dl1 cDNA (Kopczynski et al., 1988, Genes Dev. 2, 1723-1735), which includes the complete coding capacity for Delta, was inserted into the EcoRI site of pRmHa-3. This construct was called pMTDl1.

6.1.2. ANTIBODY PREPARATION

Hybridoma cell line C17.9C6 was obtained from a mouse immunized with a fusion protein based on a 2.1 kb SalI-HindIII fragment that includes coding sequences for most of the intracellular domain of

Notch (amino acids 1791-2504; Wharton et al., 1985, Cell 43, 567-581). The fragment was subcloned into pUR289 (Ruther and Muller-Hill, 1983, EMBO J. 2, 1791-1794), and then transferred into the pATH 1 expression vector (Dieckmann and Tzagoloff, 1985, J. Biol. Chem. 260, 1513-1520) as a BglII-HindIII fragment. Soluble fusion protein was expressed, precipitated by 25% $(NH_4)_2SO_4$, resuspended in 6 M urea, and purified by preparative isoelectric focusing using a Rotofor (Bio-Rad) (for details, see Fehon, 1989, Rotofor Review No. 7, Bulletin 1518, Richmond, California: Bio-Rad Laboratories).

Mouse polyclonal antisera were raised against the extracellular domain of Notch using four BstYl fragments of 0.8 kb (amino acids 237-501: Wharton et al., 1985, Cell 43, 567-581), 1.1 kb (amino acids 501-868), 0.99 kb (amino acids 868-1200), and 1.4 kb (amino acids 1465-1935) length, which spanned from the fifth EGF-like repeat across the transmembrane domain, singly inserted in-frame into the appropriate pGEX expression vector (Smith and Johnson, 1988, Gene 67, 31-40). Fusion proteins were purified on glutathione-agarose beads (SIGMA). Mouse and rat antisera were precipitated with 50% $(NH_4)_2SO_4$ and resuspended in PBS (150 mM NaCl, 14 mM Na_2HPO_4, 6 mM NaH_2PO_4) with 0.02% NaN_3.

Hybridoma cell line 201 was obtained from a mouse immunized with a fusion protein based on a 0.54 kb ClaI fragment that includes coding sequences from the extracellular domain of Delta (Kopczynski et al., 1988, Genes Dev. 2, 1723-1735) subcloned into the ClaI site within the lacZ gene of pUR 288 (Ruther and Muller-Hill, 1983, EMBO J. 2, 1791-1794). This fragment includes sequences extending from the fourth through the ninth EGF-like repeats in Delta (amino

acids 350-529). Fusion protein was prepared by isolation of inclusion bodies (Gilmer et al., 1982, Proc. Natl. Acad. Sci. USA 79, 2152-2156); inclusion bodies were solubilized in urea (Carroll and Laughon, 1987, in DNA Cloning, Volume III, D.M. Glover, ed. (Oxford: IRL Press), pp. 89-111) before use in immunization.

Rat polyclonal antisera were obtained following immunization with antigen derived from the same fusion protein construct. In this case, fusion protein was prepared by lysis of IPTG-induced cells in SDS-Laemmli buffer (Carroll and Laughon, 1987, in DNA Cloning, Volume III, D.M. Glover, ed. (Oxford: IRL Press), pp. 89-111), separation of proteins by SDS-PAGE, excision of the appropriate band from the gel, and electroelution of antigen from the gel slice for use in immunization (Harlow and Lane, 1988, Antibodies: A Laboratory Manual (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory)).

6.1.3. CELL CULTURE AND TRANSFECTION

The S2 cell line (Schneider, 1972, J. Embryol. Exp. Morph. 27, 353-365) was grown in M3 medium (prepared by Hazleton Co.) supplemented with 2.5 mg/ml Bacto-Peptone (Difco), 1 mg/ml TC Yeastolate (Difco), 11% heat-inactivated fetal calf serum (FCS) (Hyclone), and 100 U/ml penicillin-100 μg/ml streptomycin-0.25 μg/ml fungizone (Hazleton). Cells growing in log phase at ~2 x 10^6 cells/ml were transfected with 20 μg of DNA-calcium phosphate coprecipitate in 1 ml per 5 ml of culture as previously described (Wigler et al., 1979, Proc. Natl. Acad. Sci. USA 78, 1373-1376), with the exception that BES buffer (SIGMA) was used in place of HEPES buffer (Chen and Okayama, 1987, Mol. Cell. Biol. 7, 2745-

2752). After 16-18 hr, cells were transferred to conical centrifuge tubes, pelleted in a clinical centrifuge at full speed for 30 seconds, rinsed once with 1/4 volume of fresh complete medium, resuspended in their original volume of complete medium, and returned to the original flask. Transfected cells were then allowed to recover for 24 hr before induction.

6.1.4. AGGREGATION ASSAYS

Expression of the Notch and Delta metallothionein constructs was induced by the addition of $CuSO_4$ to 0.7 mM. Cells transfected with the ECN1 construct were treated similarly. Two types of aggregation assays were used. In the first assay, a total of 3 ml of cells (5-10 x 10^6 cells/ml) was placed in a 25 ml Erlenmeyer flask and rotated at 40-50 rpm on a rotary shaker for 24-48 hr at room temperature. For these experiments, cells were mixed 1-4 hr after induction began and induction was continued throughout the aggregation period. In the second assay, ~0.6 ml of cells were placed in a 0.6 ml Eppendorf tube (leaving a small bubble) after an overnight induction (12-16 hr) at room temperature and rocked gently for 1-2 hr at 4°C. The antibody inhibition and Ca^{2+} dependence experiments were performed using the latter assay. For Ca^{2+} dependence experiments, cells were first collected and rinsed in balanced saline solution (BSS) with 11% FCS (BSS-FCS; FCS was dialyzed against 0.9% NaCl, 5mM Tris [pH 7.5]) or in Ca^{2+} free BSS-FCS containing 10 mM EGTA (Snow et al., 1989, Cell 59, 313-323) and then resuspended in the same medium at the original volume. For the antibody inhibition experiments, Notch-transfected cells were collected and rinsed in M3 medium and then treated before

aggregation in M3 medium for 1 hr at 4°C with a 1:250 dilution of immune or preimmune sera from each of the four mice immunized with fusion proteins containing segments from the extracellular domain of Notch (see Antibody Preparation above).

6.1.5. IMMUNOFLUORESCENCE

Cells were collected by centrifugation (3000 rpm for 20 seconds in an Eppendorf microcentrifuge) and fixed in 0.6 ml Eppendorf tubes with 0.5 ml of freshly made 2% paraformaldehyde in PBS for 10 min at room temperature. After fixing, cells were collected by centrifugation, rinsed twice in PBS, and stained for 1 hr in primary antibody in PBS with 0.1% saponin (SIGMA) and 1% normal goat serum (Pocono Rabbit Farm, Canadensis, PA). Monoclonal antibody supernatants were diluted 1:10 and mouse or rat sera were diluted 1:1000 for this step. Cells were then rinsed once in PBS and stained for 1 hr in specific secondary antibodies (double-labeling grade goat anti-mouse and goat anti-rat, Jackson Immunoresearch) in PBS-saponin-normal goat serum. After this incubation, cells were rinsed twice in PBS and mounted on slides in 90% glycerol, 10% 1 M Tris (pH 8.0), and 0.5% n-propyl gallate. Cells were viewed under epifluorescence on a Leitz Orthoplan 2 microscope.

Confocal micrographs were taken using the Bio-Rad MRC 500 system connected to a Zeiss Axiovert compound microscope. Images were collected using the BHS and GHS filter sets, aligned using the ALIGN program, and merged using MERGE. Fluorescent bleed-through from the green into the red channel was reduced using the BLEED program (all software provided by Bio-Rad). Photographs were obtained directly from the computer monitor using Kodak Ektar 125 film.

6.1.6. CELL LYSATES, IMMUNOPRECIPITATIONS, AND WESTERN BLOTS

Nondenaturing detergent lysates of tissue culture and wild-type Canton-S embryos were prepared on ice in ~10 cell vol of lysis buffer (300 mM NaCl, 50 mM Tris [pH 8.0], 0.5% NP-40, 0.5% deoxycholate, 1 mM $CaCl_2$, 1 mM $MgCl_2$) with 1 mM phenylmethysulfonyl fluoride (PMSF) and diisopropyl fluorophosphate diluted 1:2500 as protease inhibitors. Lysates were sequentially triturated using 18G, 21G, and 25G needles attached to 1 cc tuberculin syringes and then centrifuged at full speed in a microfuge 10 min at 4°C to remove insoluble material. Immunoprecipitation was performed by adding ~1 μg of antibody (1-2 μl of polyclonal antiserum) to 250-500 μl of cell lysate and incubating for 1 hr at 4°C with agitation. To this mixture, 15 μg of goat anti-mouse antibodies (Jackson Immunoresearch; these antibodies recognize both mouse and rat IgG) were added and allowed to incubate for 1 hr at 4°C with agitation. This was followed by the addition of 100 μl of fixed Staphylococcus aureus (Staph A) bacteria (Zysorbin, Zymed; resuspended according to manufacturer's instructions), which had been collected, washed five times in lysis buffer, and incubated for another hour. Staph A-antibody complexes were then pelleted by centrifugation and washed three times in lysis buffer followed by two 15 min washes in lysis buffer. After being transferred to a new tube, precipitated material was suspended in 50 μl of SDS-PAGE sample buffer, boiled immediately for 10 min, run on 3%-15% gradient gels, blotted to nitrocellulose, and detected using monoclonal antibodies and HRP-conjugated goat anti-mouse secondary antibodies as previously described (Johansen et al., 1989, J. Cell Biol. 109, 2427-2440). For total cellular protein samples used on Western blots

(Figure 2), cells were collected by centrifugation, lysed in 10 cell vol of sample buffer that contained 1 mM PMSF, and boiled immediately.

6.2. RESULTS

6.2.1. THE EXPRESSION OF NOTCH AND DELTA IN CULTURED CELLS

To detect interactions between Notch and Delta, we examined the behavior of cells expressing these proteins on their surfaces using an aggregation assay. We chose the S2 cell line (Schneider, 1972, J. Embryol. Exp. Morph. 27, 353-365) for these studies for several reasons. First, these cells are relatively nonadhesive, grow in suspension, and have been used previously in a similar assay to study fasciclin III function (Snow et al., 1989, Cell 59, 313-323). Second, they are readily transfectable, and an inducible metallothionein promoter vector that has been designed for expression of exogenous genes in Drosophila cultured cells is available (Bunch et al., 1988, Nucl. Acids Res. 16, 1043-1061). Third, S2 cells express an aberrant Notch message and no detectable Notch due to a rearrangement of the 5' end of the Notch coding sequence (see below). These cells also express no detectable Delta (see below).

Schematic drawings of the constructs used are shown in Figure 1 (see Experimental Procedures, Section 6.1, for details). To express Notch in cultured cells, the Notch minigene MG11a, described in Ramos et al. (1989, Genetics 123, 337-348) was inserted into the metallothionein promoter vector pRmHa-3 (Bunch et al., 1988, Nucl. Acids Res. 16, 1043-1061). The Delta expression construct was made by inserting Dl1 cDNA, which contains the entire coding sequence for Delta from the major embryonic Delta transcript (5.4Z; Kopczynski et al., 1988, Genes

Dev. 2, 1723-1735), into the same vector. A third construct, designated ECN1 for "extracellular Notch 1", contains the 5' Notch promoter region and 3' Notch polyadenylation signal together with coding capacity for the extracellular and transmembrane regions of the Notch gene from genomic sequences, but lacks coding sequences for 835 amino acids of the ~1000 amino acid intracellular domain. In addition, due to a predicted frameshift, the remaining 78 carboxy-terminal amino acid residues are replaced by a novel 59 amino acid carboxyterminal tail (see Experimental Procedures).

For all of the experiments described in this paper, expression constructs were transfected into S2 cells and expressed transiently rather than in stable transformants. Expressing cells typically composed 1%-5% of the total cell population, as judged by immunofluorescent staining (data not shown). A Western blot of proteins expressed after transfection is shown in Figure 2. Nontransfected cells do not express detectable levels of Notch or Delta. However, after transfection, proteins of the predicted apparent molecular weights are readily detectable using monoclonal antibodies specific for each of these proteins, respectively. In the case of Notch, multiple bands were apparent in transfected cells below the ~300 kd full-length product. We do not yet know whether these bands represent degradation of Notch during sample preparation or perhaps synthesis or processing intermediates of Notch that are present within cells, but we consistently detect them in samples from transfected cells and from embryos. In addition, we performed immunofluorescent staining of live transfected cells with antibodies specific for the extracellular domains of each protein to test for cell surface expression of these proteins. In each

case we found surface staining as expected for a surface antigen. Taken together, these results clearly show that the Notch and Delta constructs support expression of proteins of the expected sizes and subcellular localization.

6.2.2. CELLS THAT EXPRESS NOTCH AND DELTA AGGREGATE

To test the prediction that Notch and Delta interact, we designed a simple aggregation assay to detect these interactions between proteins expressed on the surface of S2 cells. We reasoned that if Notch and Delta are able to form stable heterotypic complexes at the cell surface, then cells that express these proteins might bind to one another and form aggregates under appropriate conditions. A similar assay system has recently been described for the fasciclin III protein (Snow et al., 1989, Cell 59, 313-323).

S2 cells in log phase growth were separately transfected with either the Notch or Delta metallothionein promoter construct. After induction with $CuSO_4$, transfected cells were mixed in equal numbers and allowed to aggregate overnight at room temperature (for details, see Experimental Procedures, Section 6.1). Alternatively, in some experiments intended to reduce metabolic activity, cells were mixed gently at 4°C for 1-2 hr. To determine whether aggregates had formed, cells were processed for immunofluorescence microscopy using antibodies specific for each gene product and differently labeled fluorescent secondary antibodies. As previously mentioned, expressing cells usually constituted less than 5% of the total cell population because we used transient rather than stable transformants. The remaining cells ither did not express a given protein

or expressed at levels too low for detection by immunofluorescence microscopy. As controls, we performed aggregations with only a single type of transfected cell.

Figure 3 shows representative photomicrographs from aggregation experiments, and Table I presents the results in numerical form. As is apparent from Figure 3C and Table I, while Notch-expressing (Notch$^+$) cells alone do not form aggregates in our assay, Delta-expressing (Delta$^+$) cells do.

TABLE I

PERCENTAGES OF NOTCH$^+$ AND DELTA$^+$ CELLS IN AGGREGATES[a]

	Notch$^+$		Delta$^+$		Notch$^+$-Delta		
	Control Cells[b]	Aggregated Cells[c]	Control Cells[b]	Aggregated Cells[c]	Overall[d]	N Cells[e]	D1 Cells[f]
Experiment 1	0	0	19	37	32	26	42
Experiment 2	-	1	-	40	54	47	79
Experiment 3	0	-	12	-	43	42	44
Experiment 4	5	5	20	-	47	41	59
Experiment 5[g,h]	-	2	-	48	71	66	82
Experiment 6[h]	0	0	13	61	63	60	73

[a] Aggregates defined as clusters of four or more expressing cells. For all values, at least 100 expressing cell units (single cells or cell clusters) were scored. Notch$^+$, Notch-expressing; Delta$^+$, Delta expressing.

[b] Control cells taken directly from transfection flasks without incubation in the aggregation assay.

[c] Control cells after incubation in the aggregation assay.

[d] Combined aggregation data for both Notch$^+$ and Delta$^+$ cells in Notch$^+$-Delta$^+$ aggregates.

[e] Aggregation data for Notch$^+$ cells in Notch$^+$-Delta$^+$ aggregates.

[f] Aggregation data for Delta$^+$ cells in Notch$^+$-Delta$^+$ aggregates.

[g] Cells from this experiment from same transfection as Experiment 4.

[h] Data from 48 hr aggregation experiments. All other data are from 24 hr aggregation experiments.

The tendency for Delta$^+$ cells to aggregate was apparent even in nonaggregated control samples (Table I), where cell clusters of 4-8 cells that probably arose from adherence between mitotic sister cells commonly occurred. However, clusters were more common after incubation under aggregation conditions (e.g., 19% of Delta$^+$ cells in aggregates before incubation vs. 37% of Delta$^+$ cells in aggregates after incubation; Experiment 1 in Table I), indicating that Delta$^+$ cells are able to form stable contacts with one another in this assay. It is important to note that while nonstaining cells constituted over 90% of the cells in our transient transfections, we never found them within aggregates. On rare occasions, nonstaining cells were found at the edge of an aggregate. Due to the common occurrence of weakly staining cells at the edges of aggregates, it is likely that these apparently nonexpressing cells were transfected but expressed levels of Delta insufficient to be detected by immunofluorescence.

In remarkable contrast to control experiments with Notch$^+$ cells alone, aggregation of mixtures of Notch$^+$ and Delta$^+$ cells resulted in the formation of clusters of up to 20 or more cells (Figures 3D-3H, Table I). As Table I shows, the fraction of expressing cells found in clusters of four or more stained cells after 24 hr of aggregation ranged from 32%-54% in mixtures of Notch$^+$ and Delta$^+$ cells. This range was similar to that seen for Delta$^+$ cells alone (37%-40%) but very different from that for Notch$^+$ cells alone (only 0%-5%). Although a few clusters that consisted only of Delta$^+$ cells were found, Notch$^+$ cells were never found in clusters of greater than four to five cells unless Delta$^+$ cells were also present. Again, all cells within these

clusters expressed either Notch or Delta, even though transfected cells composed only a small fraction of the total cell population. At 48 hr (Table I, experiments 5 and 6), the degree of aggregation appeared higher (63%-71%), suggesting that aggregation had not yet reached a maximum after 24 hr under these conditions. Also, cells cotransfected with Notch and Delta constructs (so that all transfected cells express both proteins) aggregated in a similar fashion under the same experimental conditions.

These results indicate that the aggregation observed in these experiments requires the expression of Notch and Delta and is not due to the fortuitous expression of another interacting protein in nontransfected S2 cells. We further tested the specificity of this interaction by diluting $Notch^+$ and $Delta^+$ cells 10-fold with nontransfected S2 cells and allowing them to aggregate for 24 hr at room temperature. In this experiment, 39% of the expressing cells were found in aggregates with other expressing cells, although they composed less than 0.1% of the total cell population. Not surprisingly, however, these aggregates were smaller on average than those found in standard aggregation experiments. In addition, to control for the possibility that $Notch^+$ cells are nonspecifically recruited into the $Delta^+$ aggregates because they overexpress a single type of protein on the cell surface, we mixed $Delta^+$ cells with cells that expressed neuroglian, a transmembrane cell-surface protein (Bieber et al., 1989, Cell 59, 447-460), under the control of the metallothionein promoter (this metallothionein-neuroglian construct was kindly provided by A. Bieber and C. Goodman). We observed no tendency for $neuroglian^+$ cells to adhere to $Delta^+$ aggregates, indicating that Notch-Delta

aggregation is not merely the result of high levels of protein expression on the cell surface.

We also tested directly for Notch involvement in the aggregation process by examining the effect of a mixture of polyclonal antisera directed against fusion proteins that spanned almost the entire extracellular domain of Notch on aggregation (see Experimental Procedures, Section 6.1). To minimize artifacts that might arise due to a metabolic response to patching of surface antigens, antibody treatment and the aggregation assay were performed at 4°C in these experiments. Notch$^+$ cells were incubated with either preimmune or immune mouse sera for 1 hr, Delta$^+$ cells were added, and aggregation was performed for 1-2 hr. While Notch$^+$ cells pretreated with preimmune sera aggregated with Delta$^+$ cells (in one of three experiments, 23% of the Notch$^+$ cells were in Notch$^+$-Delta$^+$ cell aggregates), those treated with immune sera did not (only 2% of Notch$^+$ cells were in aggregates). This result suggests that the extracellular domain of Notch is required for Notch$^+$-Delta$^+$ cell aggregation, although we cannot rule out the possibility that the reduced aggregation was due to inhibitory steric or membrane structure effects resulting from exposure of Notch$^+$ cells to the antiserum.

Three other observations worth noting are apparent in Figure 3. First, while Delta was almost always apparent only at the cell surface (Figures 3B and 3C), Notch staining was always apparent both at the cell surface and intracellularly, frequently associated with vesicular structures (Figure 3A). Second, we consistently noted a morphological difference between Delta$^+$ and Notch$^+$ cells in mixed aggregates that were incubated overnight. Delta$^+$

cells often had long extensions that completely surrounded adjacent Notch$^+$ cells, while Notch$^+$ cells were almost always rounded in appearance without noticeable cytoplasmic extensions (Figure 3G). Third, Notch and Delta often appeared to gather within regions of contact between Notch$^+$ and Delta$^+$ cells, producing a sharp band of immunofluorescent staining (Figures 3D-3F). These bands were readily visible in optical sections viewed on the confocal microscope (Figure 3H), indicating that they were not merely due to a whole-mount artifact. We also observed that these bands formed rapidly (within 2 hr of mixing cells) and at 4°C, indicating that their formation probably did not depend upon cellular metabolism. These observations would be expected if, within regions of cell contact, Notch and Delta bind to one another and therefore become immobilized. This pattern of expression is also consistent with that observed for other proteins that mediate cell aggregation (Takeichi, 1988, Development 102, 639-655; Snow et al., 1989, Cell 59, 313-323).

6.2.3. NOTCH-DELTA-MEDIATED AGGREGATION IS CALCIUM DEPENDENT

Previous studies have suggested that EGF-like repeats that contain a particular consensus sequence may serve as calcium (Ca^{2+}) binding domains (Morita et al., 1984, J. Biol. Chem. 259, 5698-5704; Sugo et al., 1984, J. Biol. Chem. 259, 5705-5710; Rees et al., 1988, EMBO J. 7, 2053-2061; Handford et al., 1990, EMBO J. 9, 475-480). For at least two of these proteins, C and C1, Ca^{2+} binding has further been shown to be a necessary component of their interactions with other proteins (Villiers et al., 1980, FEBS Lett. 117, 289-294; Esmon et al., 1983, J. Biol. Chem. 258, 5548-5553; Johnson, et al., 1983, J. Biol. Chem. 258, 5554-

5560). Many of the EGF-homologous repeats within Notch and most of those within Delta contain the necessary consensus sequence for Ca^{2+} binding (Rees et al., 1988, EMBO J. 7, 2053-2061; Stenflo et al., 1987, Proc. Natl. Acad. Sci. USA 84, 368-372; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735; Handford et al., 1990, EMBO J. 9, 475-480), although it has not yet been determined whether or not these proteins do bind calcium. We therefore tested the ability of expressing cells to aggregate in the presence or absence of Ca^{2+} ions to determine whether there is a Ca^{2+} ion requirement for Notch-Delta aggregation. To minimize possible nonspecific effects due to metabolic responses to the removal of Ca^{2+}, these experiments were performed at 4°C. Control mixtures of $Notch^+$ and $Delta^+$ cells incubated under aggregation conditions in Ca^{2+} -containing medium at 4°C readily formed aggregates (an average of 34% ± 13%, mean ± SD, n = 3; Table II). In contrast, cells mixed in medium that lacked Ca^{2+} ions and contained EGTA formed few aggregates (5% ± 5%). These results clearly demonstrate a dependence of Notch-Delta-mediated aggregation on exogenous Ca^{2+} and are in marked contrast to those recently published for the Drosophila fasciclin III and fasciclin I proteins in S2 cells (Snow et al., 1989, Cell 59, 313-323; Elkins et al., 1990, J. Cell Biol. 110, 1825-1832), which detected no effect of Ca^{2+} ion removal on aggregation mediated by either protein.

TABLE II

EFFECT OF EXOGENOUS Ca^{2+} ON NOTCH$^+$-DELTA$^+$ AGGREGATION[a]

	Without Ca2+ Ions			With Ca^{2+} Ions		
	Overall[b]	N Cells[c]	Dl Cells[d]	Overall[b]	N Cells[c]	Dl Cells[d]
Experiment 1	4	2	5	28	28	27
Experiment 2	12	0	13	53	63	50
Experiment 3	0	0	0	22	28	17

[a] Data presented as percentage of expressing cells found in aggregates (as in Table I).
[b] Combined aggregation data for both Notch$^+$ and Delta$^+$ cells.
[c] Aggregation data for Notch$^+$ cells in Notch$^+$-Delta$^+$ aggregates.
[d] Aggregation data for Delta$^+$ cells in Notch$^+$-Delta$^+$ aggregates.

6.2.4. NOTCH AND DELTA INTERACT WITHIN A SINGLE CELL

We asked whether Notch and Delta are associated within the membrane of one cell that expresses both proteins by examining the distributions of Notch and Delta in cotransfected cells. As shown in Figures 4A and 4B, these two proteins often show very similar distributions at the surface of cotransfected cells. To test whether the observed colocalization was coincidental or represented a stable interaction between Notch and Delta, we treated live cells with an excess of polyclonal anti-Notch antiserum. This treatment resulted in "patching" of Notch on the surface of expressing cells into discrete patches as detected by immunofluorescence. There was a distinct correlation between the distributions of Notch and Delta on the surfaces of these cells after this treatment (Figures 4C and 4D), indicating that these proteins are associated within the membrane. It is important to note that these experiments do not address the question of whether this association is direct or mediated by other components, such as the cytoskeleton. To control for the possibility that Delta is nonspecifically patched in this experiment, we cotransfected cells with Notch and with the previously mentioned neuroglian construct (A. Bieber and C. Goodman, unpublished data) and patched with anti-Notch antisera. In this case there was no apparent correlation between Notch and neuroglian.

6.2.5. INTERACTIONS WITH DELTA DO NOT REQUIRE THE INTRACELLULAR DOMAIN OF NOTCH

In addition to a large extracellular domain that contains EGF-like repeats, Notch has a sizeable intracellular (IC) domain of ~940 amino acids. The IC domain includes a phosphorylation site (Kidd et al.,

1989, Genes Dev. 3, 1113-1129), a putative nucleotide binding domain, a polyglutamine stretch (Wharton et al., 1985, Cell 43, 567-581; Kidd, et al., 1986, Mol. Cell. Biol. 6, 3094-3108), and sequences homologous to the yeast cdc10 gene, which is involved in cell cycle control in yeast (Breeden and Nasmyth, 1987, Nature 329, 651-654). Given the size and structural complexity of this domain, we wondered whether it is required for Notch-Delta interactions. We therefore used a variant Notch construct from which coding sequences for ~835 amino acids of the IC domain, including all of the structural features noted above, had been deleted (leaving 25 membrane-proximal amino acids and a novel 59 amino acid carboxyl terminus; see Experimental Procedures and Figure 1 for details). This construct, designated ECN1, was expressed constitutively under control of the normal Notch promoter in transfected cells at a level lower than that observed for the metallothionein promoter constructs, but still readily detectable by immunofluorescence.

In aggregation assays, cells that expressed the ECN1 construct consistently formed aggregates with Delta$^+$ cells (31% of ECN1-expressing cells were in aggregates in one of three experiments; see also Figure 3I), but not with themselves (only 4% in aggregates), just as we observed for cells that expressed intact Notch. We also observed sharp bands of ECN1 staining within regions of contact with Delta$^+$ cells, again indicating a localization of ECN1 within regions of contact between cells. To test for interactions within the membrane, we repeated the surface antigen co-patching experiments using cells cotransfected with the ECN1 and Delta constructs. As observed for intact Notch, we found that when ECN1 was

patched using polyclonal antisera against the extracellular domain of Notch, ECN1 and Delta colocalized at the cell surface (Figures 4E and 4F). These results demonstrate that the observed interactions between Notch and Delta within the membrane do not require the deleted portion of the IC domain of Notch and are therefore probably mediated by the extracellular domain. However, it is possible that the remaining transmembrane or IC domain sequences in ECN1 are sufficient to mediate interactions within a single cell.

6.2.6. NOTCH AND DELTA FORM DETERGENT-SOLUBLE INTERMOLECULAR COMPLEXES

Together, we take the preceding results to indicate molecular interactions between Notch and Delta present within the same membrane and between these proteins expressed on different cells. As a further test for such interactions, we asked whether these proteins would coprecipitate from nondenaturing detergent extracts of cells that express Notch and Delta. If Notch and Delta form a stable intermolecular complex either between or within cells, then it should be possible to precipitate both proteins from cell extracts using specific antisera directed against one of these proteins. We performed this analysis by immunoprecipitating Delta with polyclonal antisera from NP-40/deoxycholate lysates (see Experimental Procedures) of cells cotransfected with the Notch and Delta constructs that had been allowed to aggregate overnight or of 0-24 hr wild-type embryos. We were unable to perform the converse immunoprecipitates because it was not possible to discern unambiguously a faint Delta band among background Staph A bands. It is important to note that we tested this polyclonal anti-Delta antiserum

for cross-reactivity against Notch in cell lysates (Figure 5A, lane 1) and by immunofluorescence (e.g., compare Figures 3D and 3E) and found none. After repeated washing to remove nonspecifically adhering proteins, we assayed for coprecipitation of Notch using a monoclonal antibody (MAb C17.9C6) against Notch on Western blots.

As Figure 5 shows, we did detect coprecipitation of Notch in Delta immunoprecipitates from cotransfected cells and embryos. However, coprecipitating Notch appeared to be present in much smaller quantities than Delta and was therefore difficult to detect. This disparity is most likely due to the disruption of Notch-Delta complexes during the lysis and washing steps of the procedure. However, it is also possible that this disparity reflects a nonequimolar interaction between Notch and Delta or greatly different affinities of the antisera used to detect these proteins. The fact that immunoprecipitation of Delta results in the coprecipitation of Notch constitutes direct evidence that these two proteins form stable intermolecular complexes in transfected S2 cells and in embryonic cells.

6.3. DISCUSSION

We have studied interactions between the protein products of two of the neurogenic loci, Notch and Delta, in order to understand their cellular functions better. Using an in vitro aggregation assay that employs normally nonadhesive S2 cells, we showed that cells that express Notch and Delta adhere specifically to one another. The specificity of this interaction is apparent from the observation that Notch$^+$-Delta$^+$ cell aggregates rarely contained

nonexpressing cells, even though nonexpressing cells composed the vast majority of the total cell population in these experiments. We propose that this aggregation is mediated by heterotypic binding between the extracellular domains of Notch and Delta present on the surfaces of expressing cells. Consistent with this proposal, we find that antisera directed against the extracellular domain of Notch inhibit Notch-Delta-mediated aggregation, and that the ECN1 Notch variant, which lacks almost all of the Notch intracellular domain, can mediate aggregation with cells that express Delta. We also found that cells that express only Delta aggregate with one another, while those that express only Notch do not. These findings suggest that Delta can participate in a homotypic interaction when present on apposed cell surfaces but that Notch cannot under our assay conditions.

The proposal that Notch and Delta interact at the cell surface is further supported by three lines of evidence. First, we find an intense localization of both proteins within regions of contact which Notch$^+$ and Delta$^+$ cells, implying that Notch and Delta interact directly, even when expressed in different cells. Second, Notch and Delta colocalize on the surface of cells that express both proteins, suggesting that these proteins can interact within the cell membrane. Third, Notch and Delta can be coprecipitated from nondenaturing detergent extracts of cultured cells that express both proteins as well as from extracts of embryonic cells. Together, these results strongly support the hypothesis that Notch and Delta can interact heterotypically when expressed on the surfaces of either the same or different cells.

The underlying basis for the observed genetic interactions between Notch and Delta and between Notch and mam (Xu et al., 1990, Genes Dev. 4, 464-475) may be a dose-sensitive interaction between the proteins encoded by these genes.

Two lines of evidence suggest that the Notch and Delta proteins function similarly in vitro and in vivo. First, the genetic analyses have indicated that the stoichiometry of Notch and Delta is crucial for their function in development. Our observations that both Notch-Delta and Delta-Delta associations may occur in vitro imply that Notch and Delta may compete for binding to Delta. Thus, dose-sensitive genetic interactions between Notch and Delta may be the result of competitive binding interactions between their protein products. Second, we were able to detect Notch-Delta association in lysates of cultured cells and in lysates of Drosophila embryos using immunoprecipitation. Taken together, these genetic and biochemical analyses suggest that Notch and Delta do associate in vivo in a manner similar to that which we propose on the basis of our aggregation assays.

Genetic and molecular analyses of Notch have also raised the possibility that there may be interactions between individual Notch proteins (Portin, 1975, Genetics 81, 121-133; Kelley et al., 1987, Cell 51, 539-548; Artavanis-Tsakonas, 1988, Trends Genet. 4, 95-100). Indeed, Kidd et al. (1989, Genes Dev. 3, 1113-1129) have proposed that this protein forms disulfide cross-linked dimers, although this point has not yet been rigorously proven. With or without the formation of covalent cross-links, such interactions could presumably occur either within a single cell or between cells. However, our find that N tch$^+$ cells do not aggregate homotypically suggests

that Notch-Notch associations are likely to occur within a single cell and not between cells. Alternatively, it is possible that homotypic Notch interactions require gene products that are not expressed in S2 cells.

The Notch-Delta interactions indicated by our analysis are probably mediated by the extracellular domains of these proteins. Aggregation experiments using the ECN1 construct, from which almost the entire intracellular domain of Notch has been removed or altered by in vitro mutagenesis, confirmed this conclusion. Further experiments that demonstrate ECN1-Delta associations within the membrane on the basis of their ability to co-patch indicated that these interactions are also likely to be mediated by the extracellular domains of Notch and Delta, although in this case we cannot exclude possible involvement of the transmembrane domain or the remaining portion of the Notch intracellular domain. These results are especially interesting in light of the fact that both Notch and Delta have EGF-like repeats within their extracellular domains (Wharton et al., 1985, Cell 43, 567-581; Kidd et al., 1986, Mol. Cell Biol. 6, 3094-3108; Vassin et al., 1987, EMBO J. 6, 3431-3440; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735).

A second issue of interest regarding EGF domains is the proposal that they can serve as Ca^{2+} binding domains when they contain a consensus sequence consisting of Asp, Asp/Asn, Asp/Asn, and Tyr/Phe residues at conserved positions within EGF-like repeats (Rees et al., 1988, EMBO J. 7, 2053-2061; Handford et al., 1990, EMBO J. 9, 475-480). Comparisons with a proposed consensus sequence for Ca^{2+} binding have revealed that similar sequences are found

within many of the EGF-like repeats of Notch (Rees et al., 1988, EMBO J. 7, 2053-2061) and within most of the EGF-like repeats of Delta (Kopczynski et al., 1988, Genes Dev. 2, 1723-1735). Furthermore, sequence analyses of Notch mutations have shown that certain Ax alleles are associated with changes in amino acids within this putative Ca^{2+} binding domain (Kelley et al., 1987, Cell 51, 539-548; Hartley et al., 1987, EMBO J. 6, 3407-3417; Rees et al., 1988, EMBO J. 7, 2053-2061). For example, the Ax^{E2} mutation, which correlates with a His to Tyr change in the 29th EGF-like repeat, appears to change this repeat toward the consensus for Ca^{2+} binding. Conversely, the Ax^{9B2} mutation appears to change the 24th EGF-like repeat away from this consensus as a result of an Asp to Val change. Thus, the genetic interactions between Ax alleles and Delta mutations (Xu et al., 1990, Genes Dev., 4, 464-475) raise the possibility that Ca^{2+} ions play a role in Notch-Delta interactions. Our finding that exogenous Ca^{2+} is necessary for Notch-Delta-mediated aggregation of transfected S2 cells supports this contention.

As we have argued (Johansen et al., 1989, J. Cell Biol. 109, 2427-2440; Alton et al., 1989, Dev. Genet. 10, 261-272), on the basis of previous molecular and genetic analyses one could not predict with any certainty the cellular function of either Notch or Delta beyond their involvement in cell-cell interactions. However, given the results presented here, it now seems reasonable to suggest that Notch and Delta may function in vivo to mediate adhesive interactions between cells. At the same time, it is quite possible that the observed Notch-Delta int ractions may not reflect a solely adhesive function and may in addition reflect receptor-ligand

binding interactions that occur in vivo. Indeed, the presence of a structurally complex 1000 amino acid intracellular domain within Notch may be more consistent with a role in signal transduction than with purely adhesive interactions. Given that Notch may have an adhesive function in concert with Delta, axonal expression of Notch may play some role in axon guidance.

7. EGF REPEATS 11 AND 12 OF NOTCH ARE REQUIRED AND SUFFICIENT FOR NOTCH-DELTA-MEDIATED AGGREGATION

In this study, we use the same aggregation assay as described in Section 6, together with deletion mutants of Notch to identify regions within the extracellular domain of Notch necessary for interactions with Delta. We present evidence that the EGF repeats of Notch are directly involved in this interaction and that only two of the 36 EGF repeats appear necessary. We demonstrate that these two EGF repeats are sufficient for binding to Delta and that the calcium dependence of Notch-Delta mediated aggregation also associates with these two repeats. Finally, the two corresponding EGF repeats from the Xenopus homolog of Notch also mediate aggregation with Delta, implying that not only has the structure of Notch been evolutionarily conserved, but also its function. These results suggest that the extracellular domain of Notch is surprisingly modular, and could potentially bind a variety of proteins in addition to Delta.

7.1. EXPERIMENTAL PROCEDURES

7.1.1. EXPRESSION CONSTRUCTS

The constructs described are all derivatives of the full length Notch expression construct #1 pMtNMg (see Section 6, supra). All ligations were

performed using DNA fragments cut from low melting temperature agarose gels (Sea Plaque, FMC BioProducts). The 6 kb EcoRI-XhoI fragment from pMtNMg containing the entire extracellular domain of Notch was ligated into the EcoRI-XhoI sites of the Bluescript vector (Stratagene), and named RI/XBS. All subsequent deletions and insertions of EGF repeats were performed in this subclone. The Notch sequence containing the EcoRI-XhoI fragment of these RI/XBS derivatives was then mixed with the 5.5 kb XhoI-XbaI fragment from pMtNMg containing the intracellular domain and 3' sequences needed for polyadenylation, and then inserted into the EcoRI-XbaI site of pRMHa-3 (Bunch et al., 1988, Nucl. Acids Res. 16, 1043-1061) in a three piece ligation. All subsequent numbers refer to nucleotide coordinates of the Notch sequence according to Wharton et al. (1985, Cell 43, 567-581).

For construct #2 DSph, RI/XBS was digested to completion with SphI and then recircularized, resulting in a 3.5 kb in-frame deletion from SphI(996) to SphI(4545).

For construct #3 ΔCla, RI/XBS was digested to completion with ClaI and then religated, producing a 2.7 kb in-frame deletion from ClaI(1668) to ClaI(4407). The ligation junction was checked by double strand sequencing (as described by Xu et al., 1990, Genes Dev. 4, 464-475) using the Sequenase Kit (U.S. Biochemical Corp., Cleveland). We found that although the ClaI site at position 4566 exists according to the sequence, it was not recognized under our conditions by the ClaI restriction enzyme.

For constructs #4-12, RI/XBS was partially digested with ClaI and then religated to produce all possible combinations of in-frame deletions: construct #4 ΔEGF7-17 removed the sequence between

ClaI(1668) and ClaI(2820); Construct #5 ΔEGF9-26 removed the sequence between ClaI(1905) and ClaI(3855); construct #6 ΔEGF17-31 removed the sequence between ClaI(2820) and ClaI(4407); construct #7 ΔEGF7-9 removed the sequence between ClaI(1668) and ClaI(1905); construct #8 ΔEGF9-17 removed the sequence between ClaI(1905) and ClaI(2820); construct #9 ΔEGF17-26 removed the sequence between ClaI(2820) and ClaI(3855); construct #10 ΔEGF 26-30 removed the sequence between ClaI(3855) and ClaI(4407); construct #11 ΔEGF9-30 removed the sequence between ClaI(1905) and ClaI(4407); construct #12 ΔEGF 7-26 removed the sequence between ClaI(1668) and ClaI(3855).

For constructs #13 ΔCla+EGF9-17 and #14 ΔCla+EGF17-26, the ~0.9 kb fragment between ClaI(1905) and ClaI(2820), and the ~1.0 kb fragment between ClaI(2820) and ClaI(3855), respectively, were inserted into the unique ClaI site of construct #3 ΔCla.

For construct #16 split, the 11 kb KpnI/XbaI fragment of pMtNMg was replaced with the corresponding KpnI/XbaI fragment from a Notch minigene construct containing the split mutation in EGF repeat 14.

For constructs #17-25, synthetic primers for polymerase chain reaction (PCR) were designed to amplify stretches of EGF repeats while breaking the EGF repeats at the ends of the amplified piece in the same place as the common ClaI sites just after the third cysteine of the repeat (see Figure 7). The PCR products were gel purified as usual and ligated into the ClaI site of construct #3 ΔCla which was made blunt by filling with the Klenow fragment of DNA Polymerase I (Maniatis et al., 1990, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The correct orientation of the ins rts was determined by

PCR using a sense strand primer within the insert together with an antisense strand primer in EGF repeat 35. All primers were 20-mers, and were named with the number of the nucleotide at their 5' end, according to the nucleotide coordinates of the Notch sequence in Wharton et al. (1985, Cell 43, 567-581), and S refers to a sense strand primer while A refers to an antisense strand primer. Construct #16 ΔCla+EGF(9-13) used primers S1917 and A2367. Construct #17 ΔCla+EGF(11-15) used primers S2141 and A2591. Construct #18 ΔCla+EGF(13-17) used primers S2375 and A2819. Construct #19 ΔCla+EGF(10-13) used primers S2018 and A2367. Construct #20 ΔCla+EGF(11-13) used primers S2141 and A2367. Construct #21 ΔCla+EGF(10-12) used primers S2018 and A2015. Construct #22 ΔCla+EGF(10-11) used primers S2018 and A2322. Construct #23 ΔCla+EGF(10-12) used primers S2018 and A2322. Construct #24 ΔCla+EGF(11-12) used primers S2081 and A2322.

For construct #25 ΔEGF, construct R1/XBS was digested to completion with SphI(996) and partially digested with BamHI(5135). The resulting incompatible ends were joined using a synthetic linker designed to create a unique ClaI site. This produced an in frame deletion which removed all 36 EGF repeats with the exception of the first half of repeat 1. For constructs #26-29, the EGF fragments were inserted into this ClaI site as previously described for the corresponding constructs #13, 16, 19, and 23.

For construct #30 ΔECN, construct R1/XBS was digested to completion with BglI, EcoRI and XhoI. The ~0.2 kb EcoRI-BglI fragment (722-948) and the ~0.7 kb BglI-XhoI (5873-6627) fragments were ligated with EcoRI-XhoI cut Bluescript vector and a synthetic linker designed to creat a unique ClaI site,

resulting in an in-frame del tion from BglI(941) to BglI(5873) that removed all 36 EGF repeats except f r the first third of repeat 1 as well as the 3 Notch/lin-12 repeats. For constructs #31 and 32, the EGF fragments were inserted into the unique ClaI site as previously described for constructs #19 and 23.

For constructs #33 and 34, PCR primers S1508 and A1859 based on the Xenopus Notch sequence (Coffman et al., 1990, Science 249, 1438-1441; numbers refer to nucleotide coordinates used in this paper), were used to amplify EGF repeats 11 and 12 out of a Xenopus stage 17 cDNA library (library was made by D. Melton and kindly provided by M. Danilchek). The fragment was ligated into construct #3 DCla and sequenced.

7.1.2. CELL CULTURE AND TRANSFECTION

The Drosphila S2 cell line was grown and transfected as described in Section 6, supra. The Delta-expressing stably transformed S2 cell line L-49-6-7 (kindly established by L. Cherbas) was grown in M3 medium (prepared by Hazleton Co.) supplemented with 11% heat inactivated fetal calf serum (FCS) (Hyclone), 100 U/ml penicillin-100 μg/ml streptomycin-0.25 μg/ml fungizone (Hazleton), 2 x 10^{-7} M methotrexate, 0.1 mM hypoxanthine, and 0.016 mM thymidine.

7.1.3. AGGREGATION ASSAYS AND IMMUNOFLUORESCENCE

Aggregation assays and Ca^{++} dependence experiments were as described supra, Section 6. Cells were stained with the anti-Notch monoclonal antibody 9C6.C17 and anti-Delta rat polyclonal antisera (details described in Section 6, supra). Surface expression of Notch constructs in unpermeabilized cells was assayed using rat polyclonal antisera raised against the 0.8 kb (amino acids 237-501; Wharton et

al., 1985, Cell 43, 567-581) BstYI fragment from the extracellular domain of Notch. Cells were viewed under epifluorescence on a Leitz Orthoplan 2 microscope.

7.2. RESULTS

7.2.1. EGF REPEATS 11 AND 12 OF NOTCH ARE REQUIRED FOR NOTCH-DELTA MEDIATED AGGREGATION

We have undertaken an extensive deletion analysis of the extracellular domain of the Notch protein, which we have shown (supra, Section 6) to be involved in Notch-Delta interactions, to identify the precise domain of Notch mediating these interactions. We tested the ability of cells transfected with the various deletion constructs to interact with Delta using the aggregation assay described in Section 6. Briefly, Notch deletion constructs were transiently transfected into Drosophila S2 cells, induced with $CuSO_4$, and then aggregated overnight at room temperature with a small amount of cells from the stably transformed Delta expressing cell line L49-6-7(Cherbas), yielding a population typically composed of ~1% Notch expressing cells and ~5% Delta expressing cells, with the remaining cells expressing neither protein. To assay the degree of aggregation, cells were stained with antisera specific to each gene product and examined with immunofluorescent microscopy (see experimental procedures for details). Aggregates were defined as clusters of four or more cells containing both Notch and Delta expressing cells, and the values shown in Figure 6 represent the percentage of all Notch expressing cells found in such clusters. All numbers reflect the average result from at least two separate transfection experiments in which at least 100 Notch expressing cell units (either single cells or clusters) were scored.

Schematic drawings of the constructs tested and results of the aggregation experiments are shown in Figure 6 (see Experimental Procedures for details). All expression constructs were derivatives of the full length Notch expression construct #1 pMtNMg (described in Section 6, supra).

The initial constructs (#2 DSph and #3 ΔCla) deleted large portions of the EGF repeats. Their inability to promote Notch-Delta aggregation suggested that the EGF repeats of Notch were involved in the interaction with Delta. We took advantage of a series of six in-frame ClaI restriction sites to further dissect the region between EGF repeats 7 and 30. Due to sequence homology between repeats, five of the ClaI sites occur in the same relative place within the EGF repeat, just after the third cysteine, while the sixth site occurs just before the first cysteine of EGF repeat 31 (Figure 7). Thus, by performing a partial ClaI digestion and then religating, we obtained deletions that not only preserved the open reading frame of the Notch protein but in addition frequently maintained the structural integrity and conserved spacing, at least theoretically, of the three disulfide bonds in the chimeric EGF repeats produced by the religation (Figure 6, constructs #4-14). Unfortunately, the most 3' ClaI site was resistant to digestion while the next most 3' ClaI site broke between EGF repeats 30 and 31. Therefore, when various ClaI digestion fragments were reinserted into the framework of the complete ClaI digest (construct #3 ΔCla), the overall structure of the EGF repeats was apparently interrupted at the 3' junction.

Several points about this series of constructs are worth noting. First, removal of the ClaI restriction fragment breaking in EGF repeats 9

and 17 (construct #8 ΔEGF9-17) abolished aggregation with Delta, while reinsertion of this piece into construct #3 ΔCla, which lacks EGF repeats 7-30, restored aggregation to roughly wild type levels (construct #13 ΔCla+EGF9-17), suggesting that EGF repeats 9 through 17 contain sequences important for binding to Delta. Second, all constructs in this series (#4-14) were consistent with the binding site mapping to EGF repeats 9 through 17. Expression constructs containing these repeats (#6, 7, 9, 10, 13) promoted Notch-Delta interactions while constructs lacking these repeats (#4, 5, 8, 11, 12, 14) did not. To confirm that inability to aggregate with Delta cells was not simply due to failure of the mutagenized Notch protein to reach the cell surface, but actually reflected the deletion of the necessary binding site, we tested for cell surface expression of all constructs by immunofluorescently staining live transfected cells with antibodies specific to the extracellular domain of Notch. All constructs failing to mediate Notch-Delta interactions produced a protein that appeared to be expressed normally at the cell surface. Third, although the aggregation assay is not quantitative, two constructs which contained EGF repeats 9-17, #9 ΔEGF17-26 or most noticeably #10 ΔEGF26-30, aggregated at a seemingly lower level. Cells transfected with constructs #9 ΔEGF17-26 and 10 ΔEGF26-30 showed considerably less surface staining than normal, although fixed and permeabilized cells reacted with the same antibody stained normally, indicating we had not simply deleted the epitopes recognized by the antisera. By comparing the percentage of transfected cells in either permeabilized or live cell populations, we found that roughly 50% of transfected cells for construct #9

ΔEGF17-26 and 10% for construct #10 ΔEGF26-30 produced detectable protein at the cell surface. Thus these two constructs produced proteins which often failed to reach the cell surface, perhaps because of misfolding, thereby reducing, but not abolishing, the ability of transfected cells to aggregate with Delta-expressing cells.

Having mapped the binding site to EGF repeats 9 through 17, we checked whether any Notch mutations whose molecular lesion has been determined mapped to this region. The only such mutation was split, a semidominant Notch allele that correlates with a point mutation in EGF repeat 14 (Hartley et al., 1987, EMBO J. 6, 3407-3417; Kelley et al., 1987, Mol. Cell. Biol. 6, 3094-3108). In fact, a genetic screen for second site modifiers of split revealed several alleles of Delta, suggesting a special relationship between the split allele of Notch, and Delta (Brand and Campus-Ortega, 1990, Roux's Arch. Dev. Biol. 198(5), 275-285). To test for possible effects of the split mutation on Notch-Delta mediated aggregation, an 11 kb fragment containing the missense mutation associated with split was cloned into the Notch expression construct (#15 split). However, aggregation with Delta-expressing cells was unaffected in this construct suggesting, as was confirmed by subsequent constructs, that EGF repeat 14 of Notch was not involved in the interactions with Delta modelled by our tissue culture assay.

Thus, to further map the Delta binding domain within EGF repeats 9-17, we used specific oligonucleotide primers and the PCR technique to generate several subfragments of this region. To be consistent with constructs #4-14 which produced proteins that were able to interact with Delta, we

designed the primers to splice the EGF repeats just after the third cysteine, in the same place as the common ClaI site (Figure 7). The resulting PCR products were ligated into the ClaI site of construct #3 ΔCla. Three overlapping constructs, #16, 17 and 18 were produced, only one of which, #16 ΔCla+EGF9-13, when transfected into S2 cells, allowed aggregation with Delta cells. Construct #19 ΔCla+EGF(10-13), which lacks EGF repeat 9, further defined EGF repeats 10-13 as the region necessary for Notch-Delta interactions.

Constructs #20-24 represented attempts to break this domain down even further using the same PCR strategy (see Figure 7). We asked first whether both EGF repeats 11 and 12 were necessary, and second, whether the flanking sequences from EGF repeats 10 and 13 were directly involved in binding to Delta. Constructs #20 ΔCla+EGF(11-13), in which EGF repeat 12 is the only entire repeat added, and #21 ΔCla+EGF(10-12), in which EGF repeat 11 is the only entire repeat added, failed to mediate aggregation, suggesting that the presence of either EGF repeat 11 or 12 alone was not sufficient for Notch-Delta interactions. However, since the 3' ligation juncture of these constructs interrupted the overall structure of the EGF repeats, it was possible that a short "buffer" zone was needed to allow the crucial repeat to function normally. Thus for example in construct #19 ΔCla+EGF(10-13), EGF repeat 12 might not be directly involved in binding to Delta but instead might contribute the minimum amount of buffer sequence needed to protect the structure of EGF repeat 11, thereby allowing interactions with Delta. Constructs #22-24 addressed this issue. We designed PCR primers that broke at the end of the EGF repeat and therefore were less likely to disrupt the

EGF disulfide formation at the 3' ligation juncture. C nstructs #22 ΔCla+EGF(10-11), which did not mediate aggregation, and #23 ΔCla+EGF(10-12), which did, again suggested that both repeats 11 and 12 are required while the flanking sequence from repeat 13 clearly is not. Finally, construct #24 ΔCla+EGF(11-12), although now potentially structurally disrupted at the 5' junction, convincingly demonstrated that the sequences from EGF repeat 10 are not crucial. Thus based on entirely consistent data from 24 constructs, we propose that EGF repeats 11 and 12 of Notch together define the smallest functional unit obtainable from this analysis that contains the necessary sites for binding to Delta in transfected S2 cells.

7.2.2. EGF REPEATS 11 AND 12 OF NOTCH ARE SUFFICIENT FOR NOTCH-DELTA MEDIATED AGGREGATION

The large ClaI deletion into which PCR fragments were inserted (#3 ΔCla) retains roughly 1/3 of the original 36 EGF repeats as well as the three Notch/lin-12 repeats. While these are clearly not sufficient to promote aggregation, it is possible that they form a necessary framework within which specific EGF repeats can interact with Delta. To test whether only a few EGF repeats were in fact sufficient to promote aggregation, we designed two constructs, #25 ΔEGF which deleted all 36 EGF repeats except for the first two-thirds of repeat 1, and #30 ΔECN which deleted the entire extracellular portion of Notch except for the first third of EGF repeat 1 and ~35 amino acids just before the transmembrane domain. Fragments which had mediated Notch-Delta aggregation in the background of construct #3 ΔCla, when inserted into construct #25 ΔEGF, were again able to promote interactions with Delta (constructs #26-30). Analogous constructs (#31,32) in which the Notch/lin-

12 repeats were also absent, again successfully mediated Notch-Delta aggregation. Thus EGF repeats 11 and 12 appear to function as independent modular units which are sufficient to mediate Notch-Delta interactions in S2 cells, even in the absence of most of the extracellular domain of Notch.

7.2.3. EGF REPEATS 11 AND 12 OF NOTCH MAINTAIN THE CALCIUM DEPENDENCE OF NOTCH-DELTA MEDIATED AGGREGATION

As described in Section 6, supra (Fehon et al., 1990, Cell 61, 523-534), we showed that Notch-Delta-mediated S2 cell aggregation is calcium dependent. We therefore examined the ability of cells expressing certain deletion constructs to aggregate with Delta expressing cells in the presence or absence of Ca^{++} ions. We tested constructs #1 pMtNMg as a control, and #13, 16, 19, 23, 24, 26, 27 and 28, and found that cells mixed in Ca^{++} containing medium at 4°C readily formed aggregates while cells mixed in Ca^{++} free medium containing EGTA failed to aggregate (Table III).

TABLE III

EFFECT OF EXOGENOUS Ca^{++} ON NOTCH - DELTA AGGREGATION[a]

	Without Ca^{++} Ions	With Ca^{++} Ions
1. pMtNMg	0	37
13. ΔCla+EGF(9-17)	0	31
16. ΔCla+EGF(9-13)	0	38
19. ΔCla+EGF(10-13)	0	42
23. ΔCla+EGF(10-12)	0	48
29. ΔEGF+EGF(10-12)	0	44
32. ΔECN+EGF(10-12)	0	39
33. ΔCla+XEGF(10-13	0	34

[a]Data presented as percentage of Notch-expressing cells found in aggregates (as in Figure 6).

Clearly, the calcium dependence of the interaction has been preserved in even the smallest construct, consistent with the notion that the minimal constructs containing EGF repeats 11 and 12 bind to Delta in a manner similar to that of full length Notch. This result is also interesting in light of recent studies suggesting EGF-like repeats with a particular consensus sequence may act as Ca^{++} binding domains (Morita et al., 1984, J. Biol. Chem. 259, 5698-5704; Sugo et al., 1984, J. Biol. Chem. 259, 5705-5710; Rees et al., 1988, EMBO J. 7, 2053-2061; Handford et al., 1990, EMBO J. 9, 475-480). Over half of the EGF repeats in Notch, including repeats 11 and 12, conform to this consensus, further strengthening the argument that EGF repeats 11 and 12 are responsible for promoting Notch-Delta interactions.

7.2.4. THE DELTA BINDING FUNCTION OF EGF REPEATS 11 AND 12 OF NOTCH IS CONSERVED IN THE XENOPUS HOMOLOG OF NOTCH

Having mapped the Delta binding site to EGF repeats 11 and 12 of Notch, we were interested in asking whether this function was conserved in the Notch homolog that has been identified in Xenopus (Coffman et al., 1990, Science 249, 1438-1441). This protein shows a striking similarity to Drosophila Notch in overall structure and organization. For example, within the EGF repeat region both the number and linear organization of the repeats has been preserved, suggesting a possible functional conservation as well. To test this, we made PCR primers based on the Xenopus Notch sequence (Coffman et al., 1990, Science 249, 1438-1441) and used these to obtain an ~350 bp fragment from a Xenopus Stage 17 cDNA library that includes EGF repeats 11 and 12 flanked by half of repeats 10 and 13 on either side. This fragment was cloned into construct #3 ΔCla, and three independent clones were tested for ability to interact with Delta in the cell culture aggregation assay. Two of the clones, #33a&bΔCla+XEGF(10-13), when transfected into S2 cells were able to mediate Notch-Delta interactions at a level roughly equivalent to the analogous Drosophila Notch construct #19ΔCla+EGF(10-13), and again in a calcium dependent manner (Table III). However, the third clone #33cΔCla+XEGF(10-13) failed to mediate Notch-Delta interactions although the protein was expressed normally at the cell surface as judged by staining live unpermeabilized cells. Sequence comparison of the Xenopus PCR product in constructs #33a and 33c revealed a missense mutation resulting in a leucine to

prolin change (amino acid #453, Coffman, et al., 1990, Science 249, 1438-1441) in EGF repeat 11 of construct #33c. Although this residue is not conserved between Drosophila and Xenopus Notch (Figure 8), the introduction of a proline residue might easily disrupt the structure of the EGF repeat, and thus prevent it from interacting properly with Delta.

Comparison of the amino acid sequence of EGF repeats 11 and 12 of Drosophila and Xenopus Notch reveals a high degree of amino acid identity, including the calcium binding consensus sequence (Figure 8, SEQ ID NO:1 and NO:2). However the level of homology is not strikingly different from that shared between most of the other EGF repeats, which overall exhibit about 50% identity at the amino acid level. This one to one correspondence between individual EGF repeats suggests that perhaps they too may comprise conserved functional units. Delta interactions, again in a calcium ion-dependent manner.

7.3. DISCUSSION

We have continued our study of interactions between the protein products of the genes Notch and Delta, using the in vitro S2 cell aggregation assay described in Section 6, supra. Based on an extensive deletion analysis of the extracellular domain of Notch, we show that the regions of Notch containing EGF-homologous repeats 11 and 12 are both necessary and sufficient for Notch-Delta-mediated aggregation, and that this Delta binding capability has been conserved in the same two EGF repeats of Xenopus Notch. Our finding that the aggregation mapped to EGF repeats 11 and 12 of Notch demonstrates that the EGF repeats of Notch also function as specific protein binding domains.

Recent studies have demonstrated that EGF domains containing a specific consensus sequence can bind Ca^{++} ions (Morita et al., 1984, J. Biol. Chem. 259, 5698-5704; Sugo et al., 1984, J. Biol. Chem. 259, 5705-5710; Rees et al., 1988, EMBO J. 7, 2053-2061; Handford et al., 1990, EMBO J. 9, 475-480). In fact, about one half of the EGF repeats in Notch, including repeats 11 and 12, conform to this consensus. We have shown that exogenous Ca^{++} was necessary for Notch-Delta mediated aggregation of transfected S2 cells (see Section 6; Fehon et al., 1990, Cell 61, 523-534). We tested a subset of our deletion constructs and found that EGF repeats 11 and 12 alone (#32ΔECN+EGF(11-12)) were sufficient to maintain the Ca^{++} dependence of Notch-Delta interactions.

A number of studies have suggested that the genetic interactions between Notch and Delta may reflect a dose sensitive interaction between their protein products. Genetic studies have indicated that the relative gene dosages of Notch and Delta are crucial for normal development. For example, Xu et al. (1990, Genes Dev. 4, 464-475) found that null mutations at Delta could suppress lethal interactions between heterozygous combinations of Abruptex (Ax) alleles, a class of Notch mutations that correlate with missense mutations within the EGF repeats (Hartley et al., 1987, EMBO J. 6, 3407-3417; Kelley et al., 1987, Mol. Cell Biol. 6, 3094-3108). The in vitro interactions we have described in which we observe both Notch-Delta and Delta-Delta associations (see Section 6) imply that a competitive interaction between Notch and Delta for binding to Delta may reflect the underlying basis for the observed genetic interactions. Furthermore, we were able to coimmun precipitate Notch and Delta from both tissue

culture and embryonic cell extracts (see Section 6), indicating a possible in vivo association of the two proteins. In addition, mRNA in situ analyses of Notch and Delta expression patterns in the embryo suggest that expression of the two is overlapping but not identical (Kopczynski and Muskavitch, 1989, Development 107, 623-636; Hartley et al., 1987, EMBO J. 6, 3407-3417). Detailed antibody analysis of Notch protein expression during development have recently revealed Notch expression to be more restricted at the tissue and subcellular levels than previous studies had indicated (Johansen et al., 1989, J. Cell Biol. 109, 2427-2440; Kidd et al., 1989, Genes Dev. 3, 1113-1129).

Our finding that the same two EGF repeats from the Xenopus Notch homolog are also able to mediate interactions with Delta in tissue culture cells argues strongly that a similar function will have been conserved in vivo. Although these two EGF repeats are sufficient in vitro, it is of course possible that in vivo more of the Notch molecule may be necessary to facilitate Notch-Delta interactions. In fact, we were somewhat surprised for two reasons to find that the Delta binding site did not map to EGF repeats where several of the Ax mutations have been shown to fall, first, because of the genetic screen (Xu et al., 1990, Genes Dev. 4, 464-475) demonstrating interactions between Ax alleles and Delta mutations, and second, because of sequence analyses that have shown certain Ax alleles are associated with single amino acid changes within the putative Ca^{++} binding consensus of the EGF repeats. For example, the AX^{E2} mutation changes EGF repeat 29 toward the Ca^{++} binding consensus sequence while the AX^{9B2} mutation moves EGF repeat 24 away from the consensus. It is possible

that in vivo these regions of the Notch protein may be involved in interactions, either with Delta and/or other proteins, that may not be accurately modelled by our cell culture assay.

Our in vitro mapping of the Delta binding domain to EGF repeats 11 and 12 of Notch represents the first assignment of function to a structural domain of Notch. In fact, the various deletion constructs suggest that these two EGF repeats function as a modular unit, independent of the immediate context into which they are placed. Thus, neither the remaining 34 EGF repeats nor the three Notch/lin-12 repeats appear necessary to establish a structural framework required for EGF repeats 11 and 12 to function. Interestingly, almost the opposite effect was observed: although our aggregation assay does not measure the strength of the interaction, as we narrowed down the binding site to smaller and smaller fragments, we observed an increase in the ability of the transfected cells to aggregate with Delta expressing cells, suggesting that the normal flanking EGF sequences actually impede association between the proteins. For two separate series of constructs, either in the background of construct #3 ΔC1a (compare #9, 16, 19, 23) or in the background of construct #25 ΔEGF (compare #26, 27, 28), we observed an increase in ability to aggregate such that the smallest constructs (#19, 23, 28, 29) consistently aggregated above wild type levels (#1 pMtNMg). These results imply that the surrounding EGF repeats may serve to limit the ability of EGF repeats 11 and 12 to access Delta, thereby perhaps modulating Notch-Delta interactions in vivo.

Notch encodes a structurally complex transmembrane protein that has been proposed to play a pleotropic role throughout Drosophila development.

The fact that EGF repeats 11 and 12 appear to function as an independent modular unit that is sufficient, at least in cell culture, for interactions with Delta, immediately presents the question of the role of the hypothesis is that these may also form modular binding domains for other proteins interacting with Notch at various times during development.

In addition to Xenopus Notch, lin-12 and glp-1, two genes thought to function in cell-cell interactions involved in the specification of certain cell fates during C. elegans development, encode EGF homologous transmembrane proteins which are structurally quite similar to Drosophila and Xenopus Notch. All four proteins contain EGF homologous repeats followed by three other cysteine rich repeats (Notch/lin-12 repeats) in the extracellular domain, a single transmembrane domain, and six cdc10/ankyrin repeats in the intracellular region. Unlike Xenopus Notch, which, based on both sequence comparison as well as the results of our Delta binding assay, seems likely to encode the direct functional counterpart of Drosophila Notch, lin-12 and glp-1 probably encode distinct members of the same gene family. Comparison of the predicted protein products of lin-12 and glp-1 with Notch reveal specific differences despite an overall similar organization of structural motifs. The most obvious difference is that lin-12 and glp-1 proteins contain only 13 and 10 EGF repeats, respectively, as compared to the 36 for both Xenopus and Drosophila Notch. In addition, in the nematode genes the array of EGF repeats is interrupted after the first EGF repeat by a distinct stretch of sequence absent from Notch. Furthermore, with respect to the Delta binding domain we have defined as EGF repeats 11 and 12 of Notch, there are no two contiguous EGF

repeats in the lin-12 or glp-1 proteins exhibiting the Ca^{++} binding consensus sequence, nor any two contiguous repeats exhibiting striking similarity to EGF repeats 11 and 12 of Notch, again suggesting that the lin-12 and glp-1 gene products are probably functionally distinct from Notch.

Our finding that EGF repeats 11 and 12 of Notch form a discrete Delta binding unit represents the first concrete evidence supporting the idea that each EGF repeat or small subset of repeats may play a unique role during development, possibly through direct interactions with other proteins. The homologies seen between the adhesive domain of Delta and Serrate (see Section 8.3.4, infra) suggest that the homologous portion of Serrate is "adhesive" in that it mediates binding to other toporythmic proteins. In addition, the gene scabrous, which encodes a secreted protein with similarity to fibrinogen, may interact with Notch.

In addition to the EGF repeat, multiple copies of other structural motifs commonly occur in a variety of proteins. One relevant example is the cdc10/ankyrin motif, six copies of which are found in the intracellular domain of Notch. Ankyrin contains 22 of these repeats. Perhaps repeated arrays of structural motifs may in general represent a linear assembly of a series of modular protein binding units. Given these results together with the known structural, genetic and developmental complexity of Notch, Notch may interact with a number of different ligands in a precisely regulated temporal and spacial pattern throughout development. Such context specific interactions with extracellular proteins could be mediated by the EGF and Notch/lin-12 repeats, while interactions with cytoskeletal and cytoplasmic

proteins could be mediated by the intracellular cdc10/ankyrin motifs.

8. THE AMINO-TERMINUS OF DELTA IS AN EGF-BINDING DOMAIN THAT INTERACTS WITH NOTCH AND DELTA

Aggregation of cultured cells programmed to express wild type and variant Delta proteins has been employed to delineate Delta sequences required for heterotypic interaction with Notch and homotypic Delta interaction. We have found that the amino terminus of the Delta extracellular domain is necessary and sufficient for the participation of Delta in heterotypic (Delta-Notch) and homotypic (Delta-Delta) interactions. We infer that the amino terminus of Delta is an EGF motif-binding domain (EBD), given that Notch EGF-like sequences are sufficient to mediate heterotypic interaction with Delta. The Delta EBD apparently possesses two activities: the ability to bind EGF-related sequences and the ability to self-associate. We also find that Delta is taken up by cultured cells that express Notch, which may be a reflection of a mechanism by which these proteins interact in vivo.

8.1. MATERIALS AND METHODS

8.1.1. CELL LINES

The S2 Drosophila cell line (Schneider, 1972, J. Embryol. Exp. Morph. 27, 353-365)) used in these experiments was grown as described in Section 6.

8.1.2. IMMUNOLOGICAL PROBES

Immunohistochemistry was performed as described in Section 6, supra, or sometimes with minor modifications of this procedure. Antisera and antibodies employed included mouse polyclonal anti-

Delta sera raised against a Delta ELR array segment that extends from the fourth through ninth ELRs (see Section 6); rat polyclonal anti-Delta sera raised against the same Delta segment (see Section 6); rat polyclonal anti-Notch sera raised against a Notch ELR array segment that extends from the fifth through thirteenth ELRs; mouse monoclonal antibody C17.9C6 (see Section 6), which recognizes the Notch intracellular domain; and mouse monoclonal antibody BP-104 (Hortsch et al., 1990, Neuron 4, 697-709), which recognizes the long form of Drosophila neuroglian.

8.1.3. EXPRESSION VECTOR CONSTRUCTS

Constructs employed to program expression of wild type Delta (pMTDl1) and wild type Notch (pMTNMg) are described in Section 6, supra. Constructs that direct expression of variant Delta proteins were generated using pMTDl1, the Dl1 cDNA cloned into Bluescript+ (pBSDl1; Kopczynski et al., 1988, Genes Dev. 2, 1723-1735), and pRmHa3-104 (A.J. Bieber, pers. comm.), which consists of the insertion of the lB7A-250 cDNA into the metallothionein promoter vector pRmHa-3 (Bunch et al., 1988, Nucl. Acids Res. 16, 1043-1061) and supports inducible expression of the long form of Drosophila neuroglian (Hortsch et al., 1990, Neuron 4, 697-709).

Briefly, constructs were made as follows: Del(Sca-Nae) - Cut pBSDl1 with SalI (complete digest) and ScaI (partial), isolate vector-containing fragment. Cut pBSDl1 with NaeI (partial) and SalI (complete), isolate Delta carboxyl-terminal coding fragment. Ligate fragments, transform, and isolate clones. Transfer EcoRI insert into pRmHa-3.

Del(Bam-Bgl) - Cut pBSDl1 with BglII (complete) and BamHI (partial), fill ends with Klenow DNA polymerase, ligate, transform, and isolate clones. Transfer EcoRI insert into pRmHa-3.

Del(ELR1-ELR3) - PCR-amplify basepairs 236-830 of the Dl1 cDNA using 5-ACTTCAGCAACGATCACGGG-3' (SEQ ID NO:26) and 5'-TTGGGTATGTGACAGTAATCG-3'(SEQ ID NO:27), treat with T4 DNA polymerase, ligate into pBSDl1 cut with ScaI (partial) and BglII (complete) and end-filled with Klenow DNA polymerase, transform, and isolate clones. Transfer BamHI-SalI Delta carboxyl-terminal coding fragment into pRmHa-3.

Del(ELR4-ELR5) - pBSDl1 was digested to completion with BglII and partially with PstI. The 5.6 kb vector-containing fragment was isolated, circularized using T4 DNA ligase in the presence of a 100X molar excess of the oligonucleotide 5'-GATCTGCA-3', and transformed and clones were isolated. The resulting EcoRI insert was then transferred into pRmHa-3.

Ter(Dde) - Cut pBSDl1 with DdeI (partial), end-fill with Klenow DNA polymerase, ligate with 100X molar excess of 5'-TTAAGTTAACTTAA-3' (SEQ ID NO:28), transform, and isolate clones. Transfer EcoRI insert into pRmHa-3.

Ins(Nae)A - Cut pMTDl1 with NaeI (partial), isolate vector-containing fragment, ligate with 100X molar excess of 5'-GGAAGATCTTCC-3' (SEQ ID NO:29), transform, and isolate clones.

NAE B - pMTDl1 was digested partially with NaeI, and the population of tentatively linearized circles approximately 5.8 kb in length was isolated. The fragments were recircularized using T4 DNA ligase in the presence of a 100X molar excess of the oligonucleotide 5'-GGAAGATCTTCC-3' (SEQ ID NO:29) and

transformed, and a clone (NAE A) that contained multiple inserts of the linker was isolated. NAE A was digested to completion with BglII, and the resulting 0.4 kb and 5.4 kb fragments were isolated, ligated and transformed, and clones were isolated.

Ins(Stu) - Cut pMTD11 with StuI (complete), isolate vector-containing fragment, ligate with 100X molar excess of 5'-GGAAGATCTTCC-3'(SEQ ID NO:29), transform and isolate clones.

STU B - pMTD11 was digested completely with StuI, and the resulting 5.8 kb fragment was isolated. The fragment was recircularized using T4 DNA ligase in the presence of a 100X molar excess of the oligonucleotide 5'-GGAAGATCTTCC-3' (SEQ ID NO:29) and transformed, and a clone (STU A) that contained multiple inserts of the linker was isolated. STU B was digested to completion with BglII, and the resulting 0.6 kb and 5.2 kb fragments were isolated, ligated and transformed, and clones were isolated.

NG1 - Cut pRmHa3-104 with BglII (complete) and EcoRI (complete), isolate vector-containing fragment. Cut Ins(Nae)A with EcoRI (complete) and BglII (complete), isolate Delta amino-terminal coding fragment. Ligate fragments, transform and isolate clones.

NG2 - Cut pRmHa3-104 with BglII (complete) and EcoRI (complete), isolate vector-containing fragment. Cut Del(ELR1-ELR3) with EcoRI (complete) and BglII (complete), isolate Delta amino-terminal coding fragment. Ligate fragments, transform and isolate clones.

NG3 - Cut pRmHa3-104 with BglII (complete) and EcoRI (complete), isolate vector-containing fragment. Cut pMTD11 with EcoRI (complete) and BglII (complete), isolate Delta amino-terminal coding

fragment. Ligate fragments, transform and isolate clones.

NG4 - Cut pRmHa3-104 with BglII (complete) and EcoRI (complete), isolate vector containing fragment. Cut Del(Sca-Nae) with EcoRI (complete) and BglII (complete), isolate Delta amino-terminal coding fragment. Ligate fragments, transform and isolate clones.

NG5 - Generate Del(Sca-Stu) as follows: cut pMTDl1 with ScaI (complete) and StuI (complete), isolate ScaI-ScaI amino-terminal coding fragment and StuI-ScaI carboxyl-terminal coding fragment, ligate, transform and isolate clones. Cut Del(Sca-Stu) with EcoRI (complete) and BglII (complete), isolate Delta amino terminal coding fragment. Cut pRmHa3-104 with BglII (complete) and EcoRI (complete), isolate vector-containing fragment. Ligate fragments, transform and isolate clones.

The sequence contents of the various Delta variants are shown in Table IV. Schematic diagrams of the Delta variants defined in Table IV are shown in Figure 9.

TABLE IV

SEQUENCE CONTENTS OF DELTA VARIANTS EMPLOYED IN THIS STUDY

	Nucleotides	Amino Acids
Wild type	1-2892[A]	1-833
Del(Sca-Nae)	1-235/734-2892	1-31/W/199-833
Del(Bam-Bgl)	1-713/1134-2892	1-191/332-833
Del(ELR1-ELR3)	1-830/1134-2892	1-230/332-833
Del(ELR4-ELR5)	1-1137/1405-2892	1-332/422-833
Ter(Dde)	1-2021/TTAAGTTAACTTAA[E]/2227-2892	1-626/H
Ins(Nae)A	1-733/$(GGAAGATCTTCC)_n$[F]/734-2892[B]	1-197/$(RKIF)_n$ 198-833
NAE B	1-733/GGAAGATCTTCC[F]/734-2892	1-197/RKIF 198-833
Ins(Stu)	1-535/$(GGAAGATCTTCC)_n$[F]/536-2892[B]	1-131/ $G(KIFR)_{n-1}$ KIFP/133-833
STU B	1-535/GGAAGATCTTCC[F]/536-2892	1-131/GKIFP 133-833
NG1	1-733/GGAA/2889-3955(NG)[C]	1-198/K/952-1302[D]
NG2	1-830/2889-3955(NG)	1-230/952-1302
NG3	1-1133/2889-3955(NG)	1-331/952-1302
NG4	1-235/734-1133/2889-3955(NG)	1-31/199-331/952-1302
NG5	1-235/536-1133/2889-3955(NG)	1-31/S/133-952-1302

A Coordinates for Delta sequences correspond to the sequence of the D11 cDNA (Figure 12).

B The exact number of linkers inserted has n t been determined for this construct.

C Coordinates for neuroglian (Bieber et al., 1989, Cell 59, 447-460; Hortsch et al., 1990, Neuron 4, 697-709) nucleotide sequences present in Delta-neuroglian chimeras correspond to the sequence of the 1B7A-250 cDNA (Figure 13, SEQ ID NO:5) and are indicated in bold face type.

D Neuroglian amino acid sequences are derived from conceptual translation of the 1B7A-250 cDNA nucleotide sequence (Figure 13, SEQ ID NO:5) and are indicated in **bold face** type.

E SEQ ID NO:28

F SEQ ID NO:29

8.1.4. AGGREGATION PROTOCOLS

Cell transfection and aggregation were performed as described in Section 6, supra, or with minor modifications thereof.

8.2. RESULTS

8.2.1. AMINO-TERMINAL SEQUENCES WITHIN THE DELTA EXTRACELLULAR DOMAIN ARE NECESSARY AND SUFFICIENT FOR THE HETEROTYPIC INTERACTION WITH NOTCH

Because we anticipated that some Delta variants might not be efficiently localized on the cell surface, we investigated the relationship between the level of expression of wild type Delta and the extent of aggregation with Notch-expressing cells by varying the input amount of Delta expression construct in different transfections. We found that the heterotypic Delta-Notch interaction exhibits only slight dependence on the Delta input level over a 10-fold range in this assay (Figure 9A). Given the robustness of the heterotypic interaction over the range tested and our observations that each of the Delta variants we employed exhibited substantial surface accumulation in transfected cells, we infer that the inability of a given Delta variant to support

heter typic aggregation most probably reflects a functional deficit exhibited by that variant, as opposed to the impact of reduced levels of surface expression on heterotypic aggregation.

The results of the heterotypic aggregation experiments mediated by Delta variants and wild-type Notch are shown in Table V.

TABLE V

HETEROTYPIC AGGREGATION MEDIATED BY DELTA VARIANTS AND WILD TYPE NOTCH

Construct	Aggregated Total[A]	Unaggregated Total	Expt.#	Aggregated Notch+	Aggregated Delta+[B]	Unaggregated Notch+	Unaggregated Delta+
Wild type	33(H)[C]	179	1	15	18	67	112
	58(H)	247	2	37	21	218	29
	38(H)	209	3	21	17	148	61
	29(H)	174	4	18	11	95	79
	175(B)	68	5	84	91	37	31
Del(Sca-Nae)	0(H)	207	1	0	0	125	82
	0(H)	226	2	0	0	215	11
	0(H)	287	3	0	0	215	72
	0(H)	200	4	ND[D]	ND	ND	ND
Del(Bam-Bgl)	4(H)	245	1	3	1	171	74
	0(H)	200	2	0	0	110	90
	0(H)	200	3	ND	ND	ND	ND
Del(ELR1-ELR3)	28(B)	296	1	11	17	139	157
	20(B)	90	2	9	11	53	37
	22(B)	227	3	19	13	114	113
	127(B)	97	4	19	78	66	61
Del(ELR4-ELR5)	38(H)	188	1	26	12	141	47
	36(H)	204	2	20	16	90	114
Ter(Dde)	53(H)	236	1	24	29	144	92
	51(H)	214	2	30	21	126	88

	52(H)	190	3	30	22	110	80
Ins(Nae)A	0(B)	205	1	0	0	111	94
	0(B)	254	2	0	0	161	93
	0(B)	201	3	0	0	121	80
NG1	0(B)	208	1	0	0	140	68
	0(B)	114	2	0	0	38	76
	0(B)	218	3	0	0	76	142
NG2	14(B)	106	1	7	7	54	52
	50(B)	216	2	35	15	94	122
	36(B)	168	3	12	24	29	139
NG3	71(B)	175	1	43	28	84	91
NG4	0(B)	254	1	0	0	150	104
	0(B)	215	2	0	0	35	180
	0(B)	200	3	0	0	93	107

A Total number of expressing cells in aggregates that contain four or more cells.

B Cells that express neuroglian-based constructs (NGn) were detected using a monoclonal antibody that recognizes the intracellular domain of neuroglian (see Materials and Methods).

C (H) indicates that cells were aggregated in a 25 ml Erlenmeyer flask, (B) indicates that cells were aggregated in a 12-well microtiter plate (see Materials and Methods).

D Data for individual cell types (i.e., Delta$^+$ and Notch$^+$) in aggregates and unaggregated were not recorded.

Delta amino acids (AA) 1-230 is the current minimum sequence interval defined as being sufficient for interaction with Notch. This is based on the success of NG2-Notch aggregation. Within this interval, Delta AA198-230 are critical because their deletion in the NG1 construct inactivated the Notch-binding activity observed for the NG2 construct. Also within this interval, Delta AA32-198 are critical because their deletion in the NG4 construct also inactivated the Notch-binding activity observed for the NG3 construct. The importance of Delta AA192-230 is also supported by the observation that the Del(ELR1-ELR3) variant, which contains all Delta amino acids except AA231-331, possessed Notch-binding activity, while the Del(Bam-Bgl) variant, which contains all Delta amino acids except AA192-331, was apparently inactivated for Notch-binding activity.

Conformation and/or primary sequence in the vicinity of Delta AA197/198 is apparently critical because a multimeric insertion of the tetrapeptide - Arg-Lys-Ile-Phe [in one letter code (see e.g. Lehninger et al., 1975, Biochemistry, 2d ed., p. 72), RKIF] (SEQ ID NO:30) - between these two residues, as in the Ins(Nae)A construct, inactivated the Notch-binding activity observed with wild type Delta.

In addition, the observation that the Del(ELR1-ELR3) construct supported aggregation implies that ELR1-ELR3 are not required for Delta-Notch interaction; the observation that the Del(ELR4-ELR5) construct supported aggregation implies that ELR4 and ELR5 are not required for Delta-Notch interaction, and the observation that the Ter(Dde) construct supported aggregation implies that the Delta intracellular domain is not required for Delta-Notch interaction.

8.2.2. AMINO-TERMINAL SEQUENCES WITHIN THE DELTA EXTRACELLULAR DOMAIN ARE NECESSARY AND SUFFICIENT FOR HOMOTYPIC INTERACTION

The results of the homotypic aggregation experiments mediated by Delta variants is shown in Table VI.

TABLE VI

HOMOTYPIC AGGREGATION MEDIATED BY DELTA VARIANTS

Construct	Aggregated	Unaggregated	Expt. #
Wild type	38(H)^	175	1
	48(H)	171	2
	13(H)	95	3
	33(H)	173	4
	134(B)	72	5
Del(Sca-Nae)	0(H)	200	1
	0(H)	200	2
	0(H)	200	3
Del(Bam-Bgl)	0(H)	200	1
	0(H)	200	2
	0(H)	200	3
Del(ELR1-ELR3)	160(B)	62	1
	55(B)	80	2
	0(B)	200	3
	4(B)	203	4
	41(B)	234	5
	4(B)	366	6[B]
	23(B)	325 (1:20)	
	0(B)	400	7[B]
	5(B)	347 (1:5)	
	10(B)	228 (1:20)	
	0(B)	400	8[B]
	16(B)	346 (1:5)	
	4(B)	268 (1:20)	

		4(B)	500	9[C]
		18(B)	500 (1:5)	
		12(B)	271 (1:20)	
		7(B)	128 (1:50)	
		0(B)	500	10[C]
		0(B)	500 (1:5)	
		0(B)	500 (1:20)	
		21(B)	246 (1:50)	
		0(B)	500	11[C]
		5(B)	500 (1:5)	
		8(B)	177 (1:20)	
		4(B)	69 (1:50)	
	Del(ELR4-ELR5)	21(H)	175	1
		29(H)	243	2
		35(H)	179	3
	Ter(Dde)	53(H)	164	1
		33(H)	178	2
		36(H)	203	3
	Ins(Nae)A	0(B)	200	1
		0(B)	200	2
		0(B)	200	3

A (H) indicates that cells were aggregated in a 25 ml Erlenmeyer flask; (B) indicates that cells were aggregated in a 12-well microtiter plate (see Materials and Methods).

B Transfected cells were incubated under aggregation conditions overnight, then diluted into the appropriate volume of log-phase S2 cells in the presence of inducer and incubated under aggregation conditions for an additional four to six hours.

C Transfected cells to which inducer had been added were diluted into the appropriate volume of log-phase S2 cells to which inducer had been added,

and the cell mixture was incubated under aggregation conditions overnight.

Deletion of Delta AA32-198 [Del(Sca-Nae)] or Delta AA192-331 [Del(Bam-Bgl)] from the full-length Delta protein eliminated the Delta-Delta interaction. Deletion of Delta AA231-331 [Del(ELR1-ELR3)] did not eliminate the Delta-Delta interaction. Therefore, sequences within the Delta AA32-230 are required for the Delta-Delta interaction.

Conformation and/or primary sequence in the vicinity of Delta AA197/198 is apparently critical for the Delta-Delta interaction because a multimeric insertion of the tetrapeptide -Arg-Lys-Ile-Phe- (SEQ ID NO:30) between these two residues, as in the Ins(Nae)A construct, inactivated Delta-Delta interaction.

In addition, the observation that the Del(ELR1-ELR3) construct could support aggregation implies that ELR1-ELR3 are not required for Delta-Delta interaction; the observation that the Del(ELR-ELR5) construct supported aggregation implies that ELR4 and ELR5 are not required for Delta-Delta interaction, and the observation that the Ter(Dde) construct supported aggregation implies that the Delta intracellular domain is not required for Delta-Delta interaction.

A summary of the results of assays for heterotypic and homotypic aggregation with various constructs are shown in Table VI A.

TABLE VI A

AGGREGATION MEDIATED BY WILD TYPE AND VARIANT DELTA PROTEINS			
CONSTRUCT	HETEROTYPIC AGGREGATION[a] DELTA	NOTCH	HOMOTYPIC AGGREGATION[b] DELTA
Wild Type	33 ± 12[c]	26 ± 11[c]	27 ± 10[c]
Del(Sca-Nae)	0	0	0
Del(Bam-Bgl)	0.4 ± 0.4	0.6 ± 0.6	0
Del(ELR1-ELR3)	25 ± 11[d]	15 ± 3[d]	32 ±15[d]
Del(ELR4-ELR5)	17 ± 2	18 ± 2	13 ± 2
Ter(Dde)	22 ± 1	18 ± 2	18 ± 3
NAE B	25 ± 5	0	27 ± 7
STU B	0	0	0
NG1	0	0	0
NG2	13 ± 1	23 ± 6	4 ± 1[d]
NG3	16 ± 1	13 ± 1	27 ± 17
NG4	0	0	0.5 ± 0.3

a: Mean fraction (%) of Delta or Notch cells in aggregates of four or more cells (± standard error). N=3 replicates, unless otherwise noted.
b: Mean fraction (%) of Delta cells in aggregates of four or more cells (± standard error). N= 3 replicates, unless otherwise noted.
c: N = 5 replicates.
d: N = 4 replicates.

8.2.3. DELTA SEQUENCES INVOLVED IN HETEROTYPIC AND HOMOTYPIC INTERACTIONS ARE QUALITATIVELY DISTINCT

The respective characteristics of Delta sequences repaired for heterotypic and homotypic interaction were further defined using Delta variants in which short, in-frame, translatable linker insertions were introduced into the Delta amino terminus (i.e., NAE B and STU B; Figure 9, Table VI A). Replacement of Delta residue 132 (A) with the

pentapeptide GKIFP (STU B variant) leads to the inactivation of heterotypic and homotypic interaction activities of the Delta amino terminus. This suggests that some Delta sequences required for these two distinct interactions are coincident and reside in proximity to residue 132. On the other hand, insertion of the tetrapeptide RKIF between Delta residues 198 and 199 (NAE B variant) eliminates the ability of the Delta amino terminus to mediate heterotypic interaction with Notch, but has no apparent effect on the ability of the altered amino terminus to mediate homotypic interaction. The finding that the NAE B insertion affects only one of the two activities of the Delta amino terminus implies that the Delta sequences that mediate heterotypic and homotypic interactions, while coincident, are qualitatively distinct.

8.2.4. DELTA IS TAKEN UP BY CELLS THAT EXPRESS NOTCH

During the course of many heterotypic aggregation experiments, we have noted that Delta protein can sometimes be found within cells that have been programmed to express Notch, but not Delta. We conduct heterotypic aggregation assays by mixing initially separate populations of S2 cells that have been independently transfected with expression constructs that program expression of either Delta or Notch. Yet, we often detect punctate staining of Delta within Notch-expressing cells found in heterotypic aggregates using Delta-specific antisera. Our observations are consistent with Delta binding directly to Notch at the cell surface and subsequent clearance of this Delta-Notch complex from the cell surface via endocytosis.

8.3. DISCUSSION

8.3.1. AMINO-TERMINAL SEQUENCES UNRELATED TO EGF ARE INVOLVED IN THE INTERACTION BETWEEN DELTA AND NOTCH

We have employed cell aggregation assays to define a region within the amino-proximal region of the Delta extracellular domain that is necessary and sufficient to mediate the Delta-Notch interaction. Functional analyses of a combination of deletion and sufficiency constructs revealed that this region extends, maximally, from AA1 through AA230. It is striking that this region does not include any of the EGF-like sequences that reside within the Delta extracellular domain. It is probable that the particular Delta sequences within the sufficient interval required for interaction with Notch include AA198-230 because deletion of these residues eliminates Notch-binding activity. The fact that deletion of AA32-198 also inactivates Notch-binding activity suggests that sequences amino-proximal to AA198 are also required, although the deleterious impact of this deletion could result from the removal of additional amino acids in the immediate vicinity of AA198.

Sequences within Delta sufficient for interaction with Notch can be grouped into three subdomains - N1, N2, and N3 - that differ in their respective contents of cysteine residues (Figure 10, SEQ ID NO:3). The N1 and N3 domains each contain six cysteine residues, while the N2 domain contains none. The even number of cysteines present in N1 and N3, respectively, allows for the possibility that the respective structures of these subdomains are dictated, in part, by the formation of particular disulfide bonds. The broad organizational pattern of the Delta amino-terminus is also generally analogous

to that of the extracellular domain of the vertebrate EGF receptor (Lax et al., 1988, Mol. Cell. Biol. 8, 1970-1978), in which sequences believed to interact with EGF are bounded by two cysteine-rich subdomains.

8.3.2. DELTA SEQUENCES REQUIRED FOR HOMOTYPIC AND FOR HOMOTYPIC HETEROTYPIC INTERACTIONS APPEAR TO BE COINCIDENT

Our results also indicate that sequences essential for homotypic Delta interaction reside within the interval AA32-230. Deletion of sequences or insertion of additional amino acids within this amino-proximal domain eliminate the ability of such Delta variants to singly promote cell aggregation. Thus, sequences required for Delta-Delta interaction map within the same domain of the protein as those required for Delta-Notch interaction.

8.3.3. THE DELTA AMINO TERMINUS CONSTITUTES AN EGF-BINDING MOTIF

The work described in examples supra has revealed that Notch sequences required for Delta-Notch interaction in the cell aggregation assay map within the EGF-like repeat array of the Notch extracellular domain. This finding implies that Delta and Notch interact by virtue of the binding of the Delta amino-terminus to EGF-like sequences within Notch and, therefore, that the amino-terminus of the Delta extracellular domain constitutes an EGF-binding domain (Figure 11).

These results also raise the possibility that homotypic Delta interaction involves the binding of the Delta amino-terminus to EGF-like sequences within the Delta extracellular domain (Figure 12). However, none of the EGF-like repeats within the Delta extracellular domain are identical to any of the EGF-

like repeats within the Notch extracellular domain (Figure 13, SEQ ID NO:6; Wharton et al., 1985, Cell 43, 567-581). Given this fact, if Delta homotypic interactions are indeed mediated by interaction between the Delta amino-terminus and Delta EGF-like repeats, then the Delta EGF-binding domain has the capacity to interact with at least two distinct EGF-like sequences.

8.3.4. DELTA SEQUENCES INVOLVED IN THE DELTA-NOTCH INTERACTION ARE CONSERVED IN THE SERRATE PROTEIN

Alignment of amino acid sequences from the amino termini of the Delta (Figure 13, SEQ ID NO:6, and Figure 15, SEQ ID NO:9) and Serrate (Fleming et al., 1990, Genes & Dev. 4, 2188-2201; Thomas et al., 1991, Devel. 111, 749-761) reveals a striking conservation of structural character and sequence composition. The general N1-N2-N3 subdomain structure of the Delta amino terminus is also observed within the Serrate amino terminus, as is the specific occurrence of six cysteine residues within the Delta N1- and Delta N3-homologous domains of the Serrate protein. Two notable blocks of conservation correspond to Delta AA63-73 (8/11 residues identical) and Delta AA195-206 (10/11 residues identical). The latter block is of particular interest because insertion of additional amino acids in this interval can eliminate the ability of Delta to bind to Notch or Delta.

8.3.5. CIS AND TRANS INTERACTIONS BETWEEN DELTA AND NOTCH MAY INVOLVE DIFFERENT SEQUENCES WITHIN NOTCH

Inspection of the overall structures of Delta and Notch suggests that Delta-Notch interaction could involve contacts between the Delta EGF-binding

domain with either of two regions within Notch, depending on whether the interaction were between molecules that reside on opposing membranes or within the same membrane (Figure 11). The cell aggregation assays, which presumably detect the interaction of molecules in opposing membranes, imply that the Delta EGF-binding domain interacts with Notch EGF-like repeats 11 and 12 (see examples supra). If tandem arrays of EGF-like motifs do form rod-like structures (Engel, 1989, FEBS Lett. 251, 1-7) within the Delta and Notch proteins, then the estimated displacement of the Delta EGF-binding domain from the cell surface would presumably be sufficient to accommodate the rigid array of Notch EGF-like repeats 1-10. It is also intriguing to note that the displacement of the Delta EGF-binding domain from the cell surface could place this domain in the vicinity of the Notch EGF-like repeats (25-29) that are affected by Abruptex mutations (Hartley et al., 1987, EMBO J. 6, 3407-3417; Kelley et al., 1987, Mol. Cell. Biol. 6, 3094-3108) and could allow for interaction of Delta and Notch proteins present within the same membrane.

8.3.6. INTERACTIONS ANALOGOUS TO THE DELTA-NOTCH INTERACTION IN VERTEBRATES

Given the interaction between Delta and Notch in Drosophila, it is quite probable that a Delta homologue (Helta?) exists in vertebrates and that the qualitative and molecular aspects of the Delta-Notch and Delta-Delta interactions that we have defined in Drosophila will be highly conserved in vertebrates, including humans. Such homologs can be cloned and sequenced as described supra, Section 5.2.

9. SEQUENCES WHICH MEDIATE NOTCH-SERRATE INTERACTIONS

We report a novel molecular interaction between Notch and Serrate, and show that the two EGF repeats of Notch which mediate interactions with Delta, namely EGF repeats 11 and 12, also constitute a Serrate binding domain.

To test whether Notch and Serrate directly interact, S2 cells were transfected with a Serrate expression construct and mixed with Notch expressing cells in our aggregation assay. For the Serrate expression construct, a synthetic primer containing an artificial BamHI site immediately 5' to the initiator AUG at position 442 (all sequence numbers are according to Fleming et al., 1990, Genes & Dev. 4:2188-2201) and homologous through position 464, was used in conjunction with a second primer from position 681-698 to generate a DNA fragment of ~260 base pairs. This fragment was cut with BamHI and KpnI (position 571) and ligated into Bluescript KS+ (Stratagene). This construct, BTSer5'PCR, was checked by sequencing, then cut with KpnI. The Serrate KpnI fragment (571 - 2981) was inserted and the proper orientation selected, to generate BTSer5'PCR-Kpn. The 5' SacII fragment of BTSer5'PCR-Kpn (SacII sites in Bluescript polylinker and in Serrate (1199)) was isolated and used to replace the 5' SacII fragment of cDNA C1 (Fleming et al., 1990, Genes & Dev. 4:2188-2201), thus regenerating the full length Serrate cDNA minus the 5' untranslated regions. This insert was isolated by a SalI and partial BamHI digestion and shuttled into the BamHI and SalI sites of pRmHa-3 to generate the final expression construct, Ser-mtn.

We found that Serrate expressing cells adhere to Notch expressing cells in a calcium dependent manner (Figure 6 and Table VII). However, unlike Delta, under the experimental conditions

tested, Serrate does not appear to interact homotypically. In addition, we detect no interactions between Serrate and Delta.

TABLE VII

Effect of Exogenous Ca^{++} on Notch - Serrate Aggregation[a]

	Notch-Serrate	
	Without Ca^{++}	With Ca^{++}
1. pMtNMg	0	15
32. ΔECN+EGF(10-12)	0	13
33. ΔCla+XEGF(10-13)	0	15

[a] Data presented as percentage of Notch expressing cells found in aggregates (as in Figure 6). All numbers are from single transfection experiments (rather than an average of values from several separate experiments as in Figure 6).

We have tested a subset of our Notch deletion constructs to map the Serrate-binding domain and have found that EGF repeats 11 and 12, in addition to binding to Delta, also mediate interactions with Serrate (Figure 6; Constructs #1, 7-10, 13, 16, 17, 19, 28, and 32). In addition, the Serrate-binding function of these repeats also appears to have been conserved in the corresponding two EGF repeats of Xenopus Notch (#33ΔCla+XEGF(10-13)). These results unambiguously show that Notch interacts with both Delta and Serrate, and that the same two EGF repeats of Notch mediate both interactions. We were also able to define the Serrate region which is essential for

the Notch/Serrate aggregation. Deleting nucleotides 676-1287 (i.e. amino acids 79-282) (See Figure 15) eliminates the ability of the Serrate protein to aggregate with Notch.

Notch and Serrate appear to aggregate less efficiently than Notch and Delta, perhaps because the Notch-Serrate interaction is weaker. For example, when scoring Notch-Delta aggregates, we detect ~40% of all Notch expressing cells in clusters with Delta expressing cells (Figure 6, #1 pMtNMg) and ~40% of all Delta expressing cells in contact with Notch expressing cells. For Notch-Serrate, we find only ~20% of all Notch expressing cells (Figure 6; pMtNMg) and ~15% of all Serrate expressing cells in aggregates. For the various Notch deletion constructs tested, we consistently detect a reduction in the amount of aggregation between Notch and Serrate as compared to the corresponding Notch-Delta levels (Figure 6), with the possible exception of constructs #9 and 10 which exhibit severely reduced levels of aggregation even with Delta. One trivial explanation for this reduced amount of aggregation could be that our Serrate construct simply does not express as much protein at the cell surface as the Delta construct, thereby diminishing the strength of the interaction. Alternatively, the difference in strength of interaction may indicate a fundamental functional difference between Notch-Delta and Notch-Serrate interactions that may be significant in vivo.

10. THE CLONING, SEQUENCING, AND EXPRESSION OF HUMAN NOTCH

10.1. ISOLATION AND SEQUENCING OF HUMAN NOTCH

Clones for the human Notch sequence were originally obtained using the polymerase chain

reaction (PCR) to amplify DNA from a 17-18 week human fetal brain cDNA library in the Lambda Zap II vector (Stratagene). Degenerate primers to be used in this reaction were designed by comparing the amino acid sequences of the Xenopus homolog of Notch with Drosophila Notch. Three primers (cdc1 (SEQ ID NO:10), cdc2 (SEQ ID NO:11), and cdc3 (SEQ ID NO:12); Figure 16) were designed to amplify either a 200 bp or a 400 bp fragment as primer pairs cdc1/cdc2 or cdc1/cdc3, respectively.

The 400 bp fragment obtained in this manner was then used as a probe with which to screen the same library for human Notch clones. The original screen yielded three unique clones, hN3k, hN2K, and hN5k, all of which were shown by subsequent sequence analysis to fall in the 3' end of human Notch (Figure 17). A second screen using the 5' end of hN3k as probe was undertaken to search for clones encompassing the 5' end of human Notch. One unique clone, hN4k, was obtained from this screen, and preliminary sequencing data indicate that it contains most of the 5' end of the gene (Figure 17). Together, clones hN4k, hN3k and hN5k encompass about 10 kb of the human Notch homolog, beginning early in the EGF-repeats and extending into the 3' untranslated region of the gene. All three clones are cDNA inserts in the EcoRI site of pBluescript SK⁻ (Stratagene). The host E. coli strain is XL1-Blue (see Maniatis, T., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, p. A12).

The sequence of various portions of Notch contained in the cDNA clones was determined (by use of Sequenase®, U.S. Biochemical Corp.) and is shown in Figures 19-22 (SEQ ID NO:13 through NO:25).

The complete nucleotide sequences of the human Notch cDNA contained in hN3k and hN5k was determined by the dideoxy chain termination method using the Sequenase® kit (U.S. Biochemical Corp.). Those nucleotide sequences encoding human Notch, in the appropriate reading frame, were readily identified since translation in only one out of the three possible reading frames yields a sequence which, upon comparison with the published Drosophila Notch deduced amino acid sequence, yields a sequence with a substantial degree of homology to the Drosophila Notch sequence. Since there are no introns, translation of all three possible reading frames and comparison with Drosophila Notch was easily accomplished, leading to the ready identification of the coding region. The DNA and deduced protein sequences of the human Notch cDNA in hN3k and hN5k are presented in Figures 23 and 24, respectively. Clone hN3k encodes a portion of a Notch polypeptide starting at approximately the third Notch/lin-12 repeat to several amino acids short of the carboxy-terminal amino acid. Clone hN5k encodes a portion of a Notch polypeptide starting approximately before the cdc10 region through the end of the polypeptide, and also contains a 3' untranslated region.

Comparing the DNA and protein sequences presented in Figure 23 (SEQ ID NO:31 and NO:32) with those in Figure 24 (SEQ ID NO:33 and NO:34) reveals significant differences between the sequences, suggesting that hN3k and hN5k represent part of two distinct Notch-homologous genes. Our data thus suggest that the human genome harbors more than one Notch-homologous gene. This is unlike Drosophila, where Notch appears to be a single-copy gene.

Comparison of the DNA and amino acid sequences of the human Notch homologs contained in hN3k and hN5k with the corresponding Drosophila Notch sequences (as published in Wharton et al., 1985, Cell 43:567-581) and with the corresponding Xenopus Notch sequences (as published in Coffman et al., 1990, Science 249:1438-1441 or available from Genbank® (accession number M33874)) also revealed differences.

The amino acid sequence shown in Figure 23 (hN3k) was compared with the predicted sequence of the TAN-1 polypeptide shown in Figure 2 of Ellisen et al., August 1991, Cell 66:649-661. Some differences were found between the deduced amino acid sequences; however, overall the hN3k Notch polypeptide sequence is 99% identical to the corresponding TAN-1 region (TAN-1 amino acids 1455 to 2506). Four differences were noted: in the region between the third Notch/lin-12 repeat and the first cdc10 motif, there is an arginine (hN3k) instead of an X (TAN-1 amino acid 1763); (2) there is a proline (hN3k) instead of an X (TAN-1, amino acid 1787); (3) there is a conservative change of an aspartic acid residue (hN3k) instead of a glutamic acid residue (TAN-1, amino acid 2495); and (4) the carboxyl-terminal region differs substantially between TAN-1 amino acids 2507 and 2535.

The amino acid sequence shown in Figure 24 (hN5k) was compared with the predicted sequence of the TAN-1 polypeptide shown in Figure 2 of Ellisen et al., August 1991, Cell 66:649-661. Differences were found between the deduced amino acid sequences. The deduced Notch polypeptide of hN5k is 79% identical to the TAN-1 polypeptide (64% identical to Drosophila Notch) in the cdc10 region that encompasses both the cc10 motif (TAN-1 amino acids 1860 to 2217) and the well-conserved flanking regions (Fig. 25). The cdc10

regi n covers amino acids 1860 thr ugh 2217 of the TAN-1 sequence. In addition, the hN5k encoded polypeptide is 65% identical to the TAN-1 polypeptide (44% identical to Drosophila Notch) at the carboxy-terminal end of the molecule containing a PEST (proline, glutamic acid, serine, threonine)-rich region (TAN-1 amino acids 2482 to 2551) (Fig. 25B). The stretch of 215 amino acids lying between the aforementioned regions is not well conserved among any of the Notch-homologous clones represented by hN3k, hN5k, and TAN-1. Neither the hN5k polypeptide nor Drosophila Notch shows significant levels of amino acid identity to the other proteins in this region (e.g., hN5k/TAN-1 = 24% identity; hN5k/Drosophila Notch = 11% identity; TAN-1/Drosophila Notch = 17% identity). In contrast, Xenopus Notch (Xotch) (SEQ ID NO:35), rat Notch (SEQ ID NO:36), and TAN-1 (SEQ ID NO:37) continue to share significant levels of sequence identity with one another (e.g., TAN-1/rat Notch = 75% identity, TAN-1/Xenopus Notch = 45% identity, rat Notch/Xenopus Notch = 50% identity).

Finally, examination of the sequence of the intracellular domains of the vertebrate Notch homologs shown in Figure 25B revealed an unexpected finding: all of these proteins, including hN5k, contain a putative CcN motif, associated with nuclear targeting function, in the conserved region following the last of the six cdc10 repeats (Fig. 25B). Although Drosophila Notch lacks such a defined motif, closer inspection of its sequence revealed the presence of a possible bipartite nuclear localization sequence (Robbins et al., 1991, Cell 64:615-623), as well as of possible CK II and cdc2 phosphorylation sites, all in relative proximity to one another, thus possibly defining an alternative type of CcN motif (Fig. 25B).

10.2. EXPRESSION OF HUMAN NOTCH

Expression constructs were made using the human Notch cDNA clones discussed in Section 10.1 above. In the cases of hN3k and hN2k, the entire clone was excised from its vector as an EcoRI restriction fragment and subcloned into the EcoRI restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7, 31-40). This allows for the expression of the Notch protein product from the subclone in the correct reading frame. In the case of hN5k, the clone contains two internal EcoRI restriction sites, producing 2.6, 1.5 and 0.6 kb fragments. Both the 2.6 and the 1.5 kb fragments have also been subcloned into each of the pGEX vectors.

The pGEX vector system was used to obtain expression of human Notch fusion (chimeric) proteins from the constructs described below. The cloned Notch DNA in each case was inserted, in phase, into the appropriate pGEX vector. Each construct was then electroporated into bacteria (E. coli), and was expressed as a fusion protein containing the Notch protein sequences fused to the carboxyl terminus of glutathione S-transferase protein. Expression of the fusion proteins was confirmed by analysis of bacterial protein extracts by polyacrylamide gel electrophoresis, comparing protein extracts obtained from bacteria containing the pGEX plasmids with and without the inserted Notch DNA. The fusion proteins were soluble in aqueous solution, and were purified from bacterial lysates by affinity chromatography using glutathione-coated agarose (since the carboxyl terminus of glutathione S-transferase binds to glutathionine). The expressed fusion proteins were

bound by an antibody to Drosophila Notch, as assayed by Western blotting.

The constructs used to make human Notch-glutathione S-transferase fusion proteins were as follows:

hNFP#2 - PCR was used to obtain a fragment starting just before the cdc10 repeats at nucleotide 192 of the hN5k insert to just before the PEST-rich region at nucleotide 1694. The DNA was then digested with BamHI and SmaI and the resulting fragment was ligated into pGEX-3. After expression, the fusion protein was purified by binding to glutathione agarose. The purified polypeptide was quantitated on a 4-15% gradient polyacrylamide gel. The resulting fusion protein had an approximate molecular weight of 83 kD.

hN3FP#1 - The entire hN3k DNA insert (nucleotide 1 to 3235) was excised from the Bluescript (SK) vector by digesting with EcoRI. The DNA was ligated into pGEX-3.

hN3FP#2 - A 3' segment of hN3k DNA (nucleotide 1847 to 3235) plus some of the polylinker was cut out of the Bluescript (SK) vector by digesting with XmaI. The fragment was ligated into pGEX-1.

Following purification, these fusion proteins are used to make either polyclonal and/or monoclonal antibodies to human Notch.

11. DEPOSIT OF MICROORGANISMS

The following recombinant bacteria, each carrying a plasmid encoding a portion of human Notch, were deposited on May 2, 1991 with the American Type Culture Collection, 1201 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest

Treaty on the International Recognition f the Deposit of Microorganisms for the Purposes of Patent Procedures.

Bacteria carrying	Plasmid	ATCC Accession No.
E. coli XL1-Blue	hN4k	68610
E. coli XL1-Blue	hN3k	68609
E. coli XL1-Blue	hN5k	68611

The present invention is not to be limited in scope by the microorganisms deposited or the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Artavanis-Tsakonas, Spyridon et al.

(ii) TITLE OF INVENTION: Human Notch And Delta, Binding Domains In Toporythmic Proteins, And Methods Based Thereon

(iii) NUMBER OF SEQUENCES: 37

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: U.S.A.
(F) ZIP: 10036

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 7326-009

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212 790-9090
(B) TELEFAX: 212 8698864/9741
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 77 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
Glu Asp Ile Asp Glu Cys Asp Gln Gly Ser Pro Cys Glu His Asn Gly
1               5                  10                  15

Ile Cys Val Asn Thr Pro Gly Ser Tyr Arg Cys Asn Cys Ser Gln Gly
            20                  25                  30

Phe Thr Gly Pro Arg Cys Glu Thr Asn Ile Asn Glu Cys Glu Ser His
        35                  40                  45

Pro Cys Gln Asn Glu Gly Ser Cys Leu Asp Asp Pro Gly Thr Phe Arg
    50                  55                  60

Cys Val Cys Met Pro Gly Phe Thr Gly Thr Gln Cys Glu
65                  70                  75
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Asn Asp Val Asp Glu Cys Ser Leu Gly Ala Asn Pro Cys Glu His Gly
1 5 10 15

Gly Arg Cys Thr Asn Thr Leu Gly Ser Phe Gln Cys Asn Cys Pro Gln
20 25 30

Gly Tyr Ala Gly Pro Arg Cys Glu Ile Asp Val Asn Glu Cys Leu Ser
35 40 45

Asn Pro Cys Gln Asn Asp Ser Thr Cys Leu Asp Gln Ile Gly Glu Phe
50 55 60

Gln Cys Ile Cys Met Pro Gly Tyr Glu Gly Leu Tyr Cys Glu
65 70 75

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 203 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Gly Ser Phe Glu Leu Arg Leu Lys Tyr Phe Ser Asn Asp His Gly Arg
1 5 10 15

Asp Asn Glu Gly Arg Cys Cys Ser Gly Glu Ser Asp Gly Ala Thr Gly
20 25 30

Lys Cys Leu Gly Ser Cys Lys Thr Arg Phe Arg Val Cys Leu Lys His
35 40 45

Tyr Gln Ala Thr Ile Asp Thr Thr Ser Gln Cys Thr Tyr Gly Asp Val
50 55 60

Ile Thr Pro Ile Leu Gly Glu Asn Ser Val Asn Leu Thr Asp Ala Gln
65 70 75 80

Arg Phe Gln Asn Lys Gly Phe Thr Asn Pro Ile Gln Phe Pro Phe Ser
85 90 95

Phe Ser Trp Pro Gly Thr Phe Ser Leu Ile Val Glu Ala Trp His Asp
100 105 110

Thr Asn Asn Ser Gly Asn Ala Arg Thr Asn Lys Leu L u Ile Gln Arg
115 120 125

Leu Leu Val Gln Gln Val Leu Glu Val Ser Ser Glu Trp Lys Thr Asn
130 135 140

Lys Ser Glu Ser Gln Tyr Thr Ser Leu Glu Tyr Asp Phe Arg Val Thr
145 150 155 160

Cys Asp Leu Asn Tyr Tyr Gly Ser Gly Cys Ala Lys Phe Cys Arg Pro
165 170 175

Arg Asp Asp Ser Phe Gly His Ser Thr Cys Ser Glu Thr Gly Glu Ile
180 185 190

Ile Cys Leu Thr Gly Trp Gln Gly Asp Tyr Cys
195 200

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 199 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gly Asn Phe Glu Leu Glu Ile Leu Glu Ile Ser Asn Thr Asn Ser His
1 5 10 15

Leu Leu Asn Gly Tyr Cys Cys Gly Met Pro Ala Glu Leu Arg Ala Thr
20 25 30

Lys Thr Ile Gly Cys Ser Pro Cys Thr Thr Ala Phe Arg Leu Cys Leu
35 40 45

Lys Glu Tyr Gln Thr Thr Glu Gln Gly Ala Ser Ile Ser Thr Gly Cys
50 55 60

Ser Phe Gly Asn Ala Thr Thr Lys Ile Leu Gly Gly Ser Ser Phe Val
65 70 75 80

Leu Ser Asp Pro Gly Val Gly Ala Ile Val Leu Pro Phe Thr Phe Arg
85 90 95

Trp Thr Lys Ser Phe Thr Leu Ile Leu Gln Ala Leu Asp Met Tyr Asn
100 105 110

Thr Ser Tyr Pro Asp Ala Glu Arg Leu Ile Glu Glu Thr Ser Tyr Ser
115 120 125

Gly Val Ile Leu Pro Ser Pro Glu Trp Lys Thr Leu Asp His Ile Gly
130 135 140

Arg Asn Ala Arg Ile Thr Tyr Arg Val Arg Val Gln Cys Ala Val Thr
145 150 155 160

Tyr Tyr Asn Thr Thr Cys Thr Thr Phe Cys Arg Pro Arg Asp Asp Gln
165 170 175

Phe Gly His Tyr Ala Cys Gly Ser Glu Gly Gln Lys Leu Cys Leu Asn
180 185 190

Gly Trp Gln Gly Val Asn Cys
195

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2892 base pairs
(B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 142..2640

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
GAATTCGGAG GAATTATTCA AAACATAAAC ACAATAAACA ATTTGAGTAG TTGCCGCACA      60

CACACACACA CACAGCCCGT GGATTATTAC ACTAAAAGCG ACACTCAATC CAAAAAATCA     120

GCAACAAAAA CATCAATAAA C ATG CAT TGG ATT AAA TGT TTA TTA ACA GCA        171
                        Met His Trp Ile Lys Cys Leu Leu Thr Ala
                          1               5                  10

TTC ATT TGC TTC ACA GTC ATC GTG CAG GTT CAC AGT TCC GGC AGC TTT        219
Phe Ile Cys Phe Thr Val Ile Val Gln Val His Ser Ser Gly Ser Phe
                    15                  20                  25

GAG TTG CGC CTG AAG TAC TTC AGC AAC GAT CAC GGG CGG GAC AAC GAG        267
Glu Leu Arg Leu Lys Tyr Phe Ser Asn Asp His Gly Arg Asp Asn Glu
                30                  35                  40

GGT CGC TGC TGC AGC GGG GAG TCG GAC GGA GCG ACG GGC AAG TGC CTG        315
Gly Arg Cys Cys Ser Gly Glu Ser Asp Gly Ala Thr Gly Lys Cys Leu
            45                  50                  55

GGC AGC TGC AAG ACG CGG TTT CGC GTC TGC CTA AAG CAC TAC CAG GCC        363
Gly Ser Cys Lys Thr Arg Phe Arg Val Cys Leu Lys His Tyr Gln Ala
        60                  65                  70

ACC ATC GAC ACC ACC TCC CAG TGC ACC TAC GGG GAC GTG ATC ACG CCC        411
Thr Ile Asp Thr Thr Ser Gln Cys Thr Tyr Gly Asp Val Ile Thr Pro
 75                  80                  85                  90

ATT CTC GGC GAG AAC TCG GTC AAT CTG ACC GAC GCC CAG CGC TTC CAG        459
Ile Leu Gly Glu Asn Ser Val Asn Leu Thr Asp Ala Gln Arg Phe Gln
                95                  100                 105

AAC AAG GGC TTC ACG AAT CCC ATC CAG TTC CCC TTC TCG TTC TCA TGG        507
Asn Lys Gly Phe Thr Asn Pro Ile Gln Phe Pro Phe Ser Phe Ser Trp
            110                 115                 120

CCG GGT ACC TTC TCG CTG ATC GTC GAG GCC TGG CAT GAT ACG AAC AAT        555
Pro Gly Thr Phe Ser Leu Ile Val Glu Ala Trp His Asp Thr Asn Asn
        125                 130                 135

AGC GGC AAT GCG CGA ACC AAC AAG CTC CTC ATC CAG CGA CTC TTG GTG        603
Ser Gly Asn Ala Arg Thr Asn Lys Leu Leu Ile Gln Arg Leu Leu Val
    140                 145                 150

CAG CAG GTA CTG GAG GTG TCC TCC GAA TGG AAG ACG AAC AAG TCG GAA        651
Gln Gln Val Leu Glu Val Ser Ser Glu Trp Lys Thr Asn Lys Ser Glu
155                 160                 165                 170

TCG CAG TAC ACG TCG CTG GAG TAC GAT TTC CGT GTC ACC TGC GAT CTC        699
Ser Gln Tyr Thr Ser Leu Glu Tyr Asp Phe Arg Val Thr Cys Asp Leu
                175                 180                 185

AAC TAC TAC GGA TCC GGC TGT GCC AAG TTC TGC CGG CCC CGC GAC GAT        747
Asn Tyr Tyr Gly Ser Gly Cys Ala Lys Phe Cys Arg Pro Arg Asp Asp
            190                 195                 200

TCA TTT GGA CAC TCG ACT TGC TCG GAG ACG GGC GAA ATT ATC TGT TTG        795
```

```
Ser Phe Gly His Ser Thr Cys Ser Glu Thr Gly Glu Ile Il  Cys Leu
        205                 210                 215

ACC GGA TGG CAG GGC GAT TAC TGT CAC ATA CCC AAA TGC GCC AAA GGC      843
Thr Gly Trp Gln Gly Asp Tyr Cys His Ile Pro Lys Cys Ala Lys Gly
    220                 225                 230

TGT GAA CAT GGA CAT TGC GAC AAA CCC AAT CAA TGC GTT TGC CAA CTG      891
Cys Glu His Gly His Cys Asp Lys Pro Asn Gln Cys Val Cys Gln Leu
235                 240                 245                 250

GGC TGG AAG GGA GCC TTG TGC AAC GAG TGC GTT CTG GAA CCG AAC TGC      939
Gly Trp Lys Gly Ala Leu Cys Asn Glu Cys Val Leu Glu Pro Asn Cys
                255                 260                 265

ATC CAT GGC ACC TGC AAC AAA CCC TGG ACT TGC ATC TGC AAC GAG GGT      987
Ile His Gly Thr Cys Asn Lys Pro Trp Thr Cys Ile Cys Asn Glu Gly
            270                 275                 280

TGG GGA GGC TTG TAC TGC AAC CAG GAT CTG AAC TAC TGC ACC AAC CAC     1035
Trp Gly Gly Leu Tyr Cys Asn Gln Asp Leu Asn Tyr Cys Thr Asn His
        285                 290                 295

AGA CCC TGC AAG AAT GGC GGA ACC TGC TTC AAC ACC GGC GAG GGA TTG     1083
Arg Pro Cys Lys Asn Gly Gly Thr Cys Phe Asn Thr Gly Glu Gly Leu
    300                 305                 310

TAC ACA TGC AAA TGC GCT CCA GGA TAC AGT GGT GAT GAT TGC GAA AAT     1131
Tyr Thr Cys Lys Cys Ala Pro Gly Tyr Ser Gly Asp Asp Cys Glu Asn
315                 320                 325                 330

GAG ATC TAC TCC TGC GAT GCC GAT GTC AAT CCC TGC CAG AAT GGT GGT     1179
Glu Ile Tyr Ser Cys Asp Ala Asp Val Asn Pro Cys Gln Asn Gly Gly
                335                 340                 345

ACC TGC ATC GAT GAG CCG CAC ACA AAA ACC GGC TAC AAG TGT CAT TGC     1227
Thr Cys Ile Asp Glu Pro His Thr Lys Thr Gly Tyr Lys Cys His Cys
            350                 355                 360

GCC AAC GGC TGG AGC GGA AAG ATG TGC GAG GAG AAA GTG CTC ACG TGT     1275
Ala Asn Gly Trp Ser Gly Lys Met Cys Glu Glu Lys Val Leu Thr Cys
        365                 370                 375

TCG GAC AAA CCC TGT CAT CAG GGA ATC TGC CGC AAC GTT CGT CCT GGC     1323
Ser Asp Lys Pro Cys His Gln Gly Ile Cys Arg Asn Val Arg Pro Gly
    380                 385                 390

TTG GGA AGC AAG GGT CAG GGC TAC CAG TGC GAA TGT CCC ATT GGC TAC     1371
Leu Gly Ser Lys Gly Gln Gly Tyr Gln Cys Glu Cys Pro Ile Gly Tyr
395                 400                 405                 410

AGC GGA CCC AAC TGC GAT CTC CAG CTG GAC AAC TGC AGT CCG AAT CCA     1419
Ser Gly Pro Asn Cys Asp Leu Gln Leu Asp Asn Cys Ser Pro Asn Pro
                415                 420                 425

TGC ATA AAC GGT GGA AGC TGT CAG CCG AGC GGA AAG TGT ATT TGC CCA     1467
Cys Ile Asn Gly Gly Ser Cys Gln Pro Ser Gly Lys Cys Ile Cys Pro
            430                 435                 440

GCG GGA TTT TCG GGA ACG AGA TGC GAG ACC AAC ATT GAC GAT TGT CTT     1515
Ala Gly Phe Ser Gly Thr Arg Cys Glu Thr Asn Ile Asp Asp Cys Leu
        445                 450                 455

GGC CAC CAG TGC GAG AAC GGA GGC ACC TGC ATA GAT ATG GTC AAC CAA     1563
Gly His Gln Cys Glu Asn Gly Gly Thr Cys Il  Asp Met Val Asn Gln
    460                 465                 470

TAT CGC TGC CAA TGC GTT CCC GGT TTC CAT GGC ACC CAC TGT AGT AGC     1611
Tyr Arg Cys Gln Cys Val Pro Gly Phe His Gly Thr His Cys Ser Ser
475                 480                 485                 490
```

```
AAA GTT GAC TTG TGC CTC ATC AGA CCG TGT GCC AAT GGA GGA ACC TGC      1659
Lys Val Asp Leu Cys Leu Il  Arg Pro Cys Ala Asn Gly Gly Thr Cys
                495                 500                 505

TTG AAT CTC AAC AAC GAT TAC CAG TGC ACC TGT CGT GCG GGA TTT ACT      1707
Leu Asn Leu Asn Asn Asp Tyr Gln Cys Thr Cys Arg Ala Gly Phe Thr
            510                 515                 520

GGC AAG GAT TGC TCT GTG GAC ATC GAT GAG TGC AGC AGT GGA CCC TGT      1755
Gly Lys Asp Cys Ser Val Asp Ile Asp Glu Cys Ser Ser Gly Pro Cys
        525                 530                 535

CAT AAC GGC GGC ACT TGC ATG AAC CGC GTC AAT TCG TTC GAA TGC GTG      1803
His Asn Gly Gly Thr Cys Met Asn Arg Val Asn Ser Phe Glu Cys Val
    540                 545                 550

TGT GCC AAT GGT TTC AGG GGC AAG CAG TGC GAT GAG GAG TCC TAC GAT      1851
Cys Ala Asn Gly Phe Arg Gly Lys Gln Cys Asp Glu Glu Ser Tyr Asp
555                 560                 565                 570

TCG GTG ACC TTC GAT GCC CAC CAA TAT GGA GCG ACC ACA CAA GCG AGA      1899
Ser Val Thr Phe Asp Ala His Gln Tyr Gly Ala Thr Thr Gln Ala Arg
                575                 580                 585

GCC GAT GGT TTG ACC AAT GCC CAG GTA GTC CTA ATT GCT GTT TTC TCC      1947
Ala Asp Gly Leu Thr Asn Ala Gln Val Val Leu Ile Ala Val Phe Ser
            590                 595                 600

GTT GCG ATG CCT TTG GTG GCG GTT ATT GCG GCG TGC GTG GTC TTC TGC      1995
Val Ala Met Pro Leu Val Ala Val Ile Ala Ala Cys Val Val Phe Cys
        605                 610                 615

ATG AAG CGC AAG CGT AAG CGT GCT CAG GAA AAG GAC GAC GCG GAG GCC      2043
Met Lys Arg Lys Arg Lys Arg Ala Gln Glu Lys Asp Asp Ala Glu Ala
    620                 625                 630

AGG AAG CAG AAC GAA CAG AAT GCG GTG GCC ACA ATG CAT CAC AAT GGC      2091
Arg Lys Gln Asn Glu Gln Asn Ala Val Ala Thr Met His His Asn Gly
635                 640                 645                 650

AGT GGG GTG GGT GTA GCT TTG GCT TCA GCC TCT CTG GGC GGC AAA ACT      2139
Ser Gly Val Gly Val Ala Leu Ala Ser Ala Ser Leu Gly Gly Lys Thr
                655                 660                 665

GGC AGC AAC AGC GGT CTC ACC TTC GAT GGC GGC AAC CCG AAT ATC ATC      2187
Gly Ser Asn Ser Gly Leu Thr Phe Asp Gly Gly Asn Pro Asn Ile Ile
            670                 675                 680

AAA AAC ACC TGG GAC AAG TCG GTC AAC AAC ATT TGT GCC TCA GCA GCA      2235
Lys Asn Thr Trp Asp Lys Ser Val Asn Asn Ile Cys Ala Ser Ala Ala
        685                 690                 695

GCA GCG GCG GCG GCG GCA GCA GCG GCG GAC GAG TGT CTC ATG TAC GGC      2283
Ala Ala Ala Ala Ala Ala Ala Ala Ala Asp Glu Cys Leu Met Tyr Gly
    700                 705                 710

GGA TAT GTG GCC TCG GTG GCG GAT AAC AAC AAT GCC AAC TCA GAC TTT      2331
Gly Tyr Val Ala Ser Val Ala Asp Asn Asn Asn Ala Asn Ser Asp Phe
715                 720                 725                 730

TGT GTG GCT CCG CTA CAA AGA GCC AAG TCG CAA AAG CAA CTC AAC ACC      2379
Cys Val Ala Pro Leu Gln Arg Ala Lys Ser Gln Lys Gln Leu Asn Thr
                735                 740                 745

GAT CCC ACG CTC ATG CAC CGC GGT TCG CCG GCA GGC AGC TCA GCC AAG      2427
Asp Pro Thr Leu Met His Arg Gly Ser Pro Ala Gly Ser Ser Ala Lys
            750                 755                 760

GGA GCG TCT GGC GGA GGA CCG GGA GCG GCG GAG GGC AAG AGG ATC TCT      2475
Gly Ala Ser Gly Gly Gly Pro Gly Ala Ala Glu Gly Lys Arg Ile Ser
```

```
        765                 770                 775

GTT TTA GGC GAG GGT TCC TAC TGT AGC CAG CGT TGG CCC TCG TTG GCG      2523
Val Leu Gly Glu Gly Ser Tyr Cys Ser Gln Arg Trp Pro Ser Leu Ala
    780                 785                 790

GCG GCG GGA GTG GCC GGA GCC TGT TCA TCC CAG CTA ATG GCT GCA GCT      2571
Ala Ala Gly Val Ala Gly Ala Cys Ser Ser Gln Leu Met Ala Ala Ala
795                 800                 805                 810

TCG GCA GCG GGC AGC GGA GCG GGG ACG GCG CAA CAG CAG CGA TCC GTG      2619
Ser Ala Ala Gly Ser Gly Ala Gly Thr Ala Gln Gln Gln Arg Ser Val
                815                 820                 825

GTC TGC GGC ACT CCG CAT ATG TAACTCCAAA AATCCGGAAG GGCTCCTGGT         2670
Val Cys Gly Thr Pro His Met
            830

AAATCCGGAG AAATCCGCAT GGAGGAGCTG ACAGCACATA CACAAAGAAA AGACTGGGTT    2730

GGGTTCAAAA TGTGAGAGAG ACGCCAAAAT GTTGTTGTTG ATTGAAGCAG TTTAGTCGTC    2790

ACGAAAAATG AAAAATCTGT AACAGGCATA ACTCGTAAAC TCCCTAAAAA ATTTGTATAG    2850

TAATTAGCAA AGCTGTGACC CAGCCGTTTC GATCCCGAAT TC                       2892
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 833 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met His Trp Ile Lys Cys Leu Leu Thr Ala Phe Ile Cys Phe Thr Val
 1               5                  10                  15

Ile Val Gln Val His Ser Ser Gly Ser Phe Glu Leu Arg Leu Lys Tyr
            20                  25                  30

Phe Ser Asn Asp His Gly Arg Asp Asn Glu Gly Arg Cys Cys Ser Gly
        35                  40                  45

Glu Ser Asp Gly Ala Thr Gly Lys Cys Leu Gly Ser Cys Lys Thr Arg
    50                  55                  60

Phe Arg Val Cys Leu Lys His Tyr Gln Ala Thr Ile Asp Thr Thr Ser
65                  70                  75                  80

Gln Cys Thr Tyr Gly Asp Val Ile Thr Pro Ile Leu Gly Glu Asn Ser
                85                  90                  95

Val Asn Leu Thr Asp Ala Gln Arg Phe Gln Asn Lys Gly Phe Thr Asn
            100                 105                 110

Pro Ile Gln Phe Pro Phe Ser Phe Ser Trp Pro Gly Thr Phe Ser Leu
        115                 120                 125

Ile Val Glu Ala Trp His Asp Thr Asn Asn Ser Gly Asn Ala Arg Thr
    130                 135                 140

Asn Lys Leu Leu Ile Gln Arg Leu Leu Val Gln Gln Val Leu Glu Val
145                 150                 155                 160

Ser Ser Glu Trp Lys Thr Asn Lys Ser Glu Ser Gln Tyr Thr Ser Leu
                165                 170                 175
```

Glu Tyr Asp Phe Arg Val Thr Cys Asp Leu Asn Tyr Tyr Gly Ser Gly
180 185 190

Cys Ala Lys Phe Cys Arg Pro Arg Asp Asp Ser Phe Gly His Ser Thr
195 200 205

Cys Ser Glu Thr Gly Glu Ile Ile Cys Leu Thr Gly Trp Gln Gly Asp
210 215 220

Tyr Cys His Ile Pro Lys Cys Ala Lys Gly Cys Glu His Gly His Cys
225 230 235 240

Asp Lys Pro Asn Gln Cys Val Cys Gln Leu Gly Trp Lys Gly Ala Leu
245 250 255

Cys Asn Glu Cys Val Leu Glu Pro Asn Cys Ile His Gly Thr Cys Asn
260 265 270

Lys Pro Trp Thr Cys Ile Cys Asn Glu Gly Trp Gly Gly Leu Tyr Cys
275 280 285

Asn Gln Asp Leu Asn Tyr Cys Thr Asn His Arg Pro Cys Lys Asn Gly
290 295 300

Gly Thr Cys Phe Asn Thr Gly Glu Gly Leu Tyr Thr Cys Lys Cys Ala
305 310 315 320

Pro Gly Tyr Ser Gly Asp Asp Cys Glu Asn Glu Ile Tyr Ser Cys Asp
325 330 335

Ala Asp Val Asn Pro Cys Gln Asn Gly Gly Thr Cys Ile Asp Glu Pro
340 345 350

His Thr Lys Thr Gly Tyr Lys Cys His Cys Ala Asn Gly Trp Ser Gly
355 360 365

Lys Met Cys Glu Glu Lys Val Leu Thr Cys Ser Asp Lys Pro Cys His
370 375 380

Gln Gly Ile Cys Arg Asn Val Arg Pro Gly Leu Gly Ser Lys Gly Gln
385 390 395 400

Gly Tyr Gln Cys Glu Cys Pro Ile Gly Tyr Ser Gly Pro Asn Cys Asp
405 410 415

Leu Gln Leu Asp Asn Cys Ser Pro Asn Pro Cys Ile Asn Gly Gly Ser
420 425 430

Cys Gln Pro Ser Gly Lys Cys Ile Cys Pro Ala Gly Phe Ser Gly Thr
435 440 445

Arg Cys Glu Thr Asn Ile Asp Asp Cys Leu Gly His Gln Cys Glu Asn
450 455 460

Gly Gly Thr Cys Ile Asp Met Val Asn Gln Tyr Arg Cys Gln Cys Val
465 470 475 480

Pro Gly Phe His Gly Thr His Cys Ser Ser Lys Val Asp Leu Cys Leu
485 490 495

Ile Arg Pro Cys Ala Asn Gly Gly Thr Cys Leu Asn Leu Asn Asn Asp
500 505 510

Tyr Gln Cys Thr Cys Arg Ala Gly Phe Thr Gly Lys Asp Cys Ser Val
515 520 525

Asp Ile Asp Glu Cys S r Ser ly Pro Cys His Asn Gly Gly Thr Cys
530 535 540

Met Asn Arg Val Asn Ser Phe Glu Cys Val Cys Ala Asn Gly Phe Arg

```
545                 550                 555                 560

Gly Lys Gln Cys Asp Glu  lu Ser Tyr Asp Ser Val Thr Phe Asp Ala
                565                 570                 575

His Gln Tyr Gly Ala Thr Thr Gln Ala Arg Ala Asp Gly Leu Thr Asn
            580                 585                 590

Ala Gln Val Val Leu Ile Ala Val Phe Ser Val Ala Met Pro Leu Val
        595                 600                 605

Ala Val Ile Ala Ala Cys Val Val Phe Cys Met Lys Arg Lys Arg Lys
    610                 615                 620

Arg Ala Gln Glu Lys Asp Asp Ala Glu Ala Arg Lys Gln Asn Glu Gln
625                 630                 635                 640

Asn Ala Val Ala Thr Met His His Asn Gly Ser Gly Val Gly Val Ala
                645                 650                 655

Leu Ala Ser Ala Ser Leu Gly Gly Lys Thr Gly Ser Asn Ser Gly Leu
            660                 665                 670

Thr Phe Asp Gly Gly Asn Pro Asn Ile Ile Lys Asn Thr Trp Asp Lys
        675                 680                 685

Ser Val Asn Asn Ile Cys Ala Ser Ala Ala Ala Ala Ala Ala Ala Ala
    690                 695                 700

Ala Ala Ala Asp Glu Cys Leu Met Tyr Gly Gly Tyr Val Ala Ser Val
705                 710                 715                 720

Ala Asp Asn Asn Asn Ala Asn Ser Asp Phe Cys Val Ala Pro Leu Gln
                725                 730                 735

Arg Ala Lys Ser Gln Lys Gln Leu Asn Thr Asp Pro Thr Leu Met His
            740                 745                 750

Arg Gly Ser Pro Ala Gly Ser Ser Ala Lys Gly Ala Ser Gly Gly Gly
        755                 760                 765

Pro Gly Ala Ala Glu Gly Lys Arg Ile Ser Val Leu Gly Glu Gly Ser
    770                 775                 780

Tyr Cys Ser Gln Arg Trp Pro Ser Leu Ala Ala Ala Gly Val Ala Gly
785                 790                 795                 800

Ala Cys Ser Ser Gln Leu Met Ala Ala Ala Ser Ala Ala Gly Ser Gly
                805                 810                 815

Ala Gly Thr Ala Gln Gln Gln Arg Ser Val Val Cys Gly Thr Pro His
            820                 825                 830

Met
```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1067 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GATCTACTAC GAGGAGGTTA AGGAGAGCTA TGTGGGCGAG CGACGCGAAT ACGATCCCCA 60

CATCACCGAT CCCAGGGTCA CACGCATGAA GATGGCCGGC CTGAAGCCCA ACTCCAAATA 120

CCGCATCTCC ATCACTGCCA CCACGAAAAT GGGCGAGGGA TCTGAACACT ATATCGAAAA 180

GACCACGCTC AAGGATGCCG TCAATGTGGC CCCTGCCACG CCATCTTTCT CCTGGGAGCA 240

ACTGCCATCC GACAATGGAC TAGCCAAGTT CCGCATCAAC TGGCTGCCAA GTACCGAGGG 300

TCATCCAGGC ACTCACTTCT TTACGATGCA CAGGATCAAG GGCGAAACCC AATGGATACG 360

CGAGAATGAG GAAAAGAACT CCGATTACCA GGAGGTCGGT GGCTTAGATC CGGAGACCGC 420

CTACGAGTTC CGCGTGGTGT CCGTGGATGG CCACTTTAAC ACGGAGAGTG CCACGCAGGA 480

GATCGACACG AACACCGTTG AGGGACCAAT AATGGTGGCC AACGAGACGG TGGCCAATGC 540

CGGATGGTTC ATTGGCATGA TGCTGGCCCT GGCCTTCATC ATCATCCTCT TCATCATCAT 600

CTGCATTATC CGACGCAATC GGGGCGGAAA GTACGATGTC CACGATCGGG AGCTGGCCAA 660

CGGCCGGCGG GATTATCCCG AAGAGGGCGG ATTCCACGAG TACTCGCAAC CGTTGGATAA 720

CAAGAGCGCT GGTCGCCAAT CCGTGAGTTC AGCGAACAAA CCGGGCGTGG AAAGCGATAC 780

TGATTCGATG GCCGAATACG GTGATGGCGA TACAGGACAA TTTACCGAGG ATGGCTCCTT 840

CATTGGCCAA TATGTTCCTG GAAAGCTCCA ACCGCCGGTT AGCCCACAGC CACTGAACAA 900

TTCCGCTGCG GCGCATCAGG CGGCGCCAAC TGCCGGAGGA TCGGGAGCAG CCGGATCGGC 960

AGCAGCAGCC GGAGCATCGG GTGGAGCATC GTCCGCCGGA GGAGCAGCTG CCAGCAATGG 1020

AGGAGCTGCA GCCGGAGCCG TGGCCACCTA CGTCTAAGCT TGGTACC 1067

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1320 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 442..1320

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CCGAGTCGAG CGCCGTGCTT CGAGCGGTGA TGAGCCCCTT TTCTGTCAAC GCTAAAGATC 60

TACAAAACAT CAGCGCCTAT CAAGTGGAAG TGTCAAGTGT GAACAAAACA AAAACGAGAG 120

AAGCACATAC TAAGGTCCAT ATAAATAATA AATAATAATT GTGTGTGATA ACAACATTAT 180

CCAAACAAAA CCAAACAAAA CGAAGGCAAA GTGGAGAAAA TGATACAGCA TCCAGAGTAC 240

GGCCGTTATT CAGCTATCCA GAGCAAGTGT AGTGTGGCAA AATAGAAACA AACAAAGGCA 300

CCAAAATCTG CATACATGGG CTAATTAAGG CTGCCCAGCG AATTTACATT TGTGTGGTGC 360

CAATCCAGAG TGAATCCGAA ACAAACTCCA TCTAGATCGC CAACCAGCAT CACGCTCGCA 420

AACGCCCCCA GAATGTACAA A ATG TTT AGG AAA CAT TTT CGG CGA AAA CCA 471
Met Phe Arg Lys His Phe Arg Arg Lys Pro

```
                                1               5                  10

GCT ACG TCG TCG TCG TTG GAG TCA ACA ATA GAA TCA GCA GAC AGC CTG      519
Ala Thr Ser Ser Ser Leu Glu Ser Thr Il  Glu Ser Ala Asp Ser Leu
                    15                  20                  25

GGA ATG TCC AAG AAG ACG GCG ACA AAA AGG CAG CGT CCG AGG CAT CGG      567
Gly Met Ser Lys Lys Thr Ala Thr Lys Arg Gln Arg Pro Arg His Arg
               30                  35                  40

GTA CCC AAA ATC GCG ACC CTG CCA TCG ACG ATC CGC GAT TGT CGA TCA      615
Val Pro Lys Ile Ala Thr Leu Pro Ser Thr Ile Arg Asp Cys Arg Ser
          45                  50                  55

TTA AAG TCT GCC TGC AAC TTA ATT GCT TTA ATT TTA ATA CTG TTA GTC      663
Leu Lys Ser Ala Cys Asn Leu Ile Ala Leu Ile Leu Ile Leu Leu Val
     60                  65                  70

CAT AAG ATA TCC GCA GCT GGT AAC TTC GAG CTG GAA ATA TTA GAA ATC      711
His Lys Ile Ser Ala Ala Gly Asn Phe Glu Leu Glu Ile Leu Glu Ile
 75                  80                  85                  90

TCA AAT ACC AAC AGC CAT CTA CTC AAC GGC TAT TGC TGC GGC ATG CCA      759
Ser Asn Thr Asn Ser His Leu Leu Asn Gly Tyr Cys Cys Gly Met Pro
                95                  100                 105

GCG GAA CTT AGG GCC ACC AAG ACG ATA GGC TGC TCG CCA TGC ACG ACG      807
Ala Glu Leu Arg Ala Thr Lys Thr Ile Gly Cys Ser Pro Cys Thr Thr
           110                 115                 120

GCA TTC CGG CTG TGC CTG AAG GAG TAC CAG ACC ACG GAG CAG GGT GCC      855
Ala Phe Arg Leu Cys Leu Lys Glu Tyr Gln Thr Thr Glu Gln Gly Ala
      125                 130                 135

AGC ATA TCC ACG GGC TGT TCG TTT GGC AAC GCC ACC ACC AAG ATA CTG      903
Ser Ile Ser Thr Gly Cys Ser Phe Gly Asn Ala Thr Thr Lys Ile Leu
 140                 145                 150

GGT GGC TCC AGC TTT GTG CTC AGC GAT CCG GGT GTG GGA GCC ATT GTG      951
Gly Gly Ser Ser Phe Val Leu Ser Asp Pro Gly Val Gly Ala Ile Val
155                 160                 165                 170

CTG CCC TTT ACG TTT CGT TGG ACG AAG TCG TTT ACG CTG ATA CTG CAG      999
Leu Pro Phe Thr Phe Arg Trp Thr Lys Ser Phe Thr Leu Ile Leu Gln
                175                 180                 185

GCG TTG GAT ATG TAC AAC ACA TCC TAT CCA GAT GCG GAG AGG TTA ATT     1047
Ala Leu Asp Met Tyr Asn Thr Ser Tyr Pro Asp Ala Glu Arg Leu Ile
           190                 195                 200

GAG GAA ACA TCA TAC TCG GGC GTG ATA CTG CCG TCG CCG GAG TGG AAG     1095
Glu Glu Thr Ser Tyr Ser Gly Val Ile Leu Pro Ser Pro Glu Trp Lys
      205                 210                 215

ACG CTG GAC CAC ATC GGG CGG AAC GCG CGG ATC ACC TAC CGT GTC CGG     1143
Thr Leu Asp His Ile Gly Arg Asn Ala Arg Ile Thr Tyr Arg Val Arg
 220                 225                 230

GTG CAA TGC GCC GTT ACC TAC TAC AAC ACG ACC TGC ACG ACC TTC TGC     1191
Val Gln Cys Ala Val Thr Tyr Tyr Asn Thr Thr Cys Thr Thr Phe Cys
235                 240                 245                 250

CGT CCG CGG GAC GAT CAG TTC GGT CAC TAC GCC TGC GGC TCC GAG GGT     1239
Arg Pr  Arg Asp Asp Gln Phe Gly His Tyr Ala Cys Gly Ser Glu Gly
                255                 260                 265

CAG AAG CTC TGC CTG AAT GGC TGG CAG GGC GTC AAC TGC GAG GAG GCC     1287
Gln Lys Leu Cys Leu Asn Gly Trp Gln Gly Val Asn Cys Glu Glu Ala
           270                 275                 280
```

ATA TGC AAG GCG GGC TGC GAC CCC GTC CAC GGC 1320
Ile Cys Lys Ala Gly Cys Asp Pro Val His Gly
285 290

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 293 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Phe Arg Lys His Phe Arg Arg Lys Pro Ala Thr Ser Ser Ser Leu
1 5 10 15

Glu Ser Thr Ile Glu Ser Ala Asp Ser Leu Gly Met Ser Lys Lys Thr
20 25 30

Ala Thr Lys Arg Gln Arg Pro Arg His Arg Val Pro Lys Ile Ala Thr
35 40 45

Leu Pro Ser Thr Ile Arg Asp Cys Arg Ser Leu Lys Ser Ala Cys Asn
50 55 60

Leu Ile Ala Leu Ile Leu Ile Leu Leu Val His Lys Ile Ser Ala Ala
65 70 75 80

Gly Asn Phe Glu Leu Glu Ile Leu Glu Ile Ser Asn Thr Asn Ser His
85 90 95

Leu Leu Asn Gly Tyr Cys Cys Gly Met Pro Ala Glu Leu Arg Ala Thr
100 105 110

Lys Thr Ile Gly Cys Ser Pro Cys Thr Thr Ala Phe Arg Leu Cys Leu
115 120 125

Lys Glu Tyr Gln Thr Thr Glu Gln Gly Ala Ser Ile Ser Thr Gly Cys
130 135 140

Ser Phe Gly Asn Ala Thr Thr Lys Ile Leu Gly Gly Ser Ser Phe Val
145 150 155 160

Leu Ser Asp Pro Gly Val Gly Ala Ile Val Leu Pro Phe Thr Phe Arg
165 170 175

Trp Thr Lys Ser Phe Thr Leu Ile Leu Gln Ala Leu Asp Met Tyr Asn
180 185 190

Thr Ser Tyr Pro Asp Ala Glu Arg Leu Ile Glu Glu Thr Ser Tyr Ser
195 200 205

Gly Val Ile Leu Pro Ser Pro Glu Trp Lys Thr Leu Asp His Ile Gly
210 215 220

Arg Asn Ala Arg Ile Thr Tyr Arg Val Arg Val Gln Cys Ala Val Thr
225 230 235 240

Tyr Tyr Asn Thr Thr Cys Thr Thr Phe Cys Arg Pro Arg Asp Asp Gln
245 250 255

Phe Gly His Tyr Ala Cys Gly S r Glu Gly Gln Lys Leu Cys Leu Asn
260 265 270

Gly Trp Gln Gly Val Asn Cys Glu Glu Ala Ile Cys Lys Ala Gly Cys
275 280 285

Asp Pro Val His Gly
290

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 6
(D) OTHER INFORMATION: /mod_base= i
/label= N

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 12
(D) OTHER INFORMATION: /mod_base= i
/label= N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GAYGCNAAYG TNCARGAYAA YATGGG 26

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 3
(D) OTHER INFORMATION: /mod_base= i
/label= N

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 12
(D) OTHER INFORMATION: /mod_base= i
/label= N

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 18
(D) OTHER INFORMATION: /mod_base= i
/label= N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ATNARRTCYT CNACCATNCC YTCDA 25

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 12
(D) OTHER INFORMATION: /mod_base= i
/label= N

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 18
(D) OTHER INFORMATION: /mod_base= i
/label= N

(ix) FEATURE:
(A) NAME/KEY: modified_base
(B) LOCATION: 21
(D) OTHER INFORMATION: /mod_base= i
/label= N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TCCATRTGRT CNGTDATNTC NCKRTT 26

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 267 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GAATTCCGCT GGGAGAATGG TCTGAGCTAC CTGCCCGTCC TGCTGGGGCA TCAATGGCAA 60

GTGGGGAAAG CCACACTGGG CAAACGGGCC AGGCCATTTC TGGAATGTGG TACATGGTGG 120

GCAGGGGGCC CGCAACAGCT GGAGGGCAGG TGGACTGAGG CTGGGGATCC CCCGCTGGTT 180

GGGCAATACT GCCTTTACCC ATGAGCTGGA AAGTCACAAT GGGGGGCAAG GGCTCCCGAG 240

GGTGGTTATG TGCTTCCTTC AGGTGGC 267

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 574 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAATTCCTTC CATTATACGT GACTTTTCTG AAACTGTAGC CACCCTAGTG TCTCTAACTC 60

CCTCTGGAGT TTGTCAGCTT TGGTCTTTTC AAAGAGCAG CTCTCTTCAA GCTCCTTAAT 120

GCGGGCATGC TCCAGTTTGG TCTGCGTCTC AAGATCACCT TTGGTAATTG ATTCTTCTTC 180

AACCCGGAAC TGAAGGCTGG CTCTCACCCT CTAGGCAGAG CAGGAATTCC GAGGTGGATG 240

TGTTAGATGT GAATGTCCGT GGCCCAGATG GCTGCACCCC ATTGATGTTG GCTTCTCTCC 300

GAGGAGGCAG CTCAGATTTG AGTGATGAAG ATGAAGATGC AGAGGACTGT TCTGCTAACA 360

TCATCACAGA CTTGGTCTAC CAGGGTGCCA GCCTCCAGNC CAGACAGACC GGACTGGTGA 420

GATGGCCCTG CACCTTGCAG CCCGCTACTC ACGGGCTGAT GCTGCCAAGC GTCTCCTGGA 480

TGCAGGTGCA GATGCCAATG CCCAGGACAA CATGGGCCGC TGTCCACTCC ATGCTGCAGT 540

GGCACGTGAT GCCAAGGTGT ATTCAGATCT GTTA 574

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 295 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TCCAGATTCT GATTCGCAAC CGAGTAACTG ATCTAGATGC CAGGATGAAT GATGGTACTA 60

CACCCCTGAT CCTGGCTGCC CGCCTGGCTG TGGAGGGAAT GGTGGCAGAA CTGATCAACT 120

GCCAAGCGGA TGTGAATGCA GTGGATGACC ATGGAAAATC TGCTCTTCAC TGGGCAGCTG 180

CTGTCAATAA TGTGGAGGCA ACTCTTTTGT TGTTGAAAAA TGGGGCCAAC CGAGACATGC 240

AGGACAACAA GGAAGAGACA CCTCTGTTTC TTGCTGCCCG GGAGGAGCTA TAAGC 295

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 333 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GAATTCCCAT GAGTCGGGAG CTTCGATCAA AATTGATGAG CCTTTAGAAG GATCCGAAGA 60

TCGGATCATT ACCATTACAG GAACAGGCAC CTGTAGCTGG TGGCTGGGGG TGTTGTCCAC 120

AGGCGAGGAG TAGCTGTGCT GCGAGGGGGG CGTCAGGAAC TGGGCTGCGG TCACGGGTGG 180

GACCAGCGAG GATGGCAGCG ACGTGGGCAG GGCGGGGCTC TCCTGGGGCA GAATAGTGTG 240

CACCGCCAGG CTGCTGGGGC CCAGTACTGC ACGTCTGCCT GGCTCGGCTC TCCACTCAGG 300

AAGCTCCGGC CCAGGTGGCC GCTGGCTGCT GAG 333

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 582 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GAATTCCTGC CAGGAGGACG CGGGCAACAA GGTCTGCAGC CTGCAGTGCA ACAACCACGC 60

GTGCGGCTGG GACGGCGGTG ACTGCTCCCT CAACTTCACA ATGACCCCTG GAAGAACTGC 120

ACGCAGTCTC TGCAGTGCTG GAAGTACTTC AGTGACGGCC ACTGTGACAG CCAGTGCAAC 180

TCAGCCGGCT GCCTCTTCGA CGGCTTTGAC TGCCAGCGGC GGAAGGCCAG TTGCAACCCC 240

CTGTACGACC AGTACTGCAA GGACCACTTC AGCGACGGGC ACTGCGACCA GGGCTGCAAC 300

AGCGCGGAGT NCAGNTGGGA CGGGCTGGAC TGTGCGGCAG TGTACCCGAG AGCTGGCGGC 360

GCACGCTGGT GGTGGTGGTG CTGATGCCGC CGGAGCAGCT GCGCAACAGC TCCTTCCACT 420

TCCTGCGGGA CGTCAGCCGC GTGCTGCACA CCAACGTGTC TTCAAGCGTG ACGCACACGG 480

CCAGCAGATG ATGTTCCCCT ACTACGGCCG CGAGGAGGAG CTGCGCAAGC CCCATCAAGC 540

GTGCCGCCGA GGGCTGGGCC GCACCTGACG CCTGCTGGGC CA 582

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 150 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

TCAGCCGAGT GCTGCACACC AACGTGTCTT CAAGCGTGAC GCACACGGCC AGCAGATGAT 60

GTTCCCCTAC TACGGCCGCG AGGAGGAGCT GCGCAAGCCC CATCAAGCGT GCCGCCGAGG 120

GCTGGGCCGC ACCTGACGCC TGCTGGGCCA 150

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 247 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TTACCATTAC AGGAACAGGC ACCTGTAGCT GGTGGCTGGG GGTGTTGTCC ACAGGCGAGG 60

AGTAGCTGTG CTGCGAGGGG GGCGTCAGGA ACTGGGCTGC GGTCACGGGT GGGACCAGCG 120

AGGATGGCAG CGACGTGGGC AGGGCGGGGC TCTCCTGGGG CAGAATAGTG TGCACCGCCA 180

GCTGCTGGGG CCCAGTGCTG CACGTCTGCC TGGCTCGGCT CTCCACTCAG GAAGCTCCGG 240

CCCAGGT 247

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 248 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GAATTCCATT CAGGAGGAAA GGGTGGGGAG AGAAGCAGGC ACCCACTTTC CCGTGGCTGG 60

ACTCGTTCCC AGGTGGCTCC ACCGGCAGCT GTGACCGCCG CAGGTGGGGG CGGAGTGCCA 120

TTCAGAAAAT TCCAGAAAAG CCCTACCCCA ACTCGGACGG CAACGTCACA CCCGTGGGTA 180

GCAACTGGCA CACAAACAGC CAGCGTGTCT GGGGCACGGG GGGATGGCAC CCCCTGCAGG 240

CAGAGCTG 248

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 323 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CTAAAGGGAA CAAAAGCNGG AGCTCCACCG CGGGCGGCNC NGCTCTAGAA CTAGTGGANN 60

NCCCGGGCTG CAGGAATTCC GGCGGACTGG GCTCGGGCTC AGAGCGGCGC TGTGGAAGAG 120

ATTCTAGACC GGGAGAACAA GCGAATGGCT GACAGCTGGC CTCCAAAGTC ACCAGGCTCA 180

AATCGCTCGC CCTGGACATC GAGGGATGCA GAGGATCAGA ACCGGTACCT GGATGGCATG 240

ACTCGGATTT ACAAGCATGA CCAGCCTGCT TACAGGGAGC GTGANNTTTT CACATGCAGT 300

CGACAGACAC GAGCTCTATG CAT 323

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 330 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GAATTCCGAG GTGGATGTGT TAGATGTGAA TGTCCGTGGC CCAGATGGCT GCACCCCATT 60

GATGTTGGCT TCTCTCCGAG GAGGCAGCTC AGATTTGAGT GATGAAGATG AAGATGCAGA 120

GGACTCTTCT GCTAACATCA TCACAGACTT GGTCTTACCA GGGTGCCAGC CTTCCAGGCC 180

CAAGAACAGA CCGGACTTGG TGAGATGGCC CTGCACCTTG CAGCCCGCTA CTACGGGCTG 240

ATGCTGCCAA GGTTCTGGAT GCAGGTGCAG ATGCCAATGC CCAGGACAAC ATGGGCCGCT 300

GTCCACTCCA TGCTGCAGTG GCACTGATGC 330

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 167 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CAGAGGATGG TGAGGGTCCA TGCAGATAGG TTCTCCCCAT CCTGTGAATA ATAAATGGGT 60

GCAAGGGCAG AGAGTCACCA TTTAGAATGA TAAAATGTTT GCACACTATG AAAGAGGCTG 120

ACAGAATGTT GCCACATGGA GAGATAAAGC AGAGAATGAA CAAACTT 167

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 225 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AGGATGAATG ATGGTACTAC ACCCCTGATC CTGGCTGCCC GCCTGGCTGT GGAGGGAATG 60

GTGGCAGAAC TGATCAACTG CCAAGCGGAT GTGAATGCAG TGGATGACCA TGGAAAATCT 120

GCTCTTCACT GGGCAGCTGC TGTCAATAAT GTGGAGGCAA CTCTTTTGTT GTTGAAAAAT 180

GGGGCCAACC GAGACATGCA GGACAACAAG GAAGAGACAC CTCTG 225

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 121 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AATAATAAAT GGGTGCAAGG GCAGAGAGTC ACCATTTAGA ATGATAAAAT GTTTGCACAC 60

TATGAAAGAG GCTGACAGAA TGTTGCCACA TGGAGAGATA AAGCAGAGAA TGAACAAACT 120

T 121

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

ACTTCAGCAA CGATCACGGG 20

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TTGGGTATGT GACAGTAATC G 21

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TTAAGTTAAC TTAA 14

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGAAGATCTT CC 12

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Arg Lys Ile Phe
1

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3234 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..3234

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

```
TGC CAG GAG GAC GCG GGC AAC AAG GTC TGC AGC CTG CAG TGC AAC AAC          48
Cys Gln Glu Asp Ala Gly Asn Lys Val Cys Ser Leu Gln Cys Asn Asn
 1               5                  10                  15

CAC GCG TGC GGC TGG GAC GGC GGT GAC TGC TCC CTC AAC TTC AAT GAC          96
His Ala Cys Gly Trp Asp Gly Gly Asp Cys Ser Leu Asn Phe Asn Asp
            20                  25                  30

CCC TGG AAG AAC TGC ACG CAG TCT CTG CAG TGC TGG AAG TAC TTC AGT         144
Pro Trp Lys Asn Cys Thr Gln Ser Leu Gln Cys Trp Lys Tyr Phe Ser
        35                  40                  45

GAC GGC CAC TGT GAC AGC CAG TGC AAC TCA GCC GGC TGC CTC TTC GAC         192
Asp Gly His Cys Asp Ser Gln Cys Asn Ser Ala Gly Cys Leu Phe Asp
    50                  55                  60

GGC TTT GAC TGC CAG CGT GCG GAA GGC CAG TGC AAC CCC CTG TAC GAC         240
Gly Phe Asp Cys Gln Arg Ala Glu Gly Gln Cys Asn Pro Leu Tyr Asp
65                  70                  75                  80

CAG TAC TGC AAG GAC CAC TTC AGC GAC GGG CAC TGC GAC CAG GGC TGC         288
Gln Tyr Cys Lys Asp His Phe Ser Asp Gly His Cys Asp Gln Gly Cys
                85                  90                  95

AAC AGC GCG GAG TGC GAG TGG GAC GGG CTG GAC TGT GCG GAG CAT GTA         336
Asn Ser Ala Glu Cys Glu Trp Asp Gly Leu Asp Cys Ala Glu His Val
            100                 105                 110

CCC GAG AGG CTG GC  GCC GGC ACG CTG GTG GTG GTG GTG CTG ATG CCG         384
Pro Glu Arg Leu Ala Ala Gly Thr Leu Val Val Val Val Leu Met Pro
        115                 120                 125

CCG GAG CAG CTG CGC AAC AGC TCC TTC CAC TTC CTG CGG GAG CTC AGC         432
Pro Glu Gln L u Arg Asn Ser Ser Phe His Phe Leu Arg Glu Leu Ser
    130                 135                 140
```

```
CGC GTG CTG CAC ACC AAC GTG GTC TTC AAG CGT GAC GCA CAC GGC CAG          480
Arg Val Leu His Thr Asn Val Val Phe Lys Arg Asp Ala His Gly Gln
145                 150                 155                 160

CAG ATG ATC TTC CCC TAC TAC GGC CGC GAG GAG GAG CTG CGC AAG CAC          528
Gln Met Ile Phe Pro Tyr Tyr Gly Arg Glu Glu Glu Leu Arg Lys His
                165                 170                 175

CCC ATC AAG CGT GCC GCC GAG GGC TGG GCC GCA CCT GAC GCC CTG CTG          576
Pro Ile Lys Arg Ala Ala Glu Gly Trp Ala Ala Pro Asp Ala Leu Leu
            180                 185                 190

GGC CAG GTG AAG GCC TCG CTG CTC CCT GGT GGC AGC GAG GGT GGG CGG          624
Gly Gln Val Lys Ala Ser Leu Leu Pro Gly Gly Ser Glu Gly Gly Arg
        195                 200                 205

CGG CGG AGG GAG CTG GAC CCC ATG GAC GTC CGC GGC TCC ATC GTC TAC          672
Arg Arg Arg Glu Leu Asp Pro Met Asp Val Arg Gly Ser Ile Val Tyr
    210                 215                 220

CTG GAG ATT GAC AAC CGG CAG TGT GTG CAG GCC TCC TCG CAG TGC TTC          720
Leu Glu Ile Asp Asn Arg Gln Cys Val Gln Ala Ser Ser Gln Cys Phe
225                 230                 235                 240

CAG AGT GCC ACC GAC GTG GCC GCA TTC CTG GGA GCG CTC GCC TCG CTG          768
Gln Ser Ala Thr Asp Val Ala Ala Phe Leu Gly Ala Leu Ala Ser Leu
                245                 250                 255

GGC AGC CTC AAC ATC CCC TAC AAG ATC GAG GCC GTG CAG AGT GAG ACC          816
Gly Ser Leu Asn Ile Pro Tyr Lys Ile Glu Ala Val Gln Ser Glu Thr
            260                 265                 270

GTG GAG CCG CCC CCG CCG GCG CAG CTG CAC TTC ATG TAC GTG GCG GCG          864
Val Glu Pro Pro Pro Pro Ala Gln Leu His Phe Met Tyr Val Ala Ala
        275                 280                 285

GCC GCC TTT GTG CTT CTG TTC TTC GTG GGC TGC GGG GTG CTG CTG TCC          912
Ala Ala Phe Val Leu Leu Phe Phe Val Gly Cys Gly Val Leu Leu Ser
    290                 295                 300

CGC AAG CGC CGG CGG CAG CAT GGC CAG CTC TGG TTC CCT GAG GGC TTC          960
Arg Lys Arg Arg Arg Gln His Gly Gln Leu Trp Phe Pro Glu Gly Phe
305                 310                 315                 320

AAA GTG TCT GAG GCC AGC AAG AAG AAG CGG CGG GAG CCC CTC GGC GAG         1008
Lys Val Ser Glu Ala Ser Lys Lys Lys Arg Arg Glu Pro Leu Gly Glu
                325                 330                 335

GAC TCC GTG GGC CTC AAG CCC CTG AAG AAC GCT TCA GAC GGT GCC CTC         1056
Asp Ser Val Gly Leu Lys Pro Leu Lys Asn Ala Ser Asp Gly Ala Leu
            340                 345                 350

ATG GAC GAC AAC CAG AAT GAG TGG GGG GAC GAG GAC CTG GAG ACC AAG         1104
Met Asp Asp Asn Gln Asn Glu Trp Gly Asp Glu Asp Leu Glu Thr Lys
        355                 360                 365

AAG TTC CGG TTC GAG GAG CCC GTG GTT CTG CCT GAC CTG GAC GAC CAG         1152
Lys Phe Arg Phe Glu Glu Pro Val Val Leu Pro Asp Leu Asp Asp Gln
    370                 375                 380

ACA GAC CAC CGG CAG TGG ACT CAG CAG CAC CTG GAT GCC GCT GAC CTG         1200
Thr Asp His Arg Gln Trp Thr Gln Gln His Leu Asp Ala Ala Asp Leu
385                 390                 395                 400

CGC ATG TCT GCC ATG GCC CCC ACA CCG CCC CAG GGT GAG GTT GAC GCC         1248
Arg Met Ser Ala Met Ala Pro Thr Pro Pro Gln Gly Glu Val Asp Ala
                405                 410                 415

GAC TGC ATG GAC GTC AAT GTC CGC GGG CCT GAT GGC TTC ACC CCG CTC         1296
Asp Cys Met Asp Val Asn Val Arg Gly Pro Asp Gly Phe Thr Pro Leu
```

```
                420                 425                 430

ATG ATC GCC TCC TGC AGC GGG GGC GGC CTG GAG ACG GGC AAC AGC GAG      1344
Met Ile Ala Ser Cys Ser  ly Gly Gly Leu Glu Thr Gly Asn Ser  lu
        435                 440                 445

GAA GAG GAG GAC GCG CCG GCC GTC ATC TCC GAC TTC ATC TAC CAG GGC      1392
Glu Glu Glu Asp Ala Pro Ala Val Ile Ser Asp Phe Ile Tyr Gln Gly
    450                 455                 460

GCC AGC CTG CAC AAC CAG ACA GAC CGC ACG GGC GAG ACC GCC TTG CAC      1440
Ala Ser Leu His Asn Gln Thr Asp Arg Thr Gly Glu Thr Ala Leu His
465                 470                 475                 480

CTG GCC GCC CGC TAC TCA CGC TCT GAT GCC GCC AAG CGC CTG CTG GAG      1488
Leu Ala Ala Arg Tyr Ser Arg Ser Asp Ala Ala Lys Arg Leu Leu Glu
                485                 490                 495

GCC AGC GCA GAT GCC AAC ATC CAG GAC AAC ATG GGC CGC ACC CCG CTG      1536
Ala Ser Ala Asp Ala Asn Ile Gln Asp Asn Met Gly Arg Thr Pro Leu
            500                 505                 510

CAT GCG GCT GTG TCT GCC GAC GCA CAA GGT GTC TTC CAG ATC CTG ATC      1584
His Ala Ala Val Ser Ala Asp Ala Gln Gly Val Phe Gln Ile Leu Ile
        515                 520                 525

CGG AAC CGA GCC ACA GAC CTG GAT GCC CGC ATG CAT GAT GGC ACG ACG      1632
Arg Asn Arg Ala Thr Asp Leu Asp Ala Arg Met His Asp Gly Thr Thr
    530                 535                 540

CCA CTG ATC CTG GCT GCC CGC CTG GCC GTG GAG GGC ATG CTG GAG GAC      1680
Pro Leu Ile Leu Ala Ala Arg Leu Ala Val Glu Gly Met Leu Glu Asp
545                 550                 555                 560

CTC ATC AAC TCA CAC GCC GAC GTC AAC GCC GTA GAT GAC CTG GGC AAG      1728
Leu Ile Asn Ser His Ala Asp Val Asn Ala Val Asp Asp Leu Gly Lys
                565                 570                 575

TCC GCC CTG CAC TGG GCC GCC GCC GTG AAC AAT GTG GAT GCC GCA GTT      1776
Ser Ala Leu His Trp Ala Ala Ala Val Asn Asn Val Asp Ala Ala Val
            580                 585                 590

GTG CTC CTG AAG AAC GGG GCT AAC AAA GAT ATG CAG AAC AAC AGG GAG      1824
Val Leu Leu Lys Asn Gly Ala Asn Lys Asp Met Gln Asn Asn Arg Glu
        595                 600                 605

GAG ACA CCC CTG TTT CTG GCC GCC CGG GAG GGC AGC TAC GAG ACC GCC      1872
Glu Thr Pro Leu Phe Leu Ala Ala Arg Glu Gly Ser Tyr Glu Thr Ala
    610                 615                 620

AAG GTG CTG CTG GAC CAC TTT GCC AAC CGG GAC ATC ACG GAT CAT ATG      1920
Lys Val Leu Leu Asp His Phe Ala Asn Arg Asp Ile Thr Asp His Met
625                 630                 635                 640

GAC CGC CTG CCG CGC GAC ATC GCA CAG GAG CGC ATG CAT CAC GAC ATC      1968
Asp Arg Leu Pro Arg Asp Ile Ala Gln Glu Arg Met His His Asp Ile
                645                 650                 655

GTG AGG CTG CTG GAC GAG TAC AAC CTG GTG CGC AGC CCG CAG CTG CAC      2016
Val Arg Leu Leu Asp Glu Tyr Asn Leu Val Arg Ser Pro Gln Leu His
            660                 665                 670

GGA GCC CCG CTG GGG GGC ACG CCC ACC CTG TCG CCC CCG CTC TGC TCG      2064
Gly Ala Pro Leu Gly Gly Thr Pro Thr Leu Ser Pro Pro Leu Cys Ser
        675                 680                 685

CCC AAC GGC TAC CTG GGC AGC CTC AAG CCC GGC GTG CAG GGC AAG AAG      2112
Pro Asn Gly Tyr Leu Gly Ser Leu Lys Pro Gly Val Gln Gly Lys Lys
    690                 695                 700
```

```
GTC CGC AA  CCC AGC AGC AAA GGC CTG GCC TGT GGA AGC AAG GAG GCC      2160
Val Arg Lys Pro Ser Ser Lys  ly Leu Ala Cys Gly Ser Lys Glu Ala
705                 710                 715                 720

AAG GAC CTC AAG GCA CGG AGG AAG AAG TCC CAG GAT GGC AAG GGC TGC      2208
Lys Asp Leu Lys Ala Arg Arg Lys Lys Ser Gln Asp Gly Lys Gly Cys
                725                 730                 735

CTG CTG GAC AGC TCC GGC ATG CTC TCG CCC GTG GAC TCC CTG GAG TCA      2256
Leu Leu Asp Ser Ser Gly Met Leu Ser Pro Val Asp Ser Leu Glu Ser
            740                 745                 750

CCC CAT GGC TAC CTG TCA GAC GTG GCC TCG CCG CCA CTG CTG CCC TCC      2304
Pro His Gly Tyr Leu Ser Asp Val Ala Ser Pro Pro Leu Leu Pro Ser
        755                 760                 765

CCG TTC CAG CAG TCT CCG TCC GTG CCC CTC AAC CAC CTG CCT GGG ATG      2352
Pro Phe Gln Gln Ser Pro Ser Val Pro Leu Asn His Leu Pro Gly Met
    770                 775                 780

CCC GAC ACC CAC CTG GGC ATC GGG CAC CTG AAC GTG GCG GCC AAG CCC      2400
Pro Asp Thr His Leu Gly Ile Gly His Leu Asn Val Ala Ala Lys Pro
785                 790                 795                 800

GAG ATG GCG GCG CTG GGT GGG GGC GGC CGG CTG GCC TTT GAG ACT GGC      2448
Glu Met Ala Ala Leu Gly Gly Gly Gly Arg Leu Ala Phe Glu Thr Gly
                805                 810                 815

CCA CCT CGT CTC TCC CAC CTG CCT GTG GCC TCT GGC ACC AGC ACC GTC      2496
Pro Pro Arg Leu Ser His Leu Pro Val Ala Ser Gly Thr Ser Thr Val
            820                 825                 830

CTG GGC TCC AGC AGC GGA GGG GCC CTG AAT TTC ACT GTG GGC GGG TCC      2544
Leu Gly Ser Ser Ser Gly Gly Ala Leu Asn Phe Thr Val Gly Gly Ser
        835                 840                 845

ACC AGT TTG AAT GGT CAA TGC GAG TGG CTG TCC CGG CTG CAG AGC GGC      2592
Thr Ser Leu Asn Gly Gln Cys Glu Trp Leu Ser Arg Leu Gln Ser Gly
    850                 855                 860

ATG GTG CCG AAC CAA TAC AAC CCT CTG CGG GGG AGT GTG GCA CCA GGC      2640
Met Val Pro Asn Gln Tyr Asn Pro Leu Arg Gly Ser Val Ala Pro Gly
865                 870                 875                 880

CCC CTG AGC ACA CAG GCC CCC TCC CTG CAG CAT GGC ATG GTA GGC CCG      2688
Pro Leu Ser Thr Gln Ala Pro Ser Leu Gln His Gly Met Val Gly Pro
                885                 890                 895

CTG CAC AGT AGC CTT GCT GCC AGC GCC CTG TCC CAG ATG ATG AGC TAC      2736
Leu His Ser Ser Leu Ala Ala Ser Ala Leu Ser Gln Met Met Ser Tyr
            900                 905                 910

CAG GGC CTG CCC AGC ACC CGG CTG GCC ACC CAG CCT CAC CTG GTG CAG      2784
Gln Gly Leu Pro Ser Thr Arg Leu Ala Thr Gln Pro His Leu Val Gln
        915                 920                 925

ACC CAG CAG GTG CAG CCA CAA AAC TTA CAG ATG CAG CAG CAG AAC CTG      2832
Thr Gln Gln Val Gln Pro Gln Asn Leu Gln Met Gln Gln Gln Asn Leu
    930                 935                 940

CAG CCA GCA AAC ATC CAG CAG CAG CAA AGC CTG CAG CCG CCA CCA CCA      2880
Gln Pro Ala Asn Ile Gln Gln Gln Gln Ser Leu Gln Pro Pro Pro Pro
945                 950                 955                 960

CCA CCA CAG CCG CAC CTT GGC GTG AGC TCA GCA GCC AGC GGC CAC CTG      2928
Pro Pro Gln Pro His Leu Gly Val Ser Ser Ala Ala Ser Gly His Leu
                965                 970                 975

GGC CGG AGC TTC CTG AGT GGA GAG CCG AGC CAG GCA GAC GTG CAG CCA      2976
Gly Arg Ser Phe Leu Ser Gly Glu Pro Ser Gln Ala Asp Val Gln Pro
```

```
                980                 985                 990

CTG GGC CCC AGC AGC CTG GCG GTG CAC ACT ATT CTG CCC CAG GAG AGC      3024
Leu Gly Pro Ser Ser Leu Ala Val His Thr Ile Leu Pro Gln Glu Ser
        995                1000                1005

CCC GCC CTG CCC ACG TCG CTG CCA TCC TCG CTG GTC CCA CCC GTG ACC      3072
Pro Ala Leu Pro Thr Ser Leu Pro Ser Ser Leu Val Pro Pro Val Thr
    1010                1015                1020

GCA GCC CAG TTC CTG ACG CCC CCC TCG CAG CAC AGC TAC TCC TCG CCT      3120
Ala Ala Gln Phe Leu Thr Pro Pro Ser Gln His Ser Tyr Ser Ser Pro
1025                1030                1035                1040

GTG GAC AAC ACC CCC AGC CAC CAG CTA CAG GTG CCT GTT CCT GTA ATG      3168
Val Asp Asn Thr Pro Ser His Gln Leu Gln Val Pro Val Pro Val Met
                1045                1050                1055

GTA ATG ATC CGA TCT TCG GAT CCT TCT AAA GGC TCA TCA ATT TTG ATC      3216
Val Met Ile Arg Ser Ser Asp Pro Ser Lys Gly Ser Ser Ile Leu Ile
            1060                1065                1070

GAA GCT CCC GAC TCA TGG                                             3234
Glu Ala Pro Asp Ser Trp
        1075
```

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1078 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

```
Cys Gln Glu Asp Ala Gly Asn Lys Val Cys Ser Leu Gln Cys Asn Asn
 1               5                  10                  15

His Ala Cys Gly Trp Asp Gly Gly Asp Cys Ser Leu Asn Phe Asn Asp
            20                  25                  30

Pro Trp Lys Asn Cys Thr Gln Ser Leu Gln Cys Trp Lys Tyr Phe Ser
        35                  40                  45

Asp Gly His Cys Asp Ser Gln Cys Asn Ser Ala Gly Cys Leu Phe Asp
    50                  55                  60

Gly Phe Asp Cys Gln Arg Ala Glu Gly Gln Cys Asn Pro Leu Tyr Asp
65                  70                  75                  80

Gln Tyr Cys Lys Asp His Phe Ser Asp Gly His Cys Asp Gln Gly Cys
                85                  90                  95

Asn Ser Ala Glu Cys Glu Trp Asp Gly Leu Asp Cys Ala Glu His Val
            100                 105                 110

Pro Glu Arg Leu Ala Ala Gly Thr Leu Val Val Val Val Leu Met Pro
        115                 120                 125

Pr  Glu Gln Leu Arg Asn Ser Ser Phe His Phe Leu Arg Glu Leu Ser
    130                 135                 140

Arg Val Leu His Thr Asn Val Val Phe Lys Arg Asp Ala His Gly Gln
145                 150                 155                 160

Gln M t Ile Phe Pro Tyr Tyr Gly Arg Glu Glu Glu Leu Arg Lys His
                165                 170                 175
```

Pro Ile Lys Arg Ala Ala Glu Gly Trp Ala Ala Pro Asp Ala Leu Leu
180 185 190

Gly Gln Val Lys Ala Ser Leu Leu Pro Gly Gly Ser Glu Gly Gly Arg
195 200 205

Arg Arg Arg Glu Leu Asp Pro Met Asp Val Arg Gly Ser Ile Val Tyr
210 215 220

Leu Glu Ile Asp Asn Arg Gln Cys Val Gln Ala Ser Ser Gln Cys Phe
225 230 235 240

Gln Ser Ala Thr Asp Val Ala Ala Phe Leu Gly Ala Leu Ala Ser Leu
245 250 255

Gly Ser Leu Asn Ile Pro Tyr Lys Ile Glu Ala Val Gln Ser Glu Thr
260 265 270

Val Glu Pro Pro Pro Pro Ala Gln Leu His Phe Met Tyr Val Ala Ala
275 280 285

Ala Ala Phe Val Leu Leu Phe Phe Val Gly Cys Gly Val Leu Leu Ser
290 295 300

Arg Lys Arg Arg Arg Gln His Gly Gln Leu Trp Phe Pro Glu Gly Phe
305 310 315 320

Lys Val Ser Glu Ala Ser Lys Lys Lys Arg Arg Glu Pro Leu Gly Glu
325 330 335

Asp Ser Val Gly Leu Lys Pro Leu Lys Asn Ala Ser Asp Gly Ala Leu
340 345 350

Met Asp Asp Asn Gln Asn Glu Trp Gly Asp Glu Asp Leu Glu Thr Lys
355 360 365

Lys Phe Arg Phe Glu Glu Pro Val Val Leu Pro Asp Leu Asp Asp Gln
370 375 380

Thr Asp His Arg Gln Trp Thr Gln Gln His Leu Asp Ala Ala Asp Leu
385 390 395 400

Arg Met Ser Ala Met Ala Pro Thr Pro Pro Gln Gly Glu Val Asp Ala
405 410 415

Asp Cys Met Asp Val Asn Val Arg Gly Pro Asp Gly Phe Thr Pro Leu
420 425 430

Met Ile Ala Ser Cys Ser Gly Gly Gly Leu Glu Thr Gly Asn Ser Glu
435 440 445

Glu Glu Glu Asp Ala Pro Ala Val Ile Ser Asp Phe Ile Tyr Gln Gly
450 455 460

Ala Ser Leu His Asn Gln Thr Asp Arg Thr Gly Glu Thr Ala Leu His
465 470 475 480

Leu Ala Ala Arg Tyr Ser Arg Ser Asp Ala Ala Lys Arg Leu Leu Glu
485 490 495

Ala Ser Ala Asp Ala Asn Ile Gln Asp Asn Met Gly Arg Thr Pro Leu
500 505 510

His Ala Ala Val Ser Ala Asp Ala Gln Gly Val Phe Gln Ile Leu Ile
515 520 525

Arg Asn Arg Ala Thr Asp Leu Asp Ala Arg Met His Asp Gly Thr Thr
530 535 540

Pro Leu Ile Leu Ala Ala Arg Leu Ala Val Glu Gly Met Leu Glu Asp

545 550 555 560

Leu Ile Asn Ser His Ala Asp Val Asn Ala Val Asp Asp Leu Gly Lys
565 570 575

Ser Ala Leu His Trp Ala Ala Ala Val Asn Asn Val Asp Ala Ala Val
580 585 590

Val Leu Leu Lys Asn Gly Ala Asn Lys Asp Met Gln Asn Asn Arg Glu
595 600 605

Glu Thr Pro Leu Phe Leu Ala Ala Arg Glu Gly Ser Tyr Glu Thr Ala
610 615 620

Lys Val Leu Leu Asp His Phe Ala Asn Arg Asp Ile Thr Asp His Met
625 630 635 640

Asp Arg Leu Pro Arg Asp Ile Ala Gln Glu Arg Met His His Asp Ile
645 650 655

Val Arg Leu Leu Asp Glu Tyr Asn Leu Val Arg Ser Pro Gln Leu His
660 665 670

Gly Ala Pro Leu Gly Gly Thr Pro Thr Leu Ser Pro Pro Leu Cys Ser
675 680 685

Pro Asn Gly Tyr Leu Gly Ser Leu Lys Pro Gly Val Gln Gly Lys Lys
690 695 700

Val Arg Lys Pro Ser Ser Lys Gly Leu Ala Cys Gly Ser Lys Glu Ala
705 710 715 720

Lys Asp Leu Lys Ala Arg Arg Lys Lys Ser Gln Asp Gly Lys Gly Cys
725 730 735

Leu Leu Asp Ser Ser Gly Met Leu Ser Pro Val Asp Ser Leu Glu Ser
740 745 750

Pro His Gly Tyr Leu Ser Asp Val Ala Ser Pro Pro Leu Leu Pro Ser
755 760 765

Pro Phe Gln Gln Ser Pro Ser Val Pro Leu Asn His Leu Pro Gly Met
770 775 780

Pro Asp Thr His Leu Gly Ile Gly His Leu Asn Val Ala Ala Lys Pro
785 790 795 800

Glu Met Ala Ala Leu Gly Gly Gly Gly Arg Leu Ala Phe Glu Thr Gly
805 810 815

Pro Pro Arg Leu Ser His Leu Pro Val Ala Ser Gly Thr Ser Thr Val
820 825 830

Leu Gly Ser Ser Ser Gly Gly Ala Leu Asn Phe Thr Val Gly Gly Ser
835 840 845

Thr Ser Leu Asn Gly Gln Cys Glu Trp Leu Ser Arg Leu Gln Ser Gly
850 855 860

Met Val Pro Asn Gln Tyr Asn Pro Leu Arg Gly Ser Val Ala Pro Gly
865 870 875 880

Pro Leu Ser Thr Gln Ala Pro Ser Leu Gln His Gly Met Val Gly Pro
885 890 895

Leu His Ser Ser Leu Ala Ala Ser Ala Leu Ser Gln Met Met Ser Tyr
900 905 910

Gln Gly Leu Pro Ser Thr Arg Leu Ala Thr Gln Pro His Leu Val Gln
915 920 925

```
Thr Gln Gln Val Gln Pro Gln Asn Leu Gln Met Gln Gln Gln Asn Leu
    930                 935                 940

Gln Pro Ala Asn Ile Gln Gln Gln Gln Ser Leu Gln Pro Pro Pro Pro
945                 950                 955                 960

Pro Pro Gln Pro His Leu Gly Val Ser Ser Ala Ala Ser Gly His Leu
                965                 970                 975

Gly Arg Ser Phe Leu Ser Gly Glu Pro Ser Gln Ala Asp Val Gln Pro
            980                 985                 990

Leu Gly Pro Ser Ser Leu Ala Val His Thr Ile Leu Pro Gln Glu Ser
        995                 1000                1005

Pro Ala Leu Pro Thr Ser Leu Pro Ser Ser Leu Val Pro Pro Val Thr
    1010                1015                1020

Ala Ala Gln Phe Leu Thr Pro Pro Ser Gln His Ser Tyr Ser Ser Pro
1025                1030                1035                1040

Val Asp Asn Thr Pro Ser His Gln Leu Gln Val Pro Val Pro Val Met
                1045                1050                1055

Val Met Ile Arg Ser Ser Asp Pro Ser Lys Gly Ser Ser Ile Leu Ile
            1060                1065                1070

Glu Ala Pro Asp Ser Trp
        1075
```

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4268 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 2..1972

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```
G GAG GTG GAT GTG TTA GAT GTG AAT GTC CGT GGC CCA GAT GGC TGC          46
  Glu Val Asp Val Leu Asp Val Asn Val Arg Gly Pro Asp Gly Cys
    1               5                  10                  15

ACC CCA TTG ATG TTG GCT TCT CTC CGA GGA GGC AGC TCA GAT TTG AGT        94
Thr Pro Leu Met Leu Ala Ser Leu Arg Gly Gly Ser Ser Asp Leu Ser
                20                  25                  30

GAT GAA GAT GAA GAT GCA GAG GAC TCT TCT GCT AAC ATC ATC ACA GAC       142
Asp Glu Asp Glu Asp Ala Glu Asp Ser Ser Ala Asn Ile Ile Thr Asp
            35                  40                  45

TTG GTC TAC CAG GGT GCC AGC CTC CAG GCC CAG ACA GAC CGG ACT GGT       190
Leu Val Tyr Gln Gly Ala Ser Leu Gln Ala Gln Thr Asp Arg Thr Gly
        50                  55                  60

GAG ATG GCC CTG CAC CTT GCA GCC CGC TAC TCA CGG GCT GAT GCT GCC       238
Glu Met Ala Leu His Leu Ala Ala Arg Tyr Ser Arg Ala Asp Ala Ala
    65                  70                  75

AAG CGT CTC CTG GAT GCA GGT GCA GAT GCC AAT GCC CAG GAC AAC ATG       286
Lys Arg Leu Leu Asp Ala Gly Ala Asp Ala Asn Ala Gln Asp Asn Met
```

```
80                  85                  90                  95

GGC CGC TGT CCA CTC CAT GCT GCA GTG GCA GCT GAT GCC CAA GGT GTC      334
Gly Arg Cys Pr  Leu His Ala Ala Val Ala Ala Asp Ala Gln Gly Val
                100                 105                 110

TTC CAG ATT CTG ATT CGC AAC CGA GTA ACT GAT CTA GAT GCC AGG ATG      382
Phe Gln Ile Leu Ile Arg Asn Arg Val Thr Asp Leu Asp Ala Arg Met
            115                 120                 125

AAT GAT GGT ACT ACA CCC CTG ATC CTG GCT GCC CGC CTG GCT GTG GAG      430
Asn Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg Leu Ala Val Glu
        130                 135                 140

GGA ATG GTG GCA GAA CTG ATC AAC TGC CAA GCG GAT GTG AAT GCA GTG      478
Gly Met Val Ala Glu Leu Ile Asn Cys Gln Ala Asp Val Asn Ala Val
    145                 150                 155

GAT GAC CAT GGA AAA TCT GCT CTT CAC TGG GCA GCT GCT GTC AAT AAT      526
Asp Asp His Gly Lys Ser Ala Leu His Trp Ala Ala Ala Val Asn Asn
160                 165                 170                 175

GTG GAG GCA ACT CTT TTG TTG TTG AAA AAT GGG GCC AAC CGA GAC ATG      574
Val Glu Ala Thr Leu Leu Leu Leu Lys Asn Gly Ala Asn Arg Asp Met
                180                 185                 190

CAG GAC AAC AAG GAA GAG ACA CCT CTG TTT CTT GCT GCC CGG GAG GGG      622
Gln Asp Asn Lys Glu Glu Thr Pro Leu Phe Leu Ala Ala Arg Glu Gly
            195                 200                 205

AGC TAT GAA GCA GCC AAG ATC CTG TTA GAC CAT TTT GCC AAT CGA GAC      670
Ser Tyr Glu Ala Ala Lys Ile Leu Leu Asp His Phe Ala Asn Arg Asp
        210                 215                 220

ATC ACA GAC CAT ATG GAT CGT CTT CCC CGG GAT GTG GCT CGG GAT CGC      718
Ile Thr Asp His Met Asp Arg Leu Pro Arg Asp Val Ala Arg Asp Arg
    225                 230                 235

ATG CAC CAT GAC ATT GTG CGC CTT CTG GAT GAA TAC AAT GTG ACC CCA      766
Met His His Asp Ile Val Arg Leu Leu Asp Glu Tyr Asn Val Thr Pro
240                 245                 250                 255

AGC CCT CCA GGC ACC GTG TTG ACT TCT GCT CTC TCA CCT GTC ATC TGT      814
Ser Pro Pro Gly Thr Val Leu Thr Ser Ala Leu Ser Pro Val Ile Cys
                260                 265                 270

GGG CCC AAC AGA TCT TTC CTC AGC CTG AAG CAC ACC CCA ATG GGC AAG      862
Gly Pro Asn Arg Ser Phe Leu Ser Leu Lys His Thr Pro Met Gly Lys
            275                 280                 285

AAG TCT AGA CGG CCC AGT GCC AAG AGT ACC ATG CCT ACT AGC CTC CCT      910
Lys Ser Arg Arg Pro Ser Ala Lys Ser Thr Met Pro Thr Ser Leu Pro
        290                 295                 300

AAC CTT GCC AAG GAG GCA AAG GAT GCC AAG GGT AGT AGG AGG AAG AAG      958
Asn Leu Ala Lys Glu Ala Lys Asp Ala Lys Gly Ser Arg Arg Lys Lys
    305                 310                 315

TCT CTG AGT GAG AAG GTC CAA CTG TCT GAG AGT TCA GTA ACT TTA TCC     1006
Ser Leu Ser Glu Lys Val Gln Leu Ser Glu Ser Ser Val Thr Leu Ser
320                 325                 330                 335

CCT GTT GAT TCC CTA GAA TCT CCT CAC ACG TAT GTT TCC GAC ACC ACA     1054
Pro Val Asp Ser Leu Glu Ser Pro His Thr Tyr Val Ser Asp Thr Thr
                340                 345                 350

TCC TCT CCA ATG ATT ACA TCC CCT GGG ATC TTA CAG GCC TCA CCC AAC     1102
Ser Ser Pr  Met Ile Thr Ser Pro Gly Ile Leu Gln Ala Ser Pro Asn
            355                 360                 365
```

```
CCT ATG TT  GCC ACT GCC GCC CCT CCT GCC CCA GTC CAT GCC CAG CAT      1150
Pro Met Leu Ala Thr Ala Ala Pr  Pro Ala Pro Val His Ala Gln His
        370                 375                 380

GCA CTA TCT TTT TCT AAC CTT CAT GAA ATG CAG CCT TTG GCA CAT GGG      1198
Ala Leu Ser Phe Ser Asn Leu His Glu Met Gln Pro Leu Ala His Gly
    385                 390                 395

GCC AGC ACT GTG CTT CCC TCA GTG AGC CAG TTG CTA TCC CAC CAC CAC      1246
Ala Ser Thr Val Leu Pro Ser Val Ser Gln Leu Leu Ser His His His
400                 405                 410                 415

ATT GTG TCT CCA GGC AGT GGC AGT GCT GGA AGC TTG AGT AGG CTC CAT      1294
Ile Val Ser Pro Gly Ser Gly Ser Ala Gly Ser Leu Ser Arg Leu His
                420                 425                 430

CCA GTC CCA GTC CCA GCA GAT TGG ATG AAC CGC ATG GAG GTG AAT GAG      1342
Pro Val Pro Val Pro Ala Asp Trp Met Asn Arg Met Glu Val Asn Glu
            435                 440                 445

ACC CAG TAC AAT GAG ATG TTT GGT ATG GTC CTG GCT CCA GCT GAG GGC      1390
Thr Gln Tyr Asn Glu Met Phe Gly Met Val Leu Ala Pro Ala Glu Gly
        450                 455                 460

ACC CAT CCT GGC ATA GCT CCC CAG AGC AGG CCA CCT GAA GGG AAG CAC      1438
Thr His Pro Gly Ile Ala Pro Gln Ser Arg Pro Pro Glu Gly Lys His
    465                 470                 475

ATA ACC ACC CCT CGG GAG CCC TTG CCC CCC ATT GTG ACT TTC CAG CTC      1486
Ile Thr Thr Pro Arg Glu Pro Leu Pro Pro Ile Val Thr Phe Gln Leu
480                 485                 490                 495

ATC CCT AAA GGC AGT ATT GCC CAA CCA GCG GGG GCT CCC CAG CCT CAG      1534
Ile Pro Lys Gly Ser Ile Ala Gln Pro Ala Gly Ala Pro Gln Pro Gln
                500                 505                 510

TCC ACC TGC CCT CCA GCT GTT GCG GGC CCC CTG CCC ACC ATG TAC CAG      1582
Ser Thr Cys Pro Pro Ala Val Ala Gly Pro Leu Pro Thr Met Tyr Gln
            515                 520                 525

ATT CCA GAA ATG GCC CGT TTG CCC AGT GTG GCT TTC CCC ACT GCC ATG      1630
Ile Pro Glu Met Ala Arg Leu Pro Ser Val Ala Phe Pro Thr Ala Met
        530                 535                 540

ATG CCC CAG CAG GAC GGG CAG GTA GCT CAG ACC ATT CTC CCA GCC TAT      1678
Met Pro Gln Gln Asp Gly Gln Val Ala Gln Thr Ile Leu Pro Ala Tyr
    545                 550                 555

CAT CCT TTC CCA GCC TCT GTG GGC AAG TAC CCC ACA CCC CCT TCA CAG      1726
His Pro Phe Pro Ala Ser Val Gly Lys Tyr Pro Thr Pro Pro Ser Gln
560                 565                 570                 575

CAC AGT TAT GCT TCC TCA AAT GCT GCT GAG CGA ACA CCC AGT CAC AGT      1774
His Ser Tyr Ala Ser Ser Asn Ala Ala Glu Arg Thr Pro Ser His Ser
                580                 585                 590

GGT CAC CTC CAG GGT GAG CAT CCC TAC CTG ACA CCA TCC CCA GAG TCT      1822
Gly His Leu Gln Gly Glu His Pro Tyr Leu Thr Pro Ser Pro Glu Ser
            595                 600                 605

CCT GAC CAG TGG TCA AGT TCA TCA CCC CAC TCT GCT TCT GAC TGG TCA      1870
Pro Asp Gln Trp Ser Ser Ser Ser Pro His Ser Ala Ser Asp Trp Ser
        610                 615                 620

GAT GTG ACC ACC AGC CCT ACC CCT GGG GGT GCT GGA GGA GGT CAG CGG      1918
Asp Val Thr Thr Ser Pro Thr Pr  Gly Gly Ala Gly Gly Gly Gln Arg
    625                 630                 635

GGA CCT GGG ACA CAC ATG TCT GAG CCA CCA CAC AAC AAC ATG CAG GTT      1966
Gly Pro Gly Thr His Met Ser Glu Pr  Pro His Asn Asn Met Gln Val
```

640 645 650 655

TAT GCG TGAGAGAGTC CACCTCCAGT GTAGAGACAT AACTGACTTT TGTAAATGCT 2022
Tyr Ala

GCTGAGGAAC AAATGAAGGT CATCCGGGAG AGAAATGAAG AAATCTCTGG AGCCAGCTTC 2082

TAGAGGTAGG AAAGAGAAGA TGTTCTTATT CAGATAATGC AAGAGAAGCA ATTCGTCAGT 2142

TTCACTGGGT ATCTGCAAGG CTTATTGATT ATTCTAATCT AATAAGACAA GTTTGTGGAA 2202

ATGCAAGATG AATACAAGCC TTGGGTCCAT GTTTACTCTC TTCTATTTGG AGAATAAGAT 2262

GGATGCTTAT TGAAGCCCAG ACATTCTTGC AGCTTGGACT GCATTTTAAG CCCTGCAGGC 2322

TTCTGCCATA TCCATGAGAA GATTCTACAC TAGCGTCCTG TTGGGAATTA TGCCCTGGAA 2382

TTCTGCCTGA ATTGACCTAC GCATCTCCTC CTCCTTGGAC ATTCTTTTGT CTTCATTTGG 2442

TGCTTTTGGT TTTGCACCTC TCCGTGATTG TAGCCCTACC AGCATGTTAT AGGGCAAGAC 2502

CTTTGTGCTT TTGATCATTC TGGCCCATGA AAGCAACTTT GGTCTCCTTT CCCCTCCTGT 2562

CTTCCCGGTA TCCCTTGGAG TCTCACAAGG TTTACTTTGG TATGGTTCTC AGCACAAACC 2622

TTTCAAGTAT GTTGTTTCTT TGGAAAATGG ACATACTGTA TTGTGTTCTC CTGCATATAT 2682

CATTCCTGGA GAGAGAAGGG GAGAAGAATA CTTTTCTTCA ACAAATTTTG GGGGCAGGAG 2742

ATCCCTTCAA GAGGCTGCAC CTTAATTTTT CTTGTCTGTG TGCAGGTCTT CATATAAACT 2802

TTACCAGGAA GAAGGGTGTG AGTTTGTTGT TTTTCTGTGT ATGGGCCTGG TCAGTGTAAA 2862

GTTTTATCCT TGATAGTCTA GTTACTATGA CCCTCCCCAC TTTTTTAAAA CCAGAAAAAG 2922

GTTTGGAATG TTGGAATGAC CAAGAGACAA GTTAACTCGT GCAAGAGCCA GTTACCCACC 2982

CACAGGTCCC CCTACTTCCT GCCAAGCATT CCATTGACTG CCTGTATGGA ACACATTTGT 3042

CCCAGATCTG AGCATTCTAG GCCTGTTTCA CTCACTCACC CAGCATATGA AACTAGTCTT 3102

AACTGTTGAG CCTTTCCTTT CATATCCACA GAAGACACTG TCTCAAATGT TGTACCCTTG 3162

CCATTTAGGA CTGAACTTTC CTTAGCCCAA GGGACCCAGT GACAGTTGTC TTCCGTTTGT 3222

CAGATGATCA GTCTCTACTG ATTATCTTGC TGCTTAAAGG CCTGCTCACC AATCTTTCTT 3282

TCACACCGTG TGGTCCGTGT TACTGGTATA CCCAGTATGT TCTCACTGAA GACATGGACT 3342

TTATATGTTC AAGTGCAGGA ATTGGAAAGT TGGACTTGTT TTCTATGATC CAAAACAGCC 3402

CTATAAGAAG GTTGGAAAAG GAGGAACTAT ATAGCAGCCT TTGCTATTTT CTGCTACCAT 3462

TTCTTTTCCT CTGAAGCGGC CATGACATTC CCTTTGGCAA CTAACGTAGA AACTCAACAG 3522

AACATTTTCC TTTCCTAGAG TCACCTTTTA GATGATAATG GACAACTATA GACTTGCTCA 3582

TTGTTCAGAC TGATTGCCCC TCACCTGAAT CCACTCTCTG TATTCATGCT CTTGGCAATT 3642

TCTTTGACTT TCTTTTAAGG GCAGAAGCAT TTTAGTTAAT TGTAGATAAA GAATAGTTTT 3702

CTTCCTCTTC TCCTTGGGCC AGTTAATAAT TGGTCCATGG CTACACTGCA ACTTCCGTCC 3762

AGTGCTGTGA TGCCCATGAC ACCTGCAAAA TAAGTTCTGC CTGGGCATTT TGTAGATATT 3822

AACAGGTGAA TTCCCGACTC TTTTGGTTTG AATGACAGTT CTCATTCCTT CTATGGCTGC 3882

AAGTATGCAT CAGTGCTTCC CACTTACCTG ATTTGTCTGT CGGTGGCCCC ATATGGAAAC 3942

CCTGCGTGTC TGTTGGCATA ATAGTTTACA AATGGTTTTT TCAGTCCTAT CCAAATTTAT 4002

TGAACCAACA AAAATAATTA CTTCTGCCCT GAGATAAGCA GATTAAGTTT GTTCATTCTC 4062

TGCTTTATTC TCTCCATGTG GCAACATTCT GTCAGCCTCT TTCATAGTGT GCAAACATTT 4122

TATCATTCTA AATGGTGACT CTCTGCCCTT GGACCCATTT ATTATTCACA GATGGGGAGA 4182

ACCTATCTGC ATGGACCCTC ACCATCCTCT GTGCAGCACA CACAGTGCAG GGAGCCAGTG 4242

GCGATGGCGA TGACTTTCTT CCCCTG 4268

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 657 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Glu Val Asp Val Leu Asp Val Asn Val Arg Gly Pro Asp Gly Cys Thr
1 5 10 15

Pro Leu Met Leu Ala Ser Leu Arg Gly Gly Ser Ser Asp Leu Ser Asp
20 25 30

Glu Asp Glu Asp Ala Glu Asp Ser Ser Ala Asn Ile Ile Thr Asp Leu
35 40 45

Val Tyr Gln Gly Ala Ser Leu Gln Ala Gln Thr Asp Arg Thr Gly Glu
50 55 60

Met Ala Leu His Leu Ala Ala Arg Tyr Ser Arg Ala Asp Ala Ala Lys
65 70 75 80

Arg Leu Leu Asp Ala Gly Ala Asp Ala Asn Ala Gln Asp Asn Met Gly
85 90 95

Arg Cys Pro Leu His Ala Ala Val Ala Ala Asp Ala Gln Gly Val Phe
100 105 110

Gln Ile Leu Ile Arg Asn Arg Val Thr Asp Leu Asp Ala Arg Met Asn
115 120 125

Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg Leu Ala Val Glu Gly
130 135 140

Met Val Ala Glu Leu Ile Asn Cys Gln Ala Asp Val Asn Ala Val Asp
145 150 155 160

Asp His Gly Lys Ser Ala Leu His Trp Ala Ala Ala Val Asn Asn Val
165 170 175

Glu Ala Thr Leu Leu Leu Leu Lys Asn Gly Ala Asn Arg Asp Met Gln
180 185 190

Asp Asn Lys Glu Glu Thr Pro Leu Phe Leu Ala Ala Arg Glu Gly Ser
195 200 205

Tyr Glu Ala Ala Lys Ile Leu Leu Asp His Phe Ala Asn Arg Asp Ile
210 215 220

Thr Asp His Met Asp Arg Leu Pro Arg Asp Val Ala Arg Asp Arg Met
225 230 235 240

His His Asp Ile Val Arg Leu Leu Asp Glu Tyr Asn Val Thr Pro Ser

245 250 255

Pro Pro Gly Thr Val Leu Thr Ser Ala Leu Ser Pro Val Ile Cys Gly
260 265 270

Pro Asn Arg Ser Phe Leu Ser Leu Lys His Thr Pro Met Gly Lys Lys
275 280 285

Ser Arg Arg Pro Ser Ala Lys Ser Thr Met Pro Thr Ser Leu Pro Asn
290 295 300

Leu Ala Lys Glu Ala Lys Asp Ala Lys Gly Ser Arg Arg Lys Lys Ser
305 310 315 320

Leu Ser Glu Lys Val Gln Leu Ser Glu Ser Ser Val Thr Leu Ser Pro
325 330 335

Val Asp Ser Leu Glu Ser Pro His Thr Tyr Val Ser Asp Thr Thr Ser
340 345 350

Ser Pro Met Ile Thr Ser Pro Gly Ile Leu Gln Ala Ser Pro Asn Pro
355 360 365

Met Leu Ala Thr Ala Ala Pro Pro Ala Pro Val His Ala Gln His Ala
370 375 380

Leu Ser Phe Ser Asn Leu His Glu Met Gln Pro Leu Ala His Gly Ala
385 390 395 400

Ser Thr Val Leu Pro Ser Val Ser Gln Leu Leu Ser His His His Ile
405 410 415

Val Ser Pro Gly Ser Gly Ser Ala Gly Ser Leu Ser Arg Leu His Pro
420 425 430

Val Pro Val Pro Ala Asp Trp Met Asn Arg Met Glu Val Asn Glu Thr
435 440 445

Gln Tyr Asn Glu Met Phe Gly Met Val Leu Ala Pro Ala Glu Gly Thr
450 455 460

His Pro Gly Ile Ala Pro Gln Ser Arg Pro Pro Glu Gly Lys His Ile
465 470 475 480

Thr Thr Pro Arg Glu Pro Leu Pro Pro Ile Val Thr Phe Gln Leu Ile
485 490 495

Pro Lys Gly Ser Ile Ala Gln Pro Ala Gly Ala Pro Gln Pro Gln Ser
500 505 510

Thr Cys Pro Pro Ala Val Ala Gly Pro Leu Pro Thr Met Tyr Gln Ile
515 520 525

Pro Glu Met Ala Arg Leu Pro Ser Val Ala Phe Pro Thr Ala Met Met
530 535 540

Pro Gln Gln Asp Gly Gln Val Ala Gln Thr Ile Leu Pro Ala Tyr His
545 550 555 560

Pro Phe Pro Ala Ser Val Gly Lys Tyr Pro Thr Pro Pro Ser Gln His
565 570 575

Ser Tyr Ala Ser Ser Asn Ala Ala Glu Arg Thr Pro Ser His Ser Gly
580 585 590

His Leu Gln Gly Glu His Pro Tyr Leu Thr Pro Ser Pro Glu Ser Pro
595 600 605

Asp Gln Trp Ser Ser Ser S r Pro His Ser Ala Ser Asp Trp Ser Asp
610 615 620

Val Thr Thr Ser Pr Thr Pro Gly Gly Ala Gly Gly Gly Gln Arg Gly
625 630 635 640

Pro Gly Thr His Met Ser Glu Pro Pr His Asn Asn Met Gln Val Tyr
645 650 655

Ala

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 654 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Thr Pro Pro Gln Gly Glu Ile Glu Ala Asp Cys Met Asp Val Asn Val
1 5 10 15

Arg Gly Pro Asp Gly Phe Thr Pro Leu Met Ile Ala Ser Cys Ser Gly
20 25 30

Gly Gly Leu Glu Thr Gly Asn Ser Glu Glu Glu Glu Asp Ala Ser Ala
35 40 45

Asn Met Ile Ser Asp Phe Ile Gly Gln Gly Ala Gln Leu His Asn Gln
50 55 60

Thr Asp Arg Thr Gly Glu Thr Ala Leu His Leu Ala Ala Arg Tyr Ala
65 70 75 80

Arg Ala Asp Ala Ala Lys Arg Leu Leu Glu Ser Ser Ala Asp Ala Asn
85 90 95

Val Gln Asp Asn Met Gly Arg Thr Pro Leu His Ala Ala Val Ala Ala
100 105 110

Asp Ala Gln Gly Val Phe Gln Ile Leu Ile Arg Asn Arg Ala Thr Asp
115 120 125

Leu Asp Ala Arg Met Phe Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala
130 135 140

Arg Leu Ala Val Glu Gly Met Val Glu Glu Leu Ile Asn Ala His Ala
145 150 155 160

Asp Val Asn Ala Val Asp Glu Phe Gly Lys Ser Ala Leu His Trp Ala
165 170 175

Ala Ala Val Asn Asn Val Asp Ala Ala Ala Val Leu Leu Lys Asn Ser
180 185 190

Ala Asn Lys Asp Met Gln Asn Asn Lys Glu Glu Thr Ser Leu Phe Leu
195 200 205

Ala Ala Arg Glu Gly Ser Tyr Glu Thr Ala Lys Val Leu Leu Asp His
210 215 220

Tyr Ala Asn Arg Asp Ile Thr Asp His Met Asp Arg Leu Pro Arg Asp
225 230 235 240

Ile Ala Gln Glu Arg Met His His Asp Ile Val His Leu Leu Asp Glu
245 250 255

Tyr Asn Leu Val Lys Ser Pro Thr Leu His Asn Gly Pr Leu Gly Ala
260 265 270

Thr Thr Leu Ser Pro Pro Ile Cys Ser Pro Asn Gly Tyr Met Gly Asn
275 280 285

Met Lys Pro Ser Val Gln Ser Lys Lys Ala Arg Lys Pro Ser Ile Lys
290 295 300

Gly Asn Gly Cys Lys Glu Ala Lys Glu Leu Lys Ala Arg Arg Lys Lys
305 310 315 320

Ser Gln Asp Gly Lys Thr Thr Leu Leu Asp Ser Gly Ser Ser Gly Val
325 330 335

Leu Ser Pro Val Asp Ser Leu Glu Ser Thr His Gly Tyr Leu Ser Asp
340 345 350

Val Ser Ser Pro Pro Leu Met Thr Ser Pro Phe Gln Gln Ser Pro Ser
355 360 365

Met Pro Leu Asn His Leu Thr Ser Met Pro Glu Ser Gln Leu Gly Met
370 375 380

Asn His Ile Asn Met Ala Thr Lys Gln Glu Met Ala Ala Gly Ser Asn
385 390 395 400

Arg Met Ala Phe Asp Ala Met Val Pro Arg Leu Thr His Leu Asn Ala
405 410 415

Ser Ser Pro Asn Thr Ile Met Ser Asn Gly Ser Met His Phe Thr Val
420 425 430

Gly Gly Ala Pro Thr Met Asn Ser Gln Cys Asp Trp Leu Ala Arg Leu
435 440 445

Gln Asn Gly Met Val Gln Asn Gln Tyr Asp Pro Ile Arg Asn Gly Ile
450 455 460

Gln Gln Gly Asn Ala Gln Gln Ala Gln Ala Leu Gln His Gly Leu Met
465 470 475 480

Thr Ser Leu His Asn Gly Leu Pro Ala Thr Thr Leu Ser Gln Met Met
485 490 495

Thr Tyr Gln Ala Met Pro Asn Thr Arg Leu Ala Asn Gln Pro His Leu
500 505 510

Met Gln Ala Gln Gln Met Gln Gln Gln Gln Asn Leu Gln Leu His Gln
515 520 525

Ser Met Gln Gln Gln His His Asn Ser Ser Thr Thr Ser Thr His Ile
530 535 540

Asn Ser Pro Phe Cys Ser Ser Asp Ile Ser Gln Thr Asp Leu Gln Gln
545 550 555 560

Met Ser Ser Asn Asn Ile His Ser Val Met Pro Gln Asp Thr Gln Ile
565 570 575

Phe Ala Ala Ser Leu Pro S r Asn Leu Thr Gln Ser M t Thr Thr Ala
580 585 590

Gln Phe Leu Thr Pro Pro Ser Gln His Ser Tyr Ser Ser Pro Met Asp
595 600 605

Asn Thr Pr Ser His Gln Leu Gln Val Pro Asp His Pro Phe Leu Thr

610 615 620

Pro Ser Pro Glu Ser Pro Asp Gln Trp Ser Ser Ser Ser Pro His Ser
625 630 635 640

Asn Met Ser Asp Trp Ser Glu Gly Ile Ser Ser Pro Pro Thr
645 650

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 666 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Thr Pro Pro Gln Gly Glu Val Asp Ala Asp Cys Met Asp Val Asn Val
1 5 10 15

Arg Gly Pro Asp Gly Phe Thr Pro Leu Met Ile Ala Ser Cys Ser Gly
20 25 30

Gly Gly Leu Glu Thr Gly Asn Ser Glu Glu Glu Glu Asp Ala Pro Ala
35 40 45

Val Ile Ser Asp Phe Ile Tyr Gln Gly Ala Ser Leu His Asn Gln Thr
50 55 60

Asp Arg Thr Gly Glu Thr Ala Leu His Leu Ala Ala Arg Tyr Ser Arg
65 70 75 80

Ser Asp Ala Ala Lys Arg Leu Leu Glu Ala Ser Ala Asp Ala Asn Ile
85 90 95

Gln Asp Asn Met Gly Arg Thr Pro Leu His Ala Ala Val Ser Ala Asp
100 105 110

Ala Gln Gly Val Phe Gln Ile Leu Leu Arg Asn Arg Ala Thr Asp Leu
115 120 125

Asp Ala Arg Met His Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg
130 135 140

Leu Ala Val Glu Gly Met Leu Glu Asp Leu Ile Asn Ser His Ala Asp
145 150 155 160

Val Asn Ala Val Asp Asp Leu Gly Lys Ser Ala Leu His Trp Ala Ala
165 170 175

Ala Val Asn Asn Val Asp Ala Ala Val Val Leu Leu Lys Asn Gly Ala
180 185 190

Asn Lys Asp Met Gln Asn Asn Lys Glu Glu Thr Pro Leu Phe Leu Ala
195 200 205

Ala Arg Glu Gly Ser Tyr Glu Thr Ala Lys Val Leu Leu Asp His Phe
210 215 220

Ala Asn Arg Asp Ile Thr Asp His Met Asp Arg Leu Pro Arg Asp Ile
225 230 235 240

Ala Gln Glu Arg M t His His Asp Ile Val Arg Leu Leu Asp Glu Tyr
245 250 255

Asn Leu Val Arg Ser Pro Gln Leu His Gly Thr Ala Leu Gly Gly Thr
260 265 270

Pro Thr Leu Ser Pro Thr Leu Cys Ser Pro Asn Gly Tyr Leu Gly Asn
275 280 285

Leu Lys Ser Ala Thr Gln Gly Lys Lys Ala Arg Lys Pro Ser Thr Lys
290 295 300

Gly Leu Ala Cys Ser Ser Lys Glu Ala Lys Asp Leu Lys Ala Arg Arg
305 310 315 320

Lys Lys Ser Gln Asp Gly Lys Gly Cys Leu Leu Asp Ser Ser Ser Met
325 330 335

Leu Ser Pro Val Asp Ser Leu Glu Ser Pro His Gly Tyr Leu Ser Asp
340 345 350

Val Ala Ser Pro Pro Leu Pro Ser Pro Phe Gln Gln Ser Pro Ser Met
355 360 365

Pro Leu Ser His Leu Pro Gly Met Pro Asp Thr His Leu Gly Ile Ser
370 375 380

His Leu Asn Val Ala Ala Lys Pro Glu Met Ala Ala Leu Ala Gly Gly
385 390 395 400

Ser Arg Leu Ala Phe Glu Pro Pro Pro Pro Arg Leu Ser His Leu Pro
405 410 415

Val Ala Ser Ser Ala Ser Thr Val Leu Ser Thr Asn Gly Thr Gly Ala
420 425 430

Met Asn Phe Thr Val Gly Ala Pro Ala Ser Leu Asn Gly Gln Cys Glu
435 440 445

Trp Leu Pro Arg Leu Gln Asn Gly Met Val Pro Ser Gln Tyr Asn Pro
450 455 460

Leu Arg Pro Gly Val Thr Pro Gly Thr Leu Ser Thr Gln Ala Ala Gly
465 470 475 480

Leu Gln His Gly Met Met Ser Pro Ile His Ser Ser Leu Ser Thr Asn
485 490 495

Thr Leu Ser Pro Ile Ile Tyr Gln Gly Leu Pro Asn Thr Arg Leu Ala
500 505 510

Thr Gln Pro His Leu Val Gln Thr Gln Gln Val Gln Pro Gln Asn Leu
515 520 525

Gln Ile Gln Pro Gln Asn Leu Gln Pro Pro Ser Gln Pro His Leu Ser
530 535 540

Val Ser Ser Ala Ala Asn Gly His Leu Gly Arg Ser Phe Leu Ser Gly
545 550 555 560

Glu Pro Ser Gln Ala Asp Val Gln Pro Leu Gly Pro Ser Ser Leu Pro
565 570 575

Val His Thr Ile Leu Pro Gln Glu Ser Gln Ala Leu Pro Thr Ser Leu
580 585 590

Pro Ser Ser Met Val Pro Pro Met Thr Thr Thr Gln Phe Leu Thr Pr
595 600 605

Pro Ser Gln His Ser Tyr S r Ser Ser Pro Val Asp Asn Thr Pro Ser
610 615 620

His Gln Leu Gln Val Pro Glu His Pro Phe Leu Thr Pro Ser Pro Glu

625 630 635 640

Ser Pro Asp Gln Trp Ser Ser Ser Ser Arg His Ser Asn Ile Ser Asp
645 650 655

Trp Ser Glu Gly Ile Ser Ser Pro Pro Thr
660 665

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 681 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Thr Pro Pro Gln Gly Glu Val Asp Ala Asp Cys Met Asp Val Asn Val
1 5 10 15

Arg Gly Pro Asp Gly Phe Thr Pro Leu Met Ile Ala Ser Cys Ser Gly
20 25 30

Gly Gly Leu Glu Thr Gly Asn Ser Glu Glu Glu Glu Asp Ala Pro Ala
35 40 45

Val Ile Ser Asp Phe Ile Tyr Gln Gly Ala Ser Leu His Asn Gln Thr
50 55 60

Asp Arg Thr Gly Glu Thr Ala Leu His Leu Ala Ala Arg Tyr Ser Arg
65 70 75 80

Ser Asp Ala Ala Lys Arg Leu Leu Glu Ala Ser Ala Asp Ala Asn Ile
85 90 95

Gln Asp Asn Met Gly Arg Thr Pro Leu His Ala Ala Val Ser Ala Asp
100 105 110

Ala Gln Gly Val Phe Gln Ile Leu Ile Arg Asn Arg Ala Thr Asp Leu
115 120 125

Asp Ala Arg Met His Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg
130 135 140

Leu Ala Val Glu Gly Met Leu Glu Asp Leu Ile Asn Ser His Ala Asp
145 150 155 160

Val Asn Ala Val Asp Asp Leu Gly Lys Ser Ala Leu His Trp Ala Ala
165 170 175

Ala Val Asn Asn Val Asp Ala Ala Val Val Leu Leu Lys Asn Gly Ala
180 185 190

Asn Lys Asp Met Gln Asn Asn Arg Glu Glu Thr Pro Leu Phe Leu Ala
195 200 205

Ala Arg Glu Gly Ser Tyr Glu Thr Ala Lys Val Leu Leu Asp His Phe
210 215 220

Ala Asn Arg Asp Ile Thr Asp His M t Asp Arg Leu Pro Arg Asp Ile
225 230 235 240

Ala Gln Glu Arg Met His His Asp Ile Val Arg Leu Leu Asp Glu Tyr
245 250 255

Asn Leu Val Arg Ser Pr Gln Leu His Gly Ala Pro Leu Gly Gly Thr
260 265 270

Pro Thr Leu Ser Pro Pro Leu Cys Ser Pro Asn Gly Tyr Leu Gly Ser
275 280 285

Leu Lys Pro Gly Val Gln Gly Lys Lys Val Arg Lys Pro Ser Ser Lys
290 295 300

Gly Leu Ala Cys Gly Ser Lys Glu Ala Lys Asp Leu Lys Ala Arg Arg
305 310 315 320

Lys Lys Ser Gln Asp Gly Lys Gly Cys Leu Leu Asp Ser Ser Gly Met
325 330 335

Leu Ser Pro Val Asp Ser Leu Glu Ser Pro His Gly Tyr Leu Ser Asp
340 345 350

Val Ala Ser Pro Pro Leu Leu Pro Ser Pro Phe Gln Gln Ser Pro Ser
355 360 365

Val Pro Leu Asn His Leu Pro Gly Met Pro Asp Thr His Leu Gly Ile
370 375 380

Gly His Leu Asn Val Ala Ala Lys Pro Glu Met Ala Ala Leu Gly Gly
385 390 395 400

Gly Gly Arg Leu Ala Phe Glu Thr Gly Pro Pro Arg Leu Ser His Leu
405 410 415

Pro Val Ala Ser Gly Thr Ser Thr Val Leu Gly Ser Ser Ser Gly Gly
420 425 430

Ala Leu Asn Phe Thr Val Gly Gly Ser Thr Ser Leu Asn Gly Gln Cys
435 440 445

Glu Trp Leu Ser Arg Leu Gln Ser Gly Met Val Pro Asn Gln Tyr Asn
450 455 460

Pro Leu Arg Gly Ser Val Ala Pro Gly Pro Leu Ser Thr Gln Ala Pro
465 470 475 480

Ser Leu Gln His Gly Met Val Gly Pro Leu His Ser Ser Leu Ala Ala
485 490 495

Ser Ala Leu Ser Gln Met Met Ser Tyr Gln Gly Leu Pro Ser Thr Arg
500 505 510

Leu Ala Thr Gln Pro His Leu Val Gln Thr Gln Gln Val Gln Pro Gln
515 520 525

Asn Leu Gln Met Gln Gln Gln Asn Leu Gln Pro Ala Asn Ile Gln Gln
530 535 540

Gln Gln Ser Leu Gln Pro Pro Pro Pro Pro Pro Gln Pro His Leu Gly
545 550 555 560

Val Ser Ser Ala Ala Ser Gly His Leu Gly Arg Ser Phe Leu Ser Gly
565 570 575

Glu Pro Ser Gln Ala Asp Val Gln Pro Leu Gly Pro Ser Ser Leu Ala
580 585 590

Val His Thr Ile Leu Pro Gln Glu Ser Pro Ala Leu Pro Thr Ser Leu
595 600 605

Pro Ser Ser Leu Val Pro Pro Val Thr Ala Ala Gln Phe Leu Thr Pro
610 615 620

Pro Ser Gln His Ser Tyr Ser Ser Pro Val Glu Asn Thr Pro Ser His

625 630 635 640

Gln Leu Gln Val Pro Glu His Pro Phe Leu Thr Pro Ser Pro Glu Ser
645 650 655

Pro Asp Gln Trp Ser Ser Ser Ser Pro His Ser Asn Val Ser Asp Trp
660 665 670

Ser Glu Gly Val Ser Ser Pro Pro Thr
675 680

WHAT IS CLAIMED IS:

1. A substantially purified human Notch protein.

2. A substantially purified protein comprising an amino acid sequence encoded by the DNA sequence depicted in Figure 19A (SEQ ID NO:13), 19B (SEQ ID NO:14) or 19C (SEQ ID NO:15).

3. A substantially purified protein comprising an amino acid sequence encoded by the DNA sequence depicted in Figure 20A (SEQ ID NO:16), 20B (SEQ ID NO:17), 20C (SEQ ID NO:18), or 20D (SEQ ID NO:19).

4. A substantially purified protein comprising an amino acid sequence encoded by the DNA sequence depicted in Figure 21A (SEQ ID NO:20), or 21B (SEQ ID NO:21).

5. A substantially purified protein comprising an amino acid sequence encoded by the DNA sequence depicted in Figure 22A (SEQ ID NO:22), 22B (SEQ ID NO:23), 22C (SEQ ID NO:24), or 22D (SEQ ID NO:25).

6. A substantially purified protein comprising an amino acid sequence encoded by the DNA sequence depicted in Figure 19A (SEQ ID NO:13), 19B (SEQ ID NO:14), 19C (SEQ ID NO:15), 20A (SEQ ID NO:16), 20B (SEQ ID NO:17), 20C (SEQ ID NO:18), 20D (SEQ ID NO:19), 21A (SEQ ID NO:20), 21B (SEQ ID NO:21), 22A (SEQ ID NO:22), 22B (SEQ ID NO:23), 22C

(SEQ ID NO:24), or 22D (SEQ ID NO:25), which is able to be bound by an antibody to a human Notch protein.

7. A substantially purified protein comprising a Notch amino acid sequence encoded by the DNA sequence depicted in Figure 19A (SEQ ID NO:13), 19B (SEQ ID NO:14), 19C (SEQ ID NO:15), 20A (SEQ ID NO:16), 20B (SEQ ID NO:17), 20C (SEQ ID NO:18), 20D (SEQ ID NO:19), 21A (SEQ ID NO:20), 21B (SEQ ID NO:21), 22A (SEQ ID NO:22), 22B (SEQ ID NO:23), 22C (SEQ ID NO:24), or 22D (SEQ ID NO:25) which displays one or more functional activities associated with a full-length Notch protein.

8. A substantially purified protein comprising: a fragment of a human Notch protein consisting of at least 77 amino acids.

9. A substantially purified protein comprising: a fragment of a human Notch protein consisting essentially of the extracellular domain of the protein.

10. A substantially purified protein comprising: a fragment of a human Notch protein consisting essentially of the intracellular domain of the protein.

11. A substantially purified protein comprising: a fragment of a human Notch protein consisting essentially of the extracellular and transmembrane domains of the protein.

12. A substantially purified protein comprising: a fragment of a human Notch protein

consisting essentially of the intracellular domain of the protein, as encoded by a portion of plasmid hN3k as deposited with the ATCC and assigned accession number 68609, or as encoded by a portion of plasmid hN5k as deposited with the ATCC and assigned accession number 68611.

13. A substantially purified protein comprising: a fragment of a human Notch protein consisting essentially of the region containing the cdc10 repeats of the protein.

14. A substantially purified protein comprising: a fragment of a human Notch protein consisting essentially of the region containing the cdc10 repeats, as encoded by a portion of plasmid hN3k as deposited with the ATCC and assigned accession number 68611, or as encoded by a portion of plasmid hN5k as deposited with the ATCC and assigned accession number 68611.

15. A substantially purified protein comprising a region of a human Notch protein containing the EGF homologous repeats of the protein.

16. A substantially purified protein comprising a region of a human Notch protein containing the Notch/lin-12 repeats of the protein.

17. A substantially purified fragment of a human Notch protein substantially lacking the EGF-homologous repeats of the protein, which fragment is able to be bound by an antibody to a Notch protein.

18. A substantially purified fragment of a human Notch protein lacking a portion of the EGF-homologous repeats of the protein, which fragment is able to be bound by an antibody to a Notch protein.

19. A substantially purified protein comprising an amino acid sequence encoded by at least 121 nucleotides of the human cDNA sequence contained in plasmid hN3k as deposited with the ATCC and assigned accession number 68609.

20. A substantially purified protein comprising an amino acid sequence encoded by at least 121 nucleotides of the human cDNA sequence contained in plasmid hN4k as deposited with the ATCC and assigned accession number 68610.

21. A substantially purified protein comprising an amino acid sequence encoded by at least 121 nucleotides of the human cDNA sequence contained in plasmid hN5k as deposited with the ATCC and assigned accession number 68611.

22. A substantially purified fragment of a human Notch protein consisting essentially of the intracellular domain of the protein.

23. A substantially purified fragment of a human Notch protein consisting essentially of the extracellular domain of the protein.

24. A substantially purified fragment of a human Notch protein consisting essentially of the extracellular and transmembrane domains of the protein.

25. A chimeric protein comprising the fragment of claim 8 joined to a heterologous protein sequence.

26. A chimeric protein comprising the fragment of claim 9 joined to a heterologous protein sequence.

27. A substantially purified protein comprising a functionally active portion of a human Notch protein.

28. A substantially purified protein comprising a functionally active portion of the Notch protein sequence encoded by the human cDNA sequence contained in plasmid hN3k as deposited with the ATCC and assigned accession number 68609, or encoded by the human cDNA sequence contained in plasmid hN5k as deposited with the ATCC and assigned accession number 68611.

29. A substantially purified protein comprising a functionally active portion of the Notch protein sequence encoded by the human cDNA sequence contained in plasmid hN4k as deposited with the ATCC and assigned accession number 68610.

30. A substantially purified protein comprising the amino acid sequence depicted in Figure 23.

31. A substantially purified protein comprising the amino acid sequence depicted in Figure 24.

32. A substantially purified protein comprising the Notch amino acid sequence encoded by the human Notch DNA sequence contained in plasmid hN3k as deposited with the ATCC and assigned accession number 68609.

33. A substantially purified protein comprising the Notch amino acid sequence encoded by the human Notch DNA sequence contained in plasmid hN5k as deposited with the ATCC and assigned accession number 68611.

34. A fragment of the protein of claim 30 which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Delta protein expressed on the surface of a second cell.

35. A fragment of the protein of claim 31 which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Delta protein expressed on the surface of a second cell.

36. A substantially purified protein comprising the portion of a human Notch protein with the greatest homology to the epidermal growth factor-like repeats 11 and 12 of the Drosophila Notch sequence as shown in Figure 8 (SEQ ID NO:1).

37. A derivative or analog of the protein of claim 1, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Delta protein expressed on the surface of a second cell.

38. A chimeric protein comprising the protein of claim 1 joined to a heterologous protein sequence.

39. A chimeric protein comprising the protein of claim 6 joined to a heterologous protein sequence.

40. A chimeric protein comprising the protein of claim 7 joined to a heterologous protein sequence.

41. A substantially purified fragment of a Notch protein, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Delta protein expressed on the surface of a second cell.

42. The fragment of claim 41 consisting essentially of the portion of the Notch protein with the greatest homology to the epidermal growth factor-like repeats 11 and 12 of the Drosophila Notch protein.

43. The fragment of claim 41 in which the Notch protein is a Drosophila Notch protein.

44. The fragment of claim 41 in which the Notch protein is a Xenopus Notch protein.

45. The fragment of claim 41 in which the Notch protein is a human Notch protein.

46. A chimeric protein comprising the fragment of claim 45 joined to a heterologous protein sequence.

47. A substantially purified fragment of a Drosophila Notch protein consisting essentially of the epidermal growth factor-like repeats 11 and 12 of the protein.

48. A chimeric protein comprising the fragment of claim 41 or 47 joined to a heterologous protein sequence.

49. A substantially purified fragment of a Delta protein, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell.

50. The fragment of claim 49 which is the portion of the Delta protein with the greatest homology to amino acid numbers 1-230 as depicted in Figure 13 (SEQ ID NO:6).

51. A chimeric protein comprising the fragment of claim 49 joined to a heterologous protein sequence.

52. A substantially purified fragment of a Delta protein, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a second Delta protein or fragment expressed on the surface of a second cell.

53. The fragment of claim 52 which is the portion of the Delta protein with the greatest homology to about amino acid numbers 32-230 as depicted in Figure 13 (SEQ ID NO:6).

54. A chimeric protein comprising the fragment of claim 52 joined to a heterologous protein sequence.

55. A substantially purified fragment of a Serrate protein, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell.

56. A substantially purified fragment of a Serrate protein which is the portion of the Serrate protein with the greatest homology to the amino acid sequence as depicted in Figure 15 (SEQ ID NO:9) from about amino acid numbers 85-283.

57. A chimeric protein comprising the fragment of claim 56 joined to a heterologous protein sequence.

58. A derivative or analog of the fragment of claim 41 which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Delta protein expressed on the surface of a second cell.

59. A derivative or analog of the fragment of claim 49, which is characterized by the ability in vitro, when expressed on the surface of a first cell,

to bind to a Notch protein expressed on the surface of a second cell.

60. A derivative or analog of the fragment of claim 52, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a second Delta protein expressed on the surface of a second cell.

61. A derivative or analog of the fragment of claim 55, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a second protein expressed on the surface of a second cell, which second protein is selected from the group consisting of a Notch protein, a Delta protein, and a second Serrate protein.

62. A substantially purified fragment of a human Notch protein consisting of at least 40 amino acids.

63. A substantially purified nucleic acid encoding a human Notch protein.

64. A substantially purified nucleic acid comprising a cDNA sequence encoding a human Notch protein.

65. A substantially purified nucleic acid comprising a nucleotide sequence complementary to and capable of hybridizing to the cDNA sequence of claim 64.

66. A substantially purified cDNA sequence encoding a functionally active portion of a human Notch protein.

67. A substantially purified nucleic acid comprising a nucleotide sequence complementary to and capable of hybridizing to the cDNA sequence of claim 66.

68. A substantially purified cDNA molecule comprising the DNA sequence depicted in Figure 19A (SEQ ID NO:13), 19B (SEQ ID NO:14), 19C (SEQ ID NO:15), 20A (SEQ ID NO:16), 20B (SEQ ID NO:17), 20C (SEQ ID NO:18), 20D (SEQ ID NO:19), 21A (SEQ ID NO:20), 21B (SEQ ID NO:21), 22A (SEQ ID NO:22), 22B (SEQ ID NO:23), 22C (SEQ ID NO:24), or 22D (SEQ ID NO:25).

69. The nucleic acid of claim 63 in which the Notch protein comprises an amino acid sequence encoded by the DNA sequence depicted in Figure 19A (SEQ ID NO:13), 19B (SEQ ID NO:14), 19C (SEQ ID NO:15), 20A (SEQ ID NO:16), 20B (SEQ ID NO:17), 20C (SEQ ID NO:18), 20D (SEQ ID NO:19), 21A (SEQ ID NO:20), 21B (SEQ ID NO:21), 22A (SEQ ID NO:22), 22B (SEQ ID NO:23), 22C (SEQ ID NO:24), or 22D (SEQ ID NO:25).

70. A substantially purified nucleic acid comprising a DNA sequence encoding at least a 77 amino acid portion of a human Notch protein, which portion has the greatest homology to the epidermal growth factor-like repeats 11 and 12 of the Drosophila Notch sequence as shown in Figure 8 (SEQ ID NO:1).

71. A substantially purified nucleic acid comprising the human Notch cDNA contained in plasmid hN4k, as deposited with the ATCC and assigned accession number 68610.

72. A substantially purified nucleic acid comprising the human Notch cDNA contained in plasmid hN3k, as deposited with the ATCC and assigned accession number 68609.

73. A substantially purified nucleic acid comprising the human Notch cDNA contained in plasmid hN5k, as deposited with the ATCC and assigned accession number 68611.

74. A substantially purified nucleic acid comprising the DNA coding sequence depicted in Figure 23.

75. A substantially purified nucleic acid comprising the DNA coding sequence depicted in Figure 24.

76. A substantially purified nucleic acid comprising a cDNA sequence encoding the extracellular domain of a human Notch protein.

77. A substantially purified nucleic acid comprising a cDNA sequence encoding the intracellular domain of a human Notch protein.

78. A substantially purified nucleic acid comprising a cDNA sequence encoding the extracellular and transmembrane domains of a human Notch protein.

79. A substantially purified nucleic acid comprising a cDNA sequence encoding the EGF-homologous repeats of a human Notch protein.

80. A substantially purified nucleic acid comprising a cDNA sequence encoding the Notch/lin-12 repeats of a human Notch protein.

81. A substantially purified cDNA molecule encoding a fragment of a human Notch protein of at least 77 amino acids.

82. A substantially purified cDNA molecule encoding a fragment of a human Notch protein of at least 40 amino acids.

83. A substantially purified nucleic acid encoding the amino acid sequence depicted in Figure 23.

84. A substantially purified nucleic acid encoding the amino acid sequence depicted in Figure 24.

85. A substantially purified nucleic acid encoding the protein of claim 36.

86. A substantially purified nucleic acid encoding the fragment of claim 41.

87. A substantially purified nucleic acid encoding the fragment of claim 45.

88. A substantially purified nucleic acid encoding the fragment of claim 47.

89. A substantially purified nucleic acid encoding the fragment of claim 49.

90. A substantially purified nucleic acid encoding the fragment of claim 52.

91. A substantially purified nucleic acid encoding the fragment of claim 55.

92. A nucleic acid encoding the chimeric protein of claim 48.

93. A nucleic acid encoding the chimeric protein of claim 51.

94. A nucleic acid encoding the chimeric protein of claim 54.

95. A nucleic acid vector comprising the nucleic acid of claim 63.

96. A nucleic acid vector comprising the cDNA molecule of claim 66.

97. A nucleic acid vector comprising the nucleic acid of claim 85.

98. A nucleic acid vector comprising the nucleic acid of claim 86.

99. A nucleic acid vector comprising the nucleic acid of claim 87.

100. A nucleic acid vector comprising the nucleic acid of claim 88.

101. A nucleic acid vector comprising the nucleic acid of claim 89.

102. A nucleic acid vector comprising the nucleic acid of claim 91.

103. A recombinant cell containing the nucleic acid vector of claim 95.

104. A recombinant cell containing the nucleic acid vector of claim 96.

105. A recombinant cell containing the nucleic acid vector of claim 97.

106. A recombinant cell containing the nucleic acid vector of claim 98.

107. A recombinant cell containing the nucleic acid vector of claim 99.

108. A recombinant cell containing the nucleic acid vector of claim 100.

109. A recombinant cell containing the nucleic acid vector of claim 101.

110. A recombinant cell containing the nucleic acid vector of claim 102.

111. A method for producing a human Notch protein comprising growing the recombinant cell of claim 103, such that the human Notch protein is

expressed by the cell; and isolating the expressed human Notch protein.

112. A method for producing a portion of a human Notch protein comprising growing the recombinant cell of claim 104, such that the portion of human Notch is expressed by the cell; and isolating the expressed human Notch portion.

113. A method for producing a protein comprising growing the recombinant cell of claim 105 such that the protein is expressed by the cell; and isolating the expressed protein.

114. A method for producing a fragment of a Notch protein comprising growing the recombinant cell of claim 106 such that the fragment is expressed by the cell; and isolating the expressed fragment of a Notch protein.

115. A method for producing a fragment of a human Notch protein comprising growing the recombinant cell of claim 107 such that the fragment is expressed by the cell; and isolating the expressed fragment of a human Notch protein.

116. A method for producing a fragment of a Drosophila Notch protein comprising growing the recombinant cell of claim 108 such that the fragment is expressed by the cell; and isolating the expressed fragment of a Drosophila Notch protein.

117. A method for producing a fragment of a Delta protein comprising growing the recombinant cell of claim 109 such that the fragment is expressed by

the cell; and isolating the expressed fragment of a Delta protein.

118. A method for producing a fragment of a Serrate protein comprising growing the recombinant cell of claim 110 such that the fragment is expressed by the cell; and isolating the expressed fragment of a Serrate protein.

119. An antibody which binds to a human Notch protein and which does not bind to a Drosophila Notch protein.

120. An antibody which binds to the fragment of claim 41.

121. An antibody which binds to the fragment of claim 49.

122. An antibody which binds to the fragment of claim 52.

123. An antibody which binds to the fragment of claim 55.

124. A fragment or derivative of the antibody of claim 119 containing the idiotype of the antibody.

125. A fragment or derivative of the antibody of claim 120 containing the idiotype of the antibody.

126. An antibody which binds to the Notch protein sequence encoded by plasmid hN3k, as deposited

with the ATCC and assigned accession number 68609, or to the Notch protein sequence encoded by plasmid hN5k, as deposited with the ATCC and assigned accession number 68611, and which does not bind to a Drosophila Notch protein.

127. A substantially purified nucleic acid which encodes a protein or peptide which comprises (a) a first amino acid sequence homologous to both a Serrate protein and a Delta protein; and (b) a second amino acid sequence which is not homologous to either a Serrate protein or a Delta protein.

128. A substantially purified fragment of a Notch protein, which is characterized by the ability in vitro, when expressed on the surface of a first cell, to bind to a Serrate protein expressed on the surface of a second cell.

129. A substantially purified fragment of a Serrate protein which is the portion of the Serrate protein with the greatest homology to the amino acid sequence as depicted in Figure 15 (SEQ ID NO:9) from about amino acid numbers 79-282.

130. A substantially purified fragment or derivative of a Delta protein, which is characterized by (a) the ability in vitro, when expressed on the surface of a first cell to bind to a second Delta protein or fragment or derivative expressed on the surface of a second cell; and (b) the inability, in vitro, when expressed on the surface of a third cell, to bind to a Notch protein expressed on the surface of a fourth cell.

131. A method of delivering an agent into a cell expressing a Notch protein comprising exposing a Notch-expressing cell to a molecule such that the molecule is delivered into the cell, in which the molecule comprises a Delta protein or Delta fragment or derivative bound to an agent, in which the Delta protein, fragment, or derivative is characterized by the ability, in vitro, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell.

132. An isolated nucleic acid comprising at least 25 nucleotides of the DNA coding sequence depicted in Figure 23 or 24.


NOTCH
Mglla
MT ATG TM 3'N
TRANSFECT S2 CELLS
DELTA
DH cDNA
MT ATG TM 3'Adh
TRANSFECT S2 CELLS
ECN1
N GENOMIC
5'N ATG TM 3'N
TRANSFECT S2 CELLS
INDUCE, MIX, AND AGGREGATE
INDUCE, MIX, AND AGGREGATE

FIG.1

FIG. 2B



FIG. 2A





FIG.3C



FIG.3B



FIG.3A



FIG.3F

FIG.3E



FIG.3D



FIG.3I



FIG.3H



FIG.3G



FIG. 4A



FIG. 4B



FIG.4C



FIG. 4D



FIG. 4E



FIG. 4F

FIG. 5B



FIG. 5A




% AGGREGATION
WITH DI WITH Ser
TM
SP EGF N cdc10 PA opa
1.pMtNMg 40 21
2.ΔSph 1 32 0 nt
3.ΔCla 7 31 0 nt
4.ΔEGF(7-17) 7 17 0 nt
5.ΔEGF(9-26) 9 26 0 nt
6.ΔEGF(17-30) 17 31 22 nt
7.ΔEGF(7-9) 7 9 20 14
8.ΔEGF(9-17) 9 17 0 0
9.ΔEGF(17-26) 17 26 10 8
10.ΔEGF(26-30) 26 31 5 7
11.ΔEGF(9-30) 9 30 0 nt
12.ΔEGF(7-26) 7 26 0 nt
13.ΔCla+EGF(9-17) 7 9 17 31 35 20
14.ΔCla+EGF(17-26) 7 17 26 31 0 nt
15.ΔSPLIT 14 42 nt
16.ΔCla+EGF(9-13) 7 9 13 31 47 25

FIG.6A


17. ΔCla+EGF(11-15) 7 11 15 31 0 0
18. ΔCla+EGF(13-17) 7 13 17 31 0 nt
19. ΔCla+EGF(10-13) 7 10 13 31 56 23
20. ΔCla+EGF(11-13) 7 11 13 31 0 nt
21. ΔCla+EGF(10-12) 7 10 12 31 0 nt
22. ΔCla+EGF(10-11) 7 10 11 31 0 nt
23. ΔCla+EGF(10-12) 7 10 12 31 45 nt
24. ΔCla+EGF(11-12) 7 11 12 31 11 nt
25. ΔEGF 1 0 nt
26. ΔEGF+EGF(9-17) 1 9 17 24 nt
27. ΔEGF+EGF(9-13) 1 9 13 40 nt
28. ΔEGF+EGF(10-13) 1 10 13 45 23
29. ΔEGF+EGF(10-12) 1 10 12 48 nt
30. ΔECN 1 0 nt
31. ΔECN+EGF(10-13) 1 10 13 26 nt
32. ΔECN+EGF(10-12) 1 10 12 47 22
33. ΔCla+XEGF(10-13) 7 10 13 31 42 20

FIG.6B


EGF10
EGF11
EGF12
EGF13
— G-G-G—G-G-C-G-C-G-G- G-C-C-G-G-G—G-C-C-G-G-G—C-G-C
19. ΔCla+EGF(10–13) (+)
20. ΔCla+EGF(11–13) (–)
21. ΔCla+EGF(10–12) (–)
22. ΔCla+EGF(10–11) (–)
23. ΔCla+EGF(10–12) (+)
24. ΔCla+EGF(11–12) (+)

FIG.7



FIG.8


40
30
20
10
AGGREGATION a
DI-N
2
4
8
12
20
INPUT DNA (µg)

FIG.9A


30
20
10
AGGREGATION b
DI-DI
2
4
8
12
20
INPUT DNA (µg)

FIG.9B


S
"EGF"
M
H
WILD TYPE
Del(Sca–Nae)
Del(Bam–Bgl)
Del(ELR1–ELR3)
Ter(Dde)
Ins(Nae)
Ins(Stu)
NG1
NG2
NG3
NG4
NG5
NAE B
STU B
Del(ELR4–ELR5)

FIG.9C


DI 24
N1
GSFELRLKYFSNDHGRDNEGRCCSGESDGATGKCLG.S.CKTRFRVCLKHYQATIDTTS...QC
GNFELEILEISNTNSHLLNGYCCGMPAELRATKTIGCSPCTTAFRLCLKEYQTTEQGASISTGC
SER85
STU B
EGKIFPW
TYGDVITPILGENSVNLTDAQRFQNKGFTNPIQFPFSFSWPGTFSLIVEAW
SFGNATTKILGGSSFVLSDPG.....YGAIVLPFTFRWTKSFTLILQAL
N2
HDTNNSGNARTNKLLIQRLLYQQVLEVSSEWKTNKSESQYTSLEYDFRVT
DMYNTS..YPDAERLIEETSYSGVILPSPEWKTLDHIGRNARITYRVRVQ
NAE B
CRKIFR
226
N3
CDLNYYGSGCAKFCRPRDDSFGHSTCSETGEIICLTGWQGDYC
CAVTYYNTTCTTFCRPRDDQFGHYACGSEGQKLCLNGWQGVNC
283

FIG.10



trans

FIG.11A



cis

FIG.11B



FIG.12C



FIG.12B



FIG.12A

```
GAATTCGGAG GAATTATTCA AAACATAAAC ACAATAAACA ATTTGAGTAG TTGCCGCACA   60

CACACACACA CACAGCCCGT GGATTATTAC ACTAAAAGCG ACACTCAATC CAAAAAATCA  120

GCAACAAAAA CATCAATAAA C ATG CAT TGG ATT AAA TGT TTA TTA ACA GCA     171
                        Met His Trp Ile Lys Cys Leu Leu Thr Ala
                          1               5                  10

TTC ATT TGC TTC ACA GTC ATC GTG CAG GTT CAC AGT TCC GGC AGC TTT     219
Phe Ile Cys Phe Thr Val Ile Val Gln Val His Ser Ser Gly Ser Phe
                15                  20                  25

GAG TTG CGC CTG AAG TAC TTC AGC AAC GAT CAC GGG CGG GAC AAC GAG     267
Glu Leu Arg Leu Lys Tyr Phe Ser Asn Asp His Gly Arg Asp Asn Glu
            30                  35                  40

GGT CGC TGC TGC AGC GGG GAG TCG GAC GGA GCG ACG GGC AAG TGC CTG     315
Gly Arg Cys Cys Ser Gly Glu Ser Asp Gly Ala Thr Gly Lys Cys Leu
        45                  50                  55

GGC AGC TGC AAG ACG CGG TTT CGC GTC TGC CTA AAG CAC TAC CAG GCC     363
Gly Ser Cys Lys Thr Arg Phe Arg Val Cys Leu Lys His Tyr Gln Ala
    60                  65                  70

ACC ATC GAC ACC ACC TCC CAG TGC ACC TAC GGG GAC GTG ATC ACG CCC     411
Thr Ile Asp Thr Thr Ser Gln Cys Thr Tyr Gly Asp Val Ile Thr Pro
75                  80                  85                  90

ATT CTC GGC GAG AAC TCG GTC AAT CTG ACC GAC GCC CAG CGC TTC CAG     459
Ile Leu Gly Glu Asn Ser Val Asn Leu Thr Asp Ala Gln Arg Phe Gln
                95                  100                 105

AAC AAG GGC TTC ACG AAT CCC ATC CAG TTC CCC TTC TCG TTC TCA TGG     507
Asn Lys Gly Phe Thr Asn Pro Ile Gln Phe Pro Phe Ser Phe Ser Trp
            110                 115                 120
```

FIG.13A

```
CCG GGT ACC TTC TCG CTG ATC GTC GAG GCC TGG CAT GAT ACG AAC AAT   555
Pro Gly Thr Phe Ser Leu Ile Val Glu Ala Trp His Asp Thr Asn Asn
        125                 130                 135

AGC GGC AAT GCG CGA ACC AAC AAG CTC CTC ATC CAG CGA CTC TTG GTG   603
Ser Gly Asn Ala Arg Thr Asn Lys Leu Leu Ile Gln Arg Leu Leu Val
    140                 145                 150

CAG CAG GTA CTG GAG GTG TCC TCC GAA TGG AAG ACG AAC AAG TCG GAA   651
Gln Gln Val Leu Glu Val Ser Ser Glu Trp Lys Thr Asn Lys Ser Glu
155                 160                 165                 170

TCG CAG TAC ACG TCG CTG GAG TAC GAT TTC CGT GTC ACC TGC GAT CTC   699
Ser Gln Tyr Thr Ser Leu Glu Tyr Asp Phe Arg Val Thr Cys Asp Leu
                175                 180                 185

AAC TAC TAC GGA TCC GGC TGT GCC AAG TTC TGC CGG CCC CGC GAC GAT   747
Asn Tyr Tyr Gly Ser Gly Cys Ala Lys Phe Cys Arg Pro Arg Asp Asp
            190                 195                 200

TCA TTT GGA CAC TCG ACT TGC TCG GAG ACG GGC GAA ATT ATC TGT TTG   795
Ser Phe Gly His Ser Thr Cys Ser Glu Thr Gly Glu Ile Ile Cys Leu
        205                 210                 215

ACC GGA TGG CAG GGC GAT TAC TGT CAC ATA CCC AAA TGC GCC AAA GGC   843
Thr Gly Trp Gln Gly Asp Tyr Cys His Ile Pro Lys Cys Ala Lys Gly
    220                 225                 230

TGT GAA CAT GGA CAT TGC GAC AAA CCC AAT CAA TGC GTT TGC CAA CTG   891
Cys Glu His Gly His Cys Asp Lys Pro Asn Gln Cys Val Cys Gln Leu
235                 240                 245                 250

GGC TGG AAG GGA GCC TTG TGC AAC GAG TGC GTT CTG GAA CCG AAC TGC   939
Gly Trp Lys Gly Ala Leu Cys Asn Glu Cys Val Leu Glu Pro Asn Cys
                255                 260                 265
```

FIG.13B

```
ATC CAT GGC ACC TGC AAC AAA CCC TGG ACT TGC ATC TGC AAC GAG GGT      987
Ile His Gly Thr Cys Asn Lys Pro Trp Thr Cys Ile Cys Asn Glu Gly
            270                 275                 280

TGG GGA GGC TTG TAC TGC AAC CAG GAT CTG AAC TAC TGC ACC AAC CAC     1035
Trp Gly Gly Leu Tyr Cys Asn Gln Asp Leu Asn Tyr Cys Thr Asn His
        285                 290                 295

AGA CCC TGC AAG AAT GGC GGA ACC TGC TTC AAC ACC GGC GAG GGA TTG     1083
Arg Pro Cys Lys Asn Gly Gly Thr Cys Phe Asn Thr Gly Glu Gly Leu
    300                 305                 310

TAC ACA TGC AAA TGC GCT CCA GGA TAC AGT GGT GAT GAT TGC GAA AAT     1131
Tyr Thr Cys Lys Cys Ala Pro Gly Tyr Ser Gly Asp Asp Cys Glu Asn
315                 320                 325                 330

GAG ATC TAC TCC TGC GAT GCC GAT GTC AAT CCC TGC CAG AAT GGT GGT     1179
Glu Ile Tyr Ser Cys Asp Ala Asp Val Asn Pro Cys Gln Asn Gly Gly
                335                 340                 345

ACC TGC ATC GAT GAG CCG CAC ACA AAA ACC GGC TAC AAG TGT CAT TGC     1227
Thr Cys Ile Asp Glu Pro His Thr Lys Thr Gly Tyr Lys Cys His Cys
            350                 355                 360

GCC AAC GGC TGG AGC GGA AAG ATG TGC GAG GAG AAA GTG CTC ACG TGT     1275
Ala Asn Gly Trp Ser Gly Lys Met Cys Glu Glu Lys Val Leu Thr Cys
        365                 370                 375

TCG GAC AAA CCC TGT CAT CAG GGA ATC TGC CGC AAC GTT CGT CCT GGC     1323
Ser Asp Lys Pro Cys His Gln Gly Ile Cys Arg Asn Val Arg Pro Gly
    380                 385                 390

TTG GGA AGC AAG GGT CAG GGC TAC CAG TGC GAA TGT CCC ATT GGC TAC     1371
Leu Gly Ser Lys Gly Gln Gly Tyr Gln Cys Glu Cys Pro Ile Gly Tyr
395                 400                 405                 410
```

FIG.13C

```
AGC GGA CCC AAC TGC GAT CTC CAG CTG GAC AAC TGC AGT CCG AAT CCA    1419
Ser Gly Pro Asn Cys Asp Leu Gln Leu Asp Asn Cys Ser Pro Asn Pro
                415                 420                 425

TGC ATA AAC GGT GGA AGC TGT CAG CCG AGC GGA AAG TGT ATT TGC CCA    1467
Cys Ile Asn Gly Gly Ser Cys Gln Pro Ser Gly Lys Cys Ile Cys Pro
            430                 435                 440

GCG GGA TTT TCG GGA ACG AGA TGC GAG ACC AAC ATT GAC GAT TGT CTT    1515
Ala Gly Phe Ser Gly Thr Arg Cys Glu Thr Asn Ile Asp Asp Cys Leu
        445                 450                 455

GGC CAC CAG TGC GAG AAC GGA GGC ACC TGC ATA GAT ATG GTC AAC CAA    1563
Gly His Gln Cys Glu Asn Gly Gly Thr Cys Ile Asp Met Val Asn Gln
    460                 465                 470

TAT CGC TGC CAA TGC GTT CCC GGT TTC CAT GGC ACC CAC TGT AGT AGC    1611
Tyr Arg Cys Gln Cys Val Pro Gly Phe His Gly Thr His Cys Ser Ser
475                 480                 485                 490

AAA GTT GAC TTG TGC CTC ATC AGA CCG TGT GCC AAT GGA GGA ACC TGC    1659
Lys Val Asp Leu Cys Leu Ile Arg Pro Cys Ala Asn Gly Gly Thr Cys
                495                 500                 505

TTG AAT CTC AAC AAC GAT TAC CAG TGC ACC TGT CGT GCG GGA TTT ACT    1707
Leu Asn Leu Asn Asn Asp Tyr Gln Cys Thr Cys Arg Ala Gly Phe Thr
            510                 515                 520

GGC AAG GAT TGC TCT GTG GAC ATC GAT GAG TGC AGC AGT GGA CCC TGT    1755
Gly Lys Asp Cys Ser Val Asp Ile Asp Glu Cys Ser Ser Gly Pro Cys
        525                 530                 535

CAT AAC GGC GGC ACT TGC ATG AAC CGC GTC AAT TCG TTC GAA TGC GTG    1803
His Asn Gly Gly Thr Cys Met Asn Arg Val Asn Ser Phe Glu Cys Val
    540                 545                 550
```

FIG.13D

```
TGT GCC AAT GGT TTC AGG GGC AAG CAG TGC GAT GAG GAG TCC TAC GAT   1851
Cys Ala Asn Gly Phe Arg Gly Lys Gln Cys Asp Glu Glu Ser Tyr Asp
555                 560                 565                 570

TCG GTG ACC TTC GAT GCC CAC CAA TAT GGA GCG ACC ACA CAA GCG AGA   1899
Ser Val Thr Phe Asp Ala His Gln Tyr Gly Ala Thr Thr Gln Ala Arg
                575                 580                 585

GCC GAT GGT TTG ACC AAT GCC CAG GTA GTC CTA ATT GCT GTT TTC TCC   1947
Ala Asp Gly Leu Thr Asn Ala Gln Val Val Leu Ile Ala Val Phe Ser
            590                 595                 600

GTT GCG ATG CCT TTG GTG GCG GTT ATT GCG GCG TGC GTG GTC TTC TGC   1995
Val Ala Met Pro Leu Val Ala Val Ile Ala Ala Cys Val Val Phe Cys
        605                 610                 615

ATG AAG CGC AAG CGT AAG CGT GCT CAG GAA AAG GAC GAC GCG GAG GCC   2043
Met Lys Arg Lys Arg Lys Arg Ala Gln Glu Lys Asp Asp Ala Glu Ala
    620                 625                 630

AGG AAG CAG AAC GAA CAG AAT GCG GTG GCC ACA ATG CAT CAC AAT GGC   2091
Arg Lys Gln Asn Glu Gln Asn Ala Val Ala Thr Met His His Asn Gly
635                 640                 645                 650

AGT GGG GTG GGT GTA GCT TTG GCT TCA GCC TCT CTG GGC GGC AAA ACT   2139
Ser Gly Val Gly Val Ala Leu Ala Ser Ala Ser Leu Gly Gly Lys Thr
                655                 660                 665

GGC AGC AAC AGC GGT CTC ACC TTC GAT GGC GGC AAC CCG AAT ATC ATC   2187
Gly Ser Asn Ser Gly Leu Thr Phe Asp Gly Gly Asn Pro Asn Ile Ile
            670                 675                 680

AAA AAC ACC TGG GAC AAG TCG GTC AAC AAC ATT TGT GCC TCA GCA GCA   2235
Lys Asn Thr Trp Asp Lys Ser Val Asn Asn Ile Cys Ala Ser Ala Ala
        685                 690                 695
```

FIG.13E

```
GCA GCG GCG GCG GCG GCA GCA GCG GCG GAC GAG TGT CTC ATG TAC GGC   2283
Ala Ala Ala Ala Ala Ala Ala Ala Ala Asp Glu Cys Leu Met Tyr Gly
    700                 705                 710

GGA TAT GTG GCC TCG GTG GCG GAT AAC AAC AAT GCC AAC TCA GAC TTT   2331
Gly Tyr Val Ala Ser Val Ala Asp Asn Asn Asn Ala Asn Ser Asp Phe
715                 720                 725                 730

TGT GTG GCT CCG CTA CAA AGA GCC AAG TCG CAA AAG CAA CTC AAC ACC   2379
Cys Val Ala Pro Leu Gln Arg Ala Lys Ser Gln Lys Gln Leu Asn Thr
                735                 740                 745

GAT CCC ACG CTC ATG CAC CGC GGT TCG CCG GCA GGC AGC TCA GCC AAG   2427
Asp Pro Thr Leu Met His Arg Gly Ser Pro Ala Gly Ser Ser Ala Lys
            750                 755                 760

GGA GCG TCT GGC GGA GGA CCG GGA GCG GCG GAG GGC AAG AGG ATC TCT   2475
Gly Ala Ser Gly Gly Gly Pro Gly Ala Ala Glu Gly Lys Arg Ile Ser
        765                 770                 775

GTT TTA GGC GAG GGT TCC TAC TGT AGC CAG CGT TGG CCC TCG TTG GCG   2523
Val Leu Gly Glu Gly Ser Tyr Cys Ser Gln Arg Trp Pro Ser Leu Ala
    780                 785                 790

GCG GCG GGA GTG GCC GGA GCC TGT TCA TCC CAG CTA ATG GCT GCA GCT   2571
Ala Ala Gly Val Ala Gly Ala Cys Ser Ser Gln Leu Met Ala Ala Ala
795                 800                 805                 810

TCG GCA GCG GGC AGC GGA GCG GGG ACG GCG CAA CAG CAG CGA TCC GTG   2619
Ser Ala Ala Gly Ser Gly Ala Gly Thr Ala Gln Gln Gln Arg Ser Val
                815                 820                 825

GTC TGC GGC ACT CCG CAT ATG TAACTCCAAA AATCCGGAAG GGCTCCTGGT      2670
Val Cys Gly Thr Pro His Met
            830

AAATCCGGAG AAATCCGCAT GGAGGAGCTG ACAGCACATA CACAAAGAAA AGACTGGGTT  2730
GGGTTCAAAA TGTGAGAGAG ACGCCAAAAT GTTGTTGTTG ATTGAAGCAG TTTAGTCGTC  2790
ACGAAAAATG AAAAATCTGT AACAGGCATA ACTCGTAAAC TCCCTAAAAA ATTTGTATAG  2850
TAATTAGCAA AGCTGTGACC CAGCCGTTTC GATCCCGAAT TC                     2892
```

FIG.13F

2889 GATCTACTAC

GAGGAGGTTAAGGAGAGCTATGTGGGCGAGCGACGCGAATACGATCCCCACATCACCGATCCCAGGGTC

ACACGCATGAAGATGGCCGGCCTGAAGCCCAACTCCAAATACCGCATCTCCATCACTGCCACCACGAAA

ATGGGCGAGGGATCTGAACACTATATCGAAAAGACCACGCTCAAGGATGCCGTCAATGTGGCCCCTGCC

ACGCCATCTTTCTCCTGGGAGCAACTGCCATCCGACAATGGACTAGCCAAGTTCCGCATCAACTGGCTG

CCAAGTACCGAGGGTCATCCAGGCACTCACTTCTTTACGATGCACAGGATCAAGGGCGAAACCCAATGG

ATACGCGAGAATGAGGAAAAGAACTCCGATTACCAGGAGGTCGGTGGCTTAGATCCGGAGACCGCCTAC

GAGTTCCGCGTGGTGTCCGTGGATGGCCACTTTAACACGGAGAGTGCCACGCAGGAGATCGACACGAAC

ACCGTTGAGGGACCAATAATGGTGGCCAACGAGACGGTGGCCAATGCCGGATGGTTCATTGGCATGATG

CTGGCCCTGGCCTTCATCATCATCCTCTTCATCATCATCTGCATTATCCGACGCAATCGGGGCGGAAAG

TACGATGTCCACGATCGGGAGCTGGCCAACGGCCGGCGGGATTATCCCGAAGAGGGCGGATTCCACGAG

TACTCGCAACCGTTGGATAACAAGAGCGCTGGTCGCCAATCCGTGAGTTCAGCGAACAAACCGGGCGTG

GAAAGCGATACTGATTCGATGGCCGAATACGGTGATGGCGATACAGGACAATTTACCGAGGATGGCTCC

TTCATTGGCCAATATGTTCCTGGAAAGCTCCAACCGCCGGTTAGCCCACAGCCACTGAACAATTCCGCT

GCGGCGCATCAGGCGGCGCCAACTGCCGGAGGATCGGGAGCAGCCGGATCGGCAGCAGCAGCCGGAGCA

TCGGGTGGAGCATCGTCCGCCGGAGGAGCAGCTGCCAGCAATGGAGGAGCTGCAGCCGGAGCCGTGGCC

ACCTACGTCTAAGCTTGGTACC 3955

FIG.14

FIG. 15A

```
   1  CCGAGTCGAGCGCCGTGCTTCGAGCGGTGATGAGCCCCTTTTCTGTCAACGCTAAAGATC
 121  AAGCACATACTAAGGTCCATATAAATAATAAATAATTGTGTGTGATAACAACATTAT
 241  GGCCGTTATTCAGCTATCCAGAGCAAGTGTAGTGTGGCAAAATAGAAACAAACAAAGGCA
 361  CAATCCAGAGTGAATCCGAAACAAACTCCATCTAGATCGCCAACCAGCATCACGCTCGCA

 481  TCGTCGTTGGAGTCAACAATAGAATCAGCAGACAGCCTGGGAATGTCCAAGAAGACGGCG
      SerSerLeuGluSerThrIleGluSerAlaAspSerLeuGlyMetSerLysLysThrAla

 601  CGCGATTGTCGATCATTAAAGTCTGCCTGCAACTTAATTGCTTTAATTTTAATACTGTTA
      ArgAspCysArgSerLeuLysSerAlaCysAsnLeuIleAlaLeuIleLeuIleLeuLeu
      ----------------------------------------------------------

 721  AACAGCCATCTACTCAACGGCTATTGCTGCGGCATGCCAGCGGAACTTAGGGCCACCAAG
      AsnSerHisLeuLeuAsnGlyTyrCysCysGlyMetProAlaGluLeuArgAlaThrLys

 841  ACGGAGCAGGGTGCCAGCATATCCACGGGCTGTTCGTTTGGCAACGCCACCCACCAAGATA
      ThrGluGlnGlyAlaSerIleSerThrGlyCysSerPheGlyAsnAlaThrThrLysIle

 961  ACGTTTCGTTGGACGAAGTCGTTTACGCTGATACTGCAGGCGTTGGATATGTACAACACA
      ThrPheArgTrpThrLysSerPheThrLeuIleLeuGlnAlaLeuAspMetTyrAsnThr
                #3
1081  TCGCCGGAGTGGAAGACGCTGGACCACATCGGGGCGGAACGCGCGGGATCACCTACCGTGTC
      SerProGluTrpLysThrLeuAspHisIleGlyArgAsnAlaArgIleThrTyrArgVal

1201  GACGATCAGTTCGGTCACTACGCCTGCGGCTCCGAGGGTCAGAAGCTCTGCCTGAATGGC
      AspAspGlnPheGlyHisTyrAlaCysGlySerGluGlyGlnLysLeuCysLeuAsnGly
```

FIG.15B


TACAAAACATCAGCGCCTATCAAGTGGAAGTGTCAAGTGTGAACAAAACAAAAACGAGAG
CCAAACAAAACCAAACAAAACGAAGGCAAAGTGGAGAAAATGATACAGCATCCAGAGTAC
CCAAAATCTGCATACATGGGCTAATTAAGGCTGCCCAGCGAATTTACATTTGTGTGGTGC
AACGCCCCCAGAATGTACAAAATGTTTAGGAAACATTTTCGGCGAAAACCAGCTACGTCG
MetPheArgLysHisPheArgArgLysProAlaThrSer 13
ACAAAAAGGCAGCGTCCGAGGCATCGGGTACCCAAAATCGCGACCCTGCCATCGACGATC
ThrLysArgGlnArgProArgHisArgValProLysIleAlaThrLeuProSerThrIle 53
GTCCATAAGATATCCGCAGCTGGTAACTTCGAGCTGGAAATATTAGAAATCTCAAATACC
ValHisLysIleSerAlaAlaGlyAsnPheGluLeuGluIleLeuGluIleSerAsnThr 93
#1
ACGATAGGCTGCTCGCCATGCACGACGGCATTCCGGCTGTGCCTGAAGGAGTACCAGACC
ThrIleGlyCysSerProCysThrThrAlaPheArgLeuCysLeuLysGluTyrGlnThr 133
#2
CTGGGTGGCTCCAGCTTTGTGCTCAGCGATCCGGGTGTGGGAGCCATTGTGCTGCCCTTT
LeuGlyGlySerSerPheValLeuSerAspProGlyValGlyAlaIleValLeuProPhe 173
TCCTATCCAGATGCGGAGAGGTTAATTGAGGAAACATCATACTCGGGCGTGATACTGCCG
SerTyrProAspAlaGluArgLeuIleGluGluThrSerTyrSerGlyValIleLeuPro 213
#4
CGGGTGCAATGCGCCGTTACCTACTACAACACGACCTGCACGACCTTCTGCCGTCCGCGG
ArgValGlnCysAlaValThrTyrTyrAsnThrThrCysThrThrPheCysArgProArg 253
TGGCAGGGCGTCAACTGCGAGGAGGCCATATGCAAGGCGGGCTGCGACCCCGTCCACGGC
TrpGlnGlyValAsnCysGluGluAlaIleCysLysAlaGlyCysAspProValHisGly 293

FIG. 16A

PRIMER cdc1: 5′ GAT GCI AAT GTI CAA GAT AAT ATG GG 3′
C C G C C

FIG. 16B

PRIMER cdc2: 5′ AT IAG ATC TTC IAC CAT ICC TTC AA 3′
A G C C G
T

FIG. 16C

PRIMER cdc3: 5′ TC CAT ATG ATC IGT AAT ITC ICG ATT 3′
G G G T G
T


5'END OF CODING REGION
3'END OF CODING REGION
400bp
200bp
1
2
3
h NOTCH (~10k)
hN4k
hN3k
hN2k
hN5k

FIG.17

FIG.18


HASH VALUE= 1
PROCESSING= ALIGN
hN3k= 3 5'–3' COMPOSITE
hN2k= 2 5'–3' COMPOSITE
hN5k= 5 5'–3' COMPOSITE
hn4k= 4 n'–x' COMPOSITE
hn2k= 2 3'–5' COMPOSITE
3000
1000
5000
6000
724
240
7000
632
462
8000
212
9000
10000
hN3k
hN2k
hN4k
hN5k
HASH VALUE= 1
PROCESSING= ALIGN
5500
6000
300
6500
188
7000
602
7500
184
8000
8500
240
hN3k
hN2k
hN5k

```
  1  GAATTCCGCT GGGAGAATGG TCTGAGCTAC CTGCCCGTCC TGCTGGGGCA TCAATGGCAA
 61  GTGGGGAAAG CCACACTGGG CAAACGGGCC AGGCCATTTC TGGAATGTGG TACATGGTGG
121  GCAGGGGGCC CGCAACAGCT GGAGGGCAGG TGGACTGAGG CTGGGGATCC CCCGCTGGTT
181  GGGCAATACT GCCTTTACCC ATGAGCTGGA AAGTCACAAT GGGGGGCAAG GGCTCCCGAG
241  GGTGGTTATG TGCTTCCTTC AGGTGGC
```

FIG.19A

```
  1  GAATTCCTTC CATTATACGT GACTTTTCTG AAACTGTAGC CACCCTAGTG TCTCTAACTC
 61  CCTCTGGAGT TTGTCAGCTT TGGTCTTTTC AAAGAGCAGG CTCTCTTCAA GCTCCTTAAT
121  GCGGGCATGC TCCAGTTTGG TCTGCGTCTC AAGATCACCT TTGGTAATTG ATTCTTCTTC
181  AACCCGGAAC TGAAGGCTGG CTCTCACCCT CTAGGCAGAG CAGGAATTCC GAGGTGGATG
241  TGTTAGATGT GAATGTCCGT GGCCCAGATG GCTGCACCCC ATTGATGTTG GCTTCTCTCC
301  GAGGAGGCAG CTCAGATTTG AGTGATGAAG ATGAAGATGC AGAGGACTGT TCTGCTAACA
361  TCATCACAGA CTTGGTCTAC CAGGGTGCCA GCCTCCAGNC CAGACAGACC GGACTGGTGA
421  GATGGCCCTG CACCTTGCAG CCCGCTACTC ACGGGCTGAT GCTGCCAAGC GTCTCCTGGA
481  TGCAGGTGCA GATGCCAATG CCCAGGACAA CATGGGCCGC TGTCCACTCC ATGCTGCAGT
541  GGCACGTGAT GCCAAGGTGT ATTCAGATCT GTTA
```

FIG.19B

```
  1  TCCAGATTCT GATTCGCAAC CGAGTAACTG ATCTAGATGC CAGGATGAAT GATGGTACTA
 61  CACCCCTGAT CCTGGCTGCC CGCCTGGCTG TGGAGGGAAT GGTGGCAGAA CTGATCAACT
121  GCCAAGCGGA TGTGAATGCA GTGGATGACC ATGGAAAATC TGCTCTTCAC TGGGCAGCTG
181  CTGTCAATAA TGTGGAGGCA ACTCTTTTGT TGTTGAAAAA TGGGGCCAAC CGAGACATGC
241  AGGACAACAA GGAAGAGACA CCTCTGTTTC TTGCTGCCCG GGAGGAGCTA TAAGC
```

FIG.19C

```
  1  GAATTCCCAT GAGTCGGGAG CTTCGATCAA AATTGATGAG CCTTTAGAAG GATCCGAAGA
 61  TCGGATCATT ACCATTACAG GAACAGGCAC CTGTAGCTGG TGGCTGGGGG TGTTGTCCAC
121  AGGCGAGGAG TAGCTGTGCT GCGAGGGGGG CGTCAGGAAC TGGGCTGCGG TCACGGGTGG
181  GACCAGCGAG GATGGCAGCG ACGTGGGCAG GGCGGGGCTC TCCTGGGGCA GAATAGTGTG
241  CACCGCCAGG CTGCTGGGGC CCAGTACTGC ACGTCTGCCT GGCTCGGCTC TCCACTCAGG
301  AAGCTCCGGC CCAGGTGGCC GCTGGCTGCT GAG
```

FIG.20A

```
  1  GAATTCCTGC CAGGAGGACG CGGGCAACAA GGTCTGCAGC CTGCAGTGCA ACAACCACGC
 61  GTGCGGCTGG GACGGCGGTG ACTGCTCCCT CAACTTCACA ATGACCCCTG GAAGAACTGC
121  ACGCAGTCTC TGCAGTGCTG GAAGTACTTC AGTGACGGCC ACTGTGACAC CCAGTGCAAC
181  TCAGCCGGCT GCCTCTTCGA CGGCTTTGAC TGCCAGCGGC GGAAGGCCAG TTGCAACCCC
241  CTGTACGACC AGTACTGCAA GGACCACTTG AGCGACGGGC ACTGCGACCA GGGCTGCAAC
301  AGCGCGGAGT NCAGNTGGGA CGGGCTGGAC TGTGCGGCAG TGTACCCGAG AGCTGGCGGC
361  GCACGCTGGT GGTGGTGGTG CTGATGCCGC CGGAGCAGCT GCGCAACAGC TCCTTCCACT
421  TCCTGCGGGA CGTCAGCCGC GTGCTGCACA CCAACGTGTC TTCAAGCGTG ACGCACACGG
481  CCAGCAGATG ATGTTCCCCT ACTACGGCCG CGAGGAGGAG CTGCGCAAGC CCCATCAAGC
541  GTGCCGCCGA GGGCTGGGCC GCACCTGACG CCTGCTGGGC CA
```

FIG.20B

```
  1  TCAGCCGAGT GCTGCACACC AACGTGTCTT CAAGCGTGAC GCACACGGCC AGCAGATGAT
 61  GTTCCCCTAC TACGGCCGCG AGGAGGAGCT GCGCAAGCCC CATCAAGCGT GCCGCCGAGG
121  GCTGGGCCGC ACCTGACGCC TGCTGGGCCA
```

FIG.20C

```
  1  TTACCATTAC AGGAACAGGC ACCTGTAGCT GGTGGCTGGG GGTGTTGTCC ACAGGCGAGG
 61  AGTAGCTGTG CTGCGAGGGG GGCGTCAGGA ACTGGGCTGC GGTCACGGGT GGGACCAGCG
121  AGGATGGCAG CGACGTGGGC AGGGCGGGGC TCTCCTGGGG CAGAATAGTG TGCACCGCCA
181  GCTGCTGGGG CCCAGTGCTG CACGTCTGCC TGGCTCGGCT CTCCACTCAG GAAGCTCCGG
241  CCCAGGT
```

FIG.20D

```
  1  GAATTCCATT CAGGAGGAAA GGGTGGGGAG AGAAGCAGGC ACCCACTTTC CCGTGGCTGG
 61  ACTCGTTCCC AGGTGGCTCC ACCGGCAGCT GTGACCGCCG CAGGTGGGGG CGGAGTGCCA
121  TTCAGAAAAT TCCAGAAAAG CCCTACCCCA ACTCGGACGG CAACGTCACA CCCGTGGGTA
181  GCAACTGGCA CACAAACAGC CAGCGTGTCT GGGGCACGGG GGGATGGCAC CCCCTGCAGG
241  CAGAGCTG
```

FIG.21A

```
  1  CTAAAGGGAA CAAAAGCNGG AGCTCCACCG CGGGCGGCNC NGCTCTAGAA CTAGTGGANN
 61  NCCCGGGCTG CAGGAATTCC GGCGGACTGG GCTCGGGCTC AGAGCGGCGC TGTGGAAGAG
121  ATTCTAGACC GGGAGAACAA GCGAATGGCT GACAGCTGGC CTCCAAAGTC ACCAGGCTCA
181  AATCGCTCGC CCTGGACATC GAGGGATGCA GAGGATCAGA ACCGGTACCT GGATGGCATG
241  ACTCGGATTT ACAAGCATGA CCAGCCTGCT TACAGGGAGC GTGANNTTTT CACATGCAGT
301  CGACAGACAC GAGCTCTATG CAT
```

FIG.21B

```
  1  GAATTCCGAG GTGGATGTGT TAGATGTGAA TGTCCGTGGC CCAGATGGCT GCACCCCATT
 61  GATGTTGGCT TCTCTCCGAG GAGGCAGCTC AGATTTGAGT GATGAAGATG AAGATGCAGA
121  GGACTCTTCT GCTAACATCA TCACAGACTT GGTCTTACCA GGGTGCCAGC CTTCCAGGCC
181  CAAGAACAGA CCGGACTTGG TGAGATGGCC CTGCACCTTG CAGCCCGCTA CTACGGGCTG
241  ATGCTGCCAA GGTTCTGGAT GCAGGTGCAG ATGCCAATGC CCAGGACAAC ATGGGCCGCT
301  GTCCACTCCA TGCTGCAGTG GCACTGATGC
```

FIG.22A

```
  1  CAGAGGATGG TGAGGGTCCA TGCAGATAGG TTCTCCCCAT CCTGTGAATA ATAAATGGGT
 61  GCAAGGGCAG AGAGTCACCA TTTAGAATGA TAAAATGTTT GCACACTATG AAAGAGGCTG
121  ACAGAATGTT GCCACATGGA GAGATAAAGC AGAGAATGAA CAAACTT
```

FIG.22B

```
  1  AGGATGAATG ATGGTACTAC ACCCCTGATC CTGGCTGCCC GCCTGGCTGT GGAGGGAATG
 61  GTGGCAGAAC TGATCAACTG CCAAGCGGAT GTGAATGCAG TGGATGACCA TGGAAAATCT
121  GCTCTTCACT GGGCAGCTGC TGTCAATAAT GTGGAGGCAA CTCTTTTGTT GTTGAAAAAT
181  GGGGCCAACC GAGACATGCA GGACAACAAG GAAGAGACAC CTCTG
```

FIG.22C

```
  1  AATAATAAAT GGGTGCAAGG GCAGAGAGTC ACCATTTAGA ATGATAAAAT GTTTGCACAC
 61  TATGAAAGAG GCTGACAGAA TGTTGCCACA TGGAGAGATA AAGCAGAGAA TGAACAAACT
121  T
```

FIG.22D

```
                10                  20                  30                  40
                *                   *                   *                   *
TGC CAG GAG GAC GCG GGC AAC AAG GTC TGC AGC CTG CAG TGC AAC AAC
 C   Q   E   D   A   G   N   K   V   C   S   L   Q   C   N   N>
*                   *                   *                   *
CAC GCG TGC GGC TGG GAC GGC GGT GAC TGC TCC CTC AAC TTC AAT GAC
 H   A   C   G   W   D   G   G   D   C   S   L   N   F   N   D>
50                  60                  70                  80                  90
*                   *                   *                   *                   *
CCC TGG AAG AAC TGC ACG CAG TCT CTG CAG TGC TGG AAG TAC TTC AGT
 P   W   K   N   C   T   Q   S   L   Q   C   W   K   Y   F   S>
   100                 110                 120                 130                 140
    *                   *                   *                   *                   *
GAC GGC CAC TGT GAC AGC CAG TGC AAC TCA GCC GGC TGC CTC TTC GAC
 D   G   H   C   D   S   Q   C   N   S   A   G   C   L   F   D>
*  150                 160                 170                 180                 190
   *                   *                   *                   *                   *
```

FIG. 23 A

```
                200                 210                 220                 230                 240
                 *                   *                   *                   *                   *
GGC TTT GAC TGC CAG CGT GCG GAA GGC CAG TGC AAC CCC CTG TAC GAC -
 G   F   D   C   Q   R   A   E   G   Q   C   N   P   L   Y   D>

                250                 260                 270                 280
                 *                   *                   *                   *
CAG TAC TGC AAG GAC CAC TTC AGC GAC GGG CAC TGC GAC CAG GGC TGC
 Q   Y   C   K   D   H   F   S   D   G   H   C   D   Q   G   C>

290             300                 310                 320                 330
 *               *                   *                   *                   *
AAC AGC GCG GAG TGC GAG TGG GAC GGG CTG GAC TGT GCG GAG CAT GTA
 N   S   A   E   C   E   W   D   G   L   D   C   A   E   H   V>

 340                350                 360                 370                 380
  *                  *                   *                   *                   *
CCC GAG AGG CTG GCG GCC GGC ACG CTG GTG GTG GTG GTG CTG ATG CTG
 P   E   R   L   A   A   G   T   L   V   V   V   V   L   M   P>
```

FIG.23B

```
      390             400             410             420             430
 *     *       *       *       *       *       *       *       *       *
CCG GAG CAG CTG CGC AAC AGC TCC TTC CAC TTC CTG CGG GAG CTC AGC
 P   E   Q   L   R   N   S   S   F   H   F   L   R   E   L   S>

        440             450             460             470             480
  *      *       *       *       *       *       *       *       *       *
CGC GTG CTG CAC ACC AAC GTG GTC TTC AAG CGT GAC GCA CAC GGC CAG
 R   V   L   H   T   N   V   V   F   K   R   D   A   H   G   Q>

          490             500             510             520
     *     *       *       *       *       *       *       *       *
CAG ATG ATC TTC CCC TAC TAC GGC CGC GAG GAG GAG CTG CGC AAG CAC
 Q   M   I   F   P   Y   Y   G   R   E   E   E   L   R   K   H>

530             540             550             560             570
 *       *       *       *       *       *       *       *       *       *
CCC ATC AAG CGT GCC GCC GAG GGC TGG GCC GCA CCT GAC GCC CTG CTG
 P   I   K   R   A   A   E   G   W   A   A   P   D   A   L   L>
```

FIG.23C

```
580        590        600        610        620
 *    *     *    *     *    *     *    *     *
GGC CAG GTG AAG GCC TCG CTG CTC CCT GGT GGC AGC GAG GGT GGG CGG
 G   Q   V   K   A   S   L   L   P   G   G   S   E   G   G   R>

     630        640        650        660        670
      *    *     *    *     *    *     *    *     *
 *  CGG CGG AGG GAG CTG GAC CCC ATG GAC GTC CGC GGC TCC ATC GTC TAC
     R   R   R   E   L   D   P   M   D   V   R   G   S   I   V   Y>

         680        690        700        710        720
          *    *     *    *     *    *     *    *     *
     *  CTG GAG ATT GAC AAC CGG CAG TGT GTG CAG GCC TCC TCG CAG TGC TTC
         L   E   I   D   N   R   Q   C   V   Q   A   S   S   Q   C   F>

             730        740        750        760
              *    *     *    *     *    *     *    *     *
         *  CAG AGT GCC ACC GAC GTG GCC GCA TTC CTG GGA GCG CTC GCC TCG CTG
             Q   S   A   T   D   V   A   A   F   L   G   A   L   A   S   L>
```

FIG.23D

```
770        780        790        800        810
 *    *     *    *     *    *     *    *     *
GGC AGC CTC AAC ATC CCC TAC AAG ATC GAG GCC GTG CAG AGT GAG ACC
 G   S   L   N   I   P   Y   K   I   E   A   V   Q   S   E   T>-

      820        830        840        850        860
       *    *     *    *     *    *     *    *     *
GTG GAG CCG CCC CCG CCG GCG CAG CTG CAC TTC ATG TAC GTG GCG GCG
 V   E   P   P   P   P   A   Q   L   H   F   M   Y   V   A   A>

 870        880        890        900        910
  *    *     *    *     *    *     *    *     *
GCC GCC TTT GTG CTT CTG TTC TTC GTG GGC TGC GGG GTG CTG CTG TCC
 A   A   F   V   L   L   F   F   V   G   C   G   V   L   L   S>

      920        930        940        950        960
       *    *     *    *     *    *     *    *     *
CGC AAG CGC CGG CGG CAG CAT GGC CAG CTC TGG TTC CCT GAG GGC TTC
 R   K   R   R   R   Q   H   G   Q   L   W   F   P   E   G   F>
```

FIG.23E

```
                970        980        990        1000
      *    *    *    *    *    *    *    *    *
AAA GTG TCT GAG GCC AGC AAG AAG AAG CGG CGG GAG CCC CTC GGC GAG
 K   V   S   E   A   S   K   K   K   R   R   E   P   L   G   E>

1010       1020       1030       1040       1050
  *    *    *    *    *    *    *    *    *    *
GAC TCC GTG GGC CTC AAG CCC CTG AAG AAC GCT TCA GAC GGT GCC CTC
 D   S   V   G   L   K   P   L   K   N   A   S   D   G   A   L>

 1060       1070       1080       1090       1100
    *    *    *    *    *    *    *    *    *
ATG GAC GAC AAC CAG AAT GAG TGG GGG GAC GAG GAC CTG GAG ACC AAG
 M   D   D   N   Q   N   E   W   G   D   E   D   L   E   T   K>

   1110       1120       1130       1140       1150
*    *    *    *    *    *    *    *    *    *
AAG TTC CGG TTC GAG GAG CCC GTG GTT CTG CCT GAC CTG GAC GAC CAG
 K   F   R   F   E   E   P   V   V   L   P   D   L   D   D   Q>
```

FIG.23F

```
     1160          1170          1180          1190          1200
      *     *       *     *       *     *       *     *       *     *

ACA GAC CAC CGG CAG TGG ACT CAG CAG CAC CTG GAT GCC GCT GAC CTG
 T   D   H   R   Q   W   T   Q   Q   H   L   D   A   A   D   L>

          1210          1220          1230          1240
      *     *       *     *       *     *       *     *       *

CGC ATG TCT GCC ATG GCC CCC ACA CCG CCC CAG GGT GAG GTT GAC GCC
 R   M   S   A   M   A   P   T   P   P   Q   G   E   V   D   A>

1250          1260          1270          1280          1290
  *     *       *     *       *     *       *     *       *     *

GAC TGC ATG GAC GTC AAT GTC CGC GGG CCT GAT GGC TTC ACC CCG CTC
 D   C   M   D   V   N   V   R   G   P   D   G   F   T   P   L>

 1300          1310          1320          1330          1340
    *     *       *     *       *     *       *     *       *

ATG ATC GCC TCC TGC AGC GGG GGC GGC CTG GAG ACG GGC AAC AGC GAG
 M   I   A   S   C   S   G   G   G   L   E   T   G   N   S   E>
```

FIG. 23G

```
1350        1360        1370        1380        1390
*    *      *    *      *    *      *    *      *    *
GAA GAG GAG GAC GCG CCG GCC GTC ATC TCC GAC TTC ATC TAC CAG GGC
 E   E   E   D   A   P   A   V   I   S   D   F   I   Y   Q   G>

1400        1410        1420        1430        1440
*    *      *    *      *    *      *    *      *    *
GCC AGC CTG CAC AAC CAG ACA GAC CGC ACG GGC GAG ACC GCC TTG CAC
 A   S   L   H   N   Q   T   D   R   T   G   E   T   A   L   H>

1450        1460        1470        1480
*    *      *    *      *    *      *    *
CTG GCC GCC CGC TAC TCA CGC TCT GAT GCC GCC AAG CGC CTG CTG GAG
 L   A   A   R   Y   S   R   S   D   A   A   K   R   L   L   E>

1490        1500        1510        1520        1530
*    *      *    *      *    *      *    *      *    *
GCC AGC GCA GAT GCC AAC ATC CAG GAC AAC ATG GGC CGC ACC CCG CTG
 A   S   A   D   A   N   I   Q   D   N   M   G   R   T   P   L>
```

FIG. 23H

```
1540          1550          1560          1570          1580
   *     *       *     *       *     *       *     *       *
CAT GCG GCT GTG TCT GCC GAC GCA CAA GGT GTC TTC CAG ATC CTG ATC
 H   A   A   V   S   A   D   A   Q   G   V   F   Q   I   L   I>

  1590          1600          1610          1620          1630
*     *       *     *       *     *       *     *       *     *
CGG AAC CGA GCC ACA GAC CTG GAT GCC CGC ATG CAT GAT GGC ACG ACG
 R   N   R   A   T   D   L   D   A   R   M   H   D   G   T   T>

      1640          1650          1660          1670          1680
  *     *       *     *       *     *       *     *       *     *
CCA CTG ATC CTG GCT GCC CGC CTG GCC GTG GAG GGC ATG CTG GAG GAC
 P   L   I   L   A   A   R   L   A   V   E   G   M   L   E   D>

          1690          1700          1710          1720
      *     *       *     *       *     *       *     *       *
CTC ATC AAC TCA CAC GCC GAC GTC AAC GCC GTA GAT GAC CTG GGC AAG
 L   I   N   S   H   A   D   V   N   A   V   D   D   L   G   K>

1730          1740          1750          1760          1770
   *     *       *     *       *     *       *     *       *
TCC GCC CTG CAC TGG GCC GCC GCC GTG AAC AAT GTG GAT GCC GCA GTT
 S   A   L   H   W   A   A   A   V   N   N   V   D   A   A   V>
```

FIG. 231

```
1780                1790                1800                1810                1820
   *         *         *         *         *         *         *
GTG CTC CTG AAG AAC GGG GCT AAC AAA GAT ATG CAG AAC AAC AGG GAG
 V   L   L   K   N   G   A   N   K   D   M   Q   N   N   R   E>

      1830                1840                1850                1860                1870
   *         *         *         *         *         *         *
GAG ACA CCC CTG TTT CTG GCC GCC CGG GAG GGC AGC TAC GAG ACC GCC
 E   T   P   L   F   L   A   A   R   E   G   S   Y   E   T   A>

         1880                1890                1900                1910                1920
   *         *         *         *         *         *         *
AAG GTG CTG CTG GAC CAC TTT GCC AAC CGG GAC ATC ACG GAT CAT ATG
 K   V   L   L   D   H   F   A   N   R   D   I   T   D   H   M>

            1930                1940                1950                1960
   *         *         *         *         *         *         *
GAC CGC CTG CCG CGC GAC ATC GCA CAG GAG CGC ATG CAT CAC GAC ATC
 D   R   L   P   R   D   I   A   Q   E   R   M   H   H   D   I>
```

FIG.23J

```
1970        1980        1990        2000        2010
 *    *      *    *      *    *      *    *      *
GTG AGG CTG CTG GAC GAG TAC AAC CTG GTG CGC AGC CCG CAG CTG CAC
 V   R   L   L   D   E   Y   N   L   V   R   S   P   Q   L   H>

2020        2030        2040        2050        2060
 *    *      *    *      *    *      *    *      *
GGA GCC CCG CTG GGG GGC ACG CCC ACC CTG TCG CCC CCG CTC TGC TCG
 G   A   P   L   G   G   T   P   T   L   S   P   P   L   C   S>

2070        2080        2090        2100        2110
 *    *      *    *      *    *      *    *      *
CCC AAC GGC TAC CTG GGC AGC CTC AAG CCC GGC GTG CAG GGC AAG AAG
 P   N   G   Y   L   G   S   L   K   P   G   V   Q   G   K   K>

2120        2130        2140        2150        2160
 *    *      *    *      *    *      *    *      *
GTC CGC AAG CCC AGC AGC AAA GGC CTG GCC TGT GGA AGC AAG GAG GCC
 V   R   K   P   S   S   K   G   L   A   C   G   S   K   E   A>
```

FIG.23K

```
                2170        2180        2190        2200
                 *   *       *   *       *   *       *   *
AAG GAC CTC AAG GCA CGG AGG AAG AAG TCC CAG GAT GGC AAG GGC TGC
 K   D   L   K   A   R   R   K   K   S   Q   D   G   K   G   C>

2210        2220        2230        2240        2250        2260
 *   *       *   *       *   *       *   *       *   *       *
CTG CTG GAC AGC TCC GGC ATG CTC TCG CCC GTG GAC TCC CTG GAG TCA
 L   L   D   S   S   G   M   L   S   P   V   D   S   L   E   S>

2270        2280        2290        2300        2310        2320
 *   *       *   *       *   *       *   *       *   *       *
CCC CAT GGC TAC CTG TCA GAC GTG GCC TCG CCG CCA CTG CTG CCC TCC
 P   H   G   Y   L   S   D   V   A   S   P   P   L   L   P   S>

2330        2340        2350
 *   *       *   *       *   *
CCG TTC CAG CAG TCT CCG TCC GTG CCC CTC AAC CAC CTG CCT GGG ATG
 P   F   Q   Q   S   P   S   V   P   L   N   H   L   P   G   M>
```

FIG.23L

```
                2360        2370        2380        2390        2400
                 *     *     *     *     *     *     *     *     *
CCC GAC ACC CAC CTG GGC ATC GGG CAC CTG AAC GTG GCG GCC AAG CCC
  P   D   T   H   L   G   I   G   H   L   N   V   A   A   K   P>
                2410        2420        2430        2440
                 *     *     *     *     *     *     *     *
GAG ATG GCG GCG CTG GGT GGG GGC GGC CGG CTG GCC TTT GAG ACT GGC
  E   M   A   A   L   G   G   G   G   R   L   A   F   E   T   G>
2450            2460        2470        2480        2490
 *     *     *     *     *     *     *     *     *     *
CCA CCT CGT CTC TCC CAC CTG CCT GTG GCC TCT GGC ACC AGC ACC GTC
  P   P   R   L   S   H   L   P   V   A   S   G   T   S   T   V>
 2500            2510        2520        2530        2540
  *     *     *     *     *     *     *     *     *     *
CTG GGC TCC AGC TCC AGC GGA GGG GCC CTG AAT TTC ACT GTG GGC GGG TCC
  L   G   S   S   S   S   G   G   A   L   N   F   T   V   G   G   S>
```

FIG.23M

```
                2550          2560          2570          2580          2590
                 *     *       *     *       *     *       *     *       *
*  ACC AGT TTG AAT GGT CAA TGC GAG TGG CTG TCC CGG CTG CAG AGC GGC
     T   S   L   N   G   Q   C   E   W   L   S   R   L   Q   S   G>
                 *     *       *     *       *     *       *     *
                2600          2610          2620          2630          2640
   *  ATG GTG CCG AAC CAA TAC AAC CCT CTG CGG GGG AGT GTG GCA CCA GGC
        M   V   P   N   Q   Y   N   P   L   R   G   S   V   A   P   G>
                 *     *       *     *       *     *       *     *
                2650          2660          2670          2680          2690
      *  CCC CTG AGC ACA CAG GCC CCC TCC CTG CAG CAT GGC ATG GTA GGC CCG
           P   L   S   T   Q   A   P   S   L   Q   H   G   M   V   G   P>
                 *     *       *     *       *     *       *     *
                2700          2710          2720          2730
   2690  *  CTG CAC AGT AGC CTT GCT GCC AGC GCC CTG TCC CAG ATG ATG AGC TAC
           L   H   S   S   L   A   A   S   A   L   S   Q   M   M   S   Y>
```

FIG.23N

```
2740          2750          2760          2770          2780
   *     *       *     *       *     *       *     *       *
CAG GGC CTG CCC AGC ACC CGG CTG GCC ACC CAG CCT CAC CTG GTG CAG
 Q   G   L   P   S   T   R   L   A   T   Q   P   H   L   V   Q>

   2790          2800          2810          2820          2830
*     *       *     *       *     *       *     *       *     *
ACC CAG CAG GTG CAG CCA CAA AAC TTA CAG ATG CAG CAG CAG AAC CTG
 T   Q   Q   V   Q   P   Q   N   L   Q   M   Q   Q   Q   N   L>

      2840          2850          2860          2870          2880
  *     *       *     *       *     *       *     *       *     *
CAG CCA GCA AAC ATC CAG CAG CAG CAA AGC CTG CAG CCG CCA CCA CCA
 Q   P   A   N   I   Q   Q   Q   Q   S   L   Q   P   P   P   P>

         2890          2900          2910          2920
     *     *       *     *       *     *       *     *       *
CCA CCA CAG CCG CAC CTT GGC GTG AGC TCA GCA GCC AGC GGC CAC CTG
 P   P   Q   P   H   L   G   V   S   S   A   A   S   G   H   L>

2930          2940          2950          2960          2970
   *     *       *     *       *     *       *     *       *
GGC CGG AGC TTC CTG AGT GGA GAG CCG AGC CAG GCA GAC GTG CAG CCA

 G   R   S   F   L   S   G   E   P   S   Q   A   D   V   Q   P>
```

FIG. 23 0

```
2980        2990        3000        3010        3020
 *     *     *     *     *     *     *     *     *
CTG GGC CCC AGC AGC CTG GCG GTG CAC ACT ATT CTG CCC CAG GAG AGC
 L   G   P   S   S   L   A   V   H   T   I   L   P   Q   E   S>

      3030        3040        3050        3060        3070
 *     *     *     *     *     *     *     *     *     *
CCC GCC CTG CCC ACG TCG CTG CCA TCC TCG CTG GTC CCA CCC GTG ACC
 P   A   L   P   T   S   L   P   S   S   L   V   P   P   V   T>

      3080        3090        3100        3110        3120
 *     *     *     *     *     *     *     *     *     *
GCA GCC CAG TTC CTG ACG CCC CCC TCG CAG CAC AGC TAC TCC TCG CCT
 A   A   Q   F   L   T   P   P   S   Q   H   S   Y   S   S   P>
```

FIG.23P

```
                3130        3140        3150        3160        3170
                 *   *   *   *   *   *   *   *   *   *   *   *   *
GTG GAC AAC ACC CCC AGC CAC CAG CTA CAG GTG CCT GTT CCT GTA ATG
 V   D   N   T   P   S   H   Q   L   Q   V   P   V   P   V   M>
                 *   *   *   *   *   *   *   *   *   *   *   *   *
                3180        3190        3200        3210        3220
GTA ATG ATC CGA TCT TCG GAT CCT TCT AAA GGC TCA TCA ATT TTG ATC
 V   M   I   R   S   S   D   P   S   K   G   S   S   I   L   I>
                 *   *   *   *   *   *   *   *   *   *   *   *   *
                3230
GAA GCT CCC GAC TCA TGG
 E   A   P   D   S   W>
```

FIG.23Q

```
G GAG GTG GAT GTG TTA GAT GTG AAT GTC CGT GGC CCA GAT GGC TGC      46
  Glu Val Asp Val Leu Asp Val Asn Val Arg Gly Pro Asp Gly Cys
    1               5                  10                  15

ACC CCA TTG ATG TTG GCT TCT CTC CGA GGA GGC AGC TCA GAT TTG AGT    94
Thr Pro Leu Met Leu Ala Ser Leu Arg Gly Gly Ser Ser Asp Leu Ser
                20                  25                  30

GAT GAA GAT GAA GAT GCA GAG GAC TCT TCT GCT AAC ATC ATC ACA GAC   142
Asp Glu Asp Glu Asp Ala Glu Asp Ser Ser Ala Asn Ile Ile Thr Asp
            35                  40                  45

TTG GTC TAC CAG GGT GCC AGC CTC CAG GCC CAG ACA GAC CGG ACT GGT   190
Leu Val Tyr Gln Gly Ala Ser Leu Gln Ala Gln Thr Asp Arg Thr Gly
        50                  55                  60

GAG ATG GCC CTG CAC CTT GCA GCC CGC TAC TCA CGG GCT GAT GCT GCC   238
Glu Met Ala Leu His Leu Ala Ala Arg Tyr Ser Arg Ala Asp Ala Ala
    65                  70                  75

AAG CGT CTC CTG GAT GCA GGT GCA GAT GCC AAT GCC CAG GAC AAC ATG   286
Lys Arg Leu Leu Asp Ala Gly Ala Asp Ala Asn Ala Gln Asp Asn Met
80                  85                  90                  95

GGC CGC TGT CCA CTC CAT GCT GCA GTG GCA GCT GAT GCC CAA GGT GTC   334
Gly Arg Cys Pro Leu His Ala Ala Val Ala Ala Asp Ala Gln Gly Val
                100                 105                 110

TTC CAG ATT CTG ATT CGC AAC CGA GTA ACT GAT CTA GAT GCC AGG ATG   382
Phe Gln Ile Leu Ile Arg Asn Arg Val Thr Asp Leu Asp Ala Arg Met
            115                 120                 125

AAT GAT GGT ACT ACA CCC CTG ATC CTG GCT GCC CGC CTG GCT GTG GAG   430
Asn Asp Gly Thr Thr Pro Leu Ile Leu Ala Ala Arg Leu Ala Val Glu
        130                 135                 140
```

FIG.24A

```
GGA ATG GTG GCA GAA CTG ATC AAC TGC CAA GCG GAT GTG AAT GCA GTG    478
Gly Met Val Ala Glu Leu Ile Asn Cys Gln Ala Asp Val Asn Ala Val
    145                 150                 155

GAT GAC CAT GGA AAA TCT GCT CTT CAC TGG GCA GCT GCT GTC AAT AAT    526
Asp Asp His Gly Lys Ser Ala Leu His Trp Ala Ala Ala Val Asn Asn
160                 165                 170                 175

GTG GAG GCA ACT CTT TTG TTG TTG AAA AAT GGG GCC AAC CGA GAC ATG    574
Val Glu Ala Thr Leu Leu Leu Leu Lys Asn Gly Ala Asn Arg Asp Met
                180                 185                 190

CAG GAC AAC AAG GAA GAG ACA CCT CTG TTT CTT GCT GCC CGG GAG GGG    622
Gln Asp Asn Lys Glu Glu Thr Pro Leu Phe Leu Ala Ala Arg Glu Gly
            195                 200                 205

AGC TAT GAA GCA GCC AAG ATC CTG TTA GAC CAT TTT GCC AAT CGA GAC    670
Ser Tyr Glu Ala Ala Lys Ile Leu Leu Asp His Phe Ala Asn Arg Asp
        210                 215                 220

ATC ACA GAC CAT ATC GAT CGT CTT CCC CGG GAT GTG GCT CGG GAT CGC    718
Ile Thr Asp His Met Asp Arg Leu Pro Arg Asp Val Ala Arg Asp Arg
    225                 230                 235

ATG CAC CAT GAC ATT GTG CGC CTT CTG GAT GAA TAC AAT GTG ACC CCA    766
Met His His Asp Ile Val Arg Leu Leu Asp Glu Tyr Asn Val Thr Pro
240                 245                 250                 255

AGC CCT CCA GGC ACC GTG TTG ACT TCT GCT CTC TCA CCT GTC ATC TGT    814
Ser Pro Pro Gly Thr Val Leu Thr Ser Ala Leu Ser Pro Val Ile Cys
                260                 265                 270

GGG CCC AAC AGA TCT TTC CTC AGC CTG AAG CAC ACC CCA ATG GGC AAG    862
Gly Pro Asn Arg Ser Phe Leu Ser Leu Lys His Thr Pro Met Gly Lys
            275                 280                 285
```

FIG.24B

```
AAG TCT AGA CGG CCC AGT GCC AAG AGT ACC ATG CCT ACT AGC CTC CCT   910
Lys Ser Arg Arg Pro Ser Ala Lys Ser Thr Met Pro Thr Ser Leu Pro
        290                 295                 300

AAC CTT GCC AAG GAG GCA AAG GAT GCC AAG GGT AGT AGG AGG AAG AAG   958
Asn Leu Ala Lys Glu Ala Lys Asp Ala Lys Gly Ser Arg Arg Lys Lys
    305                 310                 315

TCT CTG AGT GAG AAG GTC CAA CTG TCT GAG AGT TCA GTA ACT TTA TCC  1006
Ser Leu Ser Glu Lys Val Gln Leu Ser Glu Ser Ser Val Thr Leu Ser
320                 325                 330                 335

CCT GTT GAT TCC CTA GAA TCT CCT CAC ACG TAT GTT TCC GAC ACC ACA  1054
Pro Val Asp Ser Leu Glu Ser Pro His Thr Tyr Val Ser Asp Thr Thr
                340                 345                 350

TCC TCT CCA ATG ATT ACA TCC CCT GGG ATC TTA CAG GCC TCA CCC AAC  1102
Ser Ser Pro Met Ile Thr Ser Pro Gly Ile Leu Gln Ala Ser Pro Asn
            355                 360                 365

CCT ATG TTG GCC ACT GCC GCC CCT CCT GCC CCA GTC CAT GCC CAG CAT  1150
Pro Met Leu Ala Thr Ala Ala Pro Pro Ala Pro Val His Ala Gln His
        370                 375                 380

GCA CTA TCT TTT TCT AAC CTT CAT GAA ATG CAG CCT TTG GCA CAT GGG  1198
Ala Leu Ser Phe Ser Asn Leu His Glu Met Gln Pro Leu Ala His Gly
    385                 390                 395

GCC AGC ACT GTG CTT CCC TCA GTG AGC CAG TTG CTA TCC CAC CAC CAC  1246
Ala Ser Thr Val Leu Pro Ser Val Ser Gln Leu Leu Ser His His His
400                 405                 410                 415

ATT GTG TCT CCA GGC AGT GGC AGT GCT GGA AGC TTG AGT AGG CTC CAT  1294
Ile Val Ser Pro Gly Ser Gly Ser Ala Gly Ser Leu Ser Arg Leu His
                420                 425                 430

CCA GTC CCA GTC CCA GCA GAT TGG ATG AAC CGC ATG GAG GTG AAT GAG  1342
Pro Val Pro Val Pro Ala Asp Trp Met Asn Arg Met Glu Val Asn Glu
            435                 440                 445
```

FIG.24C

SUBSTITUTE SHEET

```
ACC CAG TAC AAT GAG ATG TTT GGT ATG GTC CTG GCT CCA GCT GAG GGC  1390
Thr Gln Tyr Asn Glu Met Phe Gly Met Val Leu Ala Pro Ala Glu Gly
        450                 455                 460

ACC CAT CCT GGC ATA GCT CCC CAG AGC AGG CCA CCT GAA GGG AAG CAC  1438
Thr His Pro Gly Ile Ala Pro Gln Ser Arg Pro Pro Glu Gly Lys His
    465                 470                 475

ATA ACC ACC CCT CGG GAG CCC TTG CCC CCC ATT GTG ACT TTC CAG CTC  1486
Ile Thr Thr Pro Arg Glu Pro Leu Pro Pro Ile Val Thr Phe Gln Leu
480                 485                 490                 495

ATC CCT AAA GGC AGT ATT GCC CAA CCA GCG GGG GCT CCC CAG CCT CAG  1534
Ile Pro Lys Gly Ser Ile Ala Gln Pro Ala Gly Ala Pro Gln Pro Gln
                500                 505                 510

TCC ACC TGC CCT CCA GCT GTT GCG GGC CCC CTG CCC ACC ATG TAC CAG  1582
Ser Thr Cys Pro Pro Ala Val Ala Gly Pro Leu Pro Thr Met Tyr Gln
            515                 520                 525

ATT CCA GAA ATG GCC CGT TTG CCC AGT GTG GCT TTC CCC ACT GCC ATG  1630
Ile Pro Glu Met Ala Arg Leu Pro Ser Val Ala Phe Pro Thr Ala Met
        530                 535                 540

ATG CCC CAG CAG GAC GGG CAG GTA GCT CAG ACC ATT CTC CCA GCC TAT  1678
Met Pro Gln Gln Asp Gly Gln Val Ala Gln Thr Ile Leu Pro Ala Tyr
    545                 550                 555

CAT CCT TTC CCA GCC TCT GTG GGC AAG TAC CCC ACA CCC CCT TCA CAG  1726
His Pro Phe Pro Ala Ser Val Gly Lys Tyr Pro Thr Pro Pro Ser Gln
560                 565                 570                 575

CAC AGT TAT GCT TCC TCA AAT GCT GCT GAG CGA ACA CCC AGT CAC AGT  1774
His Ser Tyr Ala Ser Ser Asn Ala Ala Glu Arg Thr Pro Ser His Ser
                580                 585                 590

GGT CAC CTC CAG GGT GAG CAT CCC TAC CTG ACA CCA TCC CCA GAG TCT  1822
Gly His Leu Gln Gly Glu His Pro Tyr Leu Thr Pro Ser Pro Glu Ser
            595                 600                 605
```

FIG.24D

```
CCT GAC CAG TGG TCA AGT TCA TCA CCC CAC TCT GCT TCT GAC TGG TCA      1870
Pro Asp Gln Trp Ser Ser Ser Ser Pro His Ser Ala Ser Asp Trp Ser
        610                 615                 620

GAT GTG ACC ACC AGC CCT ACC CCT GGG GGT GCT GGA GGA GGT CAG CGG      1918
Asp Val Thr Thr Ser Pro Thr Pro Gly Gly Ala Gly Gly Gly Gln Arg
    625                 630                 635

GGA CCT GGG ACA CAC ATG TCT GAG CCA CCA CAC AAC AAC ATG CAG GTT      1966
Gly Pro Gly Thr His Met Ser Glu Pro Pro His Asn Asn Met Gln Val
640                 645                 650                 655

TAT GCG TGAGAGAGTC CACCTCCAGT GTAGAGACAT AACTGACTTT TGTAAATGCT      2022
Tyr Ala

GCTGAGGAAC AAATGAAGGT CATCCGGGAG AGAAATGAAG AAATCTCTGG AGCCAGCTTC  2082

TAGAGGTAGG AAAGAGAAGA TGTTCTTATT CAGATAATGC AAGAGAAGCA ATTCGTCAGT  2142

TTCACTGGGT ATCTGCAAGG CTTATTGATT ATTCTAATCT AATAAGACAA GTTTGTGGAA  2202

ATGCAAGATG AATACAAGCC TTGGGTCCAT GTTTACTCTC TTCTATTTGG AGAATAAGAT  2262

GGATGCTTAT TGAAGCCCAG ACATTCTTGC AGCTTGGACT GCATTTTAAG CCCTGCAGGC  2322

TTCTGCCATA TCCATGAGAA GATTCTACAC TAGCGTCCTG TTGGGAATTA TGCCCTGGAA  2382

TTCTGCCTGA ATTGACCTAC GCATCTCCTC CTCCTTGGAC ATTCTTTTGT CTTCATTTGG  2442

TGCTTTTGGT TTTGCACCTC TCCGTGATTG TAGCCCTACC AGCATGTTAT AGGGCAAGAC  2502

CTTTGTGCTT TTGATCATTC TGGCCCATGA AAGCAACTTT GGTCTCCTTT CCCCTCCTGT  2562

CTTCCCGGTA TCCCTTGGAG TCTCACAAGG TTTACTTTGG TATGGTTCTC AGCACAAACC  2622

TTTCAAGTAT GTTGTTTCTT TGGAAAATGG ACATACTGTA TTGTGTTCTC CTGCATATAT  2682

CATTCCTGGA GAGAGAAGGG GAGAAGAATA CTTTTCTTCA ACAAATTTTG GGGGCAGGAG  2742

ATCCCTTCAA GAGGCTGCAC CTTAATTTTT CTTGTCTGTG TGCAGGTCTT CATATAAACT  2802
```

FIG.24E

TTACCAGGAA GAAGGGTGTG AGTTTGTTGT TTTTCTGTGT ATGGGCCTGG TCAGTGTAAA 2862

GTTTTATCCT TGATAGTCTA GTTACTATGA CCCTCCCCAC TTTTTTAAAA CCAGAAAAAG 2922

GTTTGGAATG TTGGAATGAC CAAGAGACAA GTTAACTCGT GCAAGAGCCA GTTACCCACC 2982

CACAGGTCCC CCTACTTCCT GCCAAGCATT CCATTGACTG CCTGTATGGA ACACATTTGT 3042

CCCAGATCTG AGCATTCTAG GCCTGTTTCA CTCACTCACC CAGCATATGA AACTAGTCTT 3102

AACTGTTGAG CCTTTCCTTT CATATCCACA GAAGACACTG TCTCAAATGT TGTACCCTTG 3162

CCATTTAGGA CTGAACTTTC CTTAGCCCAA GGGACCCAGT GACAGTTGTC TTCCGTTTGT 3222

CAGATGATCA GTCTCTACTG ATTATCTTGC TGCTTAAAGG CCTGCTCACC AATCTTTCTT 3282

TCACACCGTG TGGTCCGTGT TACTGGTATA CCCAGTATGT TCTCACTGAA GACATGGACT 3342

TTATATGTTC AAGTGCAGGA ATTGGAAAGT TGGACTTGTT TTCTATGATC CAAAACAGCC 3402

CTATAAGAAG GTTGGAAAAG GAGGAACTAT ATAGCAGCCT TTGCTATTTT CTGCTACCAT 3462

TTCTTTTCCT CTGAAGCGGC CATGACATTC CCTTTGGCAA CTAACGTAGA AACTCAACAG 3522

FIG.24F

AACATTTTCC TTTCCTAGAG TCACCTTTTA GATGATAATG GACAACTATA GACTTGCTCA 3582

TTGTTCAGAC TGATTGCCCC TCACCTGAAT CCACTCTCTG TATTCATGCT CTTGGCAATT 3642

TCTTTGACTT TCTTTTAAGG GCAGAAGCAT TTTAGTTAAT TGTAGATAAA GAATAGTTTT 3702

CTTCCTCTTC TCCTTGGGCC AGTTAATAAT TGGTCCATGG CTACACTGCA ACTTCCGTCC 3762

AGTGCTGTGA TGCCCATGAC ACCTGCAAAA TAAGTTCTGC CTGGGCATTT TGTAGATATT 3822

AACAGGTGAA TTCCCGACTC TTTTGGTTTG AATGACAGTT CTCATTCCTT CTATGGCTGC 3882

AAGTATGCAT CAGTGCTTCC CACTTACCTG ATTTGTCTGT CGGTGGCCCC ATATGGAAAC 3942

CCTGCGTGTC TGTTGGCATA ATAGTTTACA AATGGTTTTT TCAGTCCTAT CCAAATTTAT 4002

TGAACCAACA AAAATAATTA CTTCTGCCCT GAGATAAGCA GATTAAGTTT GTTCATTCTC 4062

TGCTTTATTC TCTCCATGTG GCAACATTCT GTCAGCCTCT TTCATAGTGT GCAAACATTT 4122

TATCATTCTA AATGGTGACT CTCTGCCCTT GGACCCATTT ATTATTCACA GATGGGGAGA 4182

ACCTATCTGC ATGGACCCTC ACCATCCTCT GTGCAGCACA CACAGTGCAG GGAGCCAGTG 4242

GCGATGGCGA TGACTTTCTT CCCCTG 4268

FIG.24G


PEST
ops
cdc10 REPEATS
TM
NOTCH/lin-12 REPEATS
EGF REPEATS
SIGNAL

FIG.25A


CDC10-1
CDC10 REGION
CDC10-2
CDC10-3
CDC10-4
CDC10-5
CDC10-6
PRIMER cdc-1
PRIMER cdc-3
NLS
BNTS
CK-11 cdc2
cdc2
hN5k
TAN-1
rat NOTCH
XENOPUS NOTCH
DROSOPH NOTCH
1860
1857
1855
1883
1952
1944
1950
1976
2058
2050
2056
2082
2154
2144
2149
2187

FIG.25B


hN5k
TAN-1 2218
rat NOTCH 2209
XENOPUS NOTCH 2214
DROSOPH NOTCH 2285
CK-11
CK-11
hN5k
TAN-1 2250
rat NOTCH 2242
XENOPUS NOTCH 2247
DROSOPH NOTCH 2390
hN5k
TAN-1 2354
rat NOTCH 2344
XENOPUS NOTCH 2343
DROSOPH NOTCH 2495
hN5k
TAN-1 2448
rat NOTCH 2423
XENOPUS NOTCH 2416
DROSOPH NOTCH 2599
PEST-CONTAINING REGION

FIG.25C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/03651

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C12N 15/12, 15/63; C12P 21/00; C07K 13/00
US CL :435/69.1, 172.3, 320.1; 536/27; 530/350
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 172.3, 320.1; 536/27; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, PIR 32 search terms: notch gene, protein, human, human notch sequence

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P Y	CELL, Volume 66, issued 23 August 1991, L.W. Ellisen et al, "TAN-1, the Human Homolog of the Drosophila Notch Gene, Is Broken by Chromosomal Translocations in T Lymphoblastic Neoplasms", pages 649-661, see the entire document.	63-70, 74-87, 132 1-42, 45, 46, 58, 71-73, 95-99, 103-107, 111-115, 128
Y,P	DEVELOPMENT, Volume 113, issued 01 September 1991, G. Weinmaster et al, "A homolog of Drosophila Notch expressed during mammalian development", pages 199-205, Summary page 199, Figure 1 page 200 and page 201, 1st column, 2nd paragraph.	1-42, 45, 46, 58, 62-87, 95-99, 103-107, 111-115, 128, 132
A	CELL, Volume 50, issued 03 July 1987, T.C. Reynolds et al, "Analysis of DNA Surrounding the Breakpoints of Chromosomal Translocations Involving the β T Cell Receptor Gene in Human Lymphoblastic Neoplasms", pages 107-117, see Summary page 107.	63-87

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 20 July 1992	Date of mailing of the international search report 31 JUL 1992
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer STEPHEN WALSH Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*